WEST Search History

Hide Items | Restore | Clear | Cancel

DATE: Monday, April 12, 2004

Hide?	Set Name	Query	Hit Count
	DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ		
☐	L22	alpha-2-antiplasmin OR a2-antiplasmin	162
☐	L21	L20 AND alpha-2-antiplasmin	28
☐	L20	L19 AND stroke	199
☐	L19	L18 AND antiplasmin	661
☐	L18	(plasmin)	5742
☐	L17	L16 AND antiplasmin	20
☐	L16	(424/130.1.CCLS.)	1342
☐	L15	L14 AND stroke	63
☐	L14	L13 AND plasmin	297
☐	L13	(514/1,2.CCLS.)	6796
☐	L12	L11 AND plasmin	50
☐	L11	L10 AND antiplasmin	74
☐	L10	514/2.CCLS.	5970
☐	L9	Collen-D.IN.	21
☐	L8	Collen-Desire.IN.	22
☐	L7	Collen-D-J.IN.	18
☐	L6	Collen-Desire-J.IN.	15
☐	L5	Collen-Desire-Jose.IN.	15
☐	L4	Collen.IN.	199
☐	L3	Nagai-N.IN.	130
☐	L2	Nagai-Nobuo.IN.	111
☐	L1	(Nagai.IN.)	33466

END OF SEARCH HISTORY

h e b b cg b chh e e f e ch e c ch

NCBI PubMed National Library of Medicine NLM

Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Book

Search PubMed for plasmin AND stroke Go Clear

Limits Preview/Index History Clipboard Details

About Entrez

Text Version

Entrez PubMed
Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby

Related Resources
Order Documents
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

Privacy Policy

Display Summary Show: 500 Sort Send to Text

Items 1-108 of 108 One page.

1: Quinton TM, Kim S, Derian CK, Jin J, Kunapuli SP. Related Articles, Links

Plasmin-mediated activation of platelets occurs by cleavage of protease-activated receptor 4.
J Biol Chem. 2004 Feb 18 [Epub ahead of print]
PMID: 14973136 [PubMed - as supplied by publisher]

2: Smith PK, Datta SK, Muhlbaier LH, Samsa G, Nadel A, Lipscomb J. Related Articles, Links

Cost analysis of aprotinin for coronary artery bypass patients: analysis of the randomized trials.
Ann Thorac Surg. 2004 Feb;77(2):635-42; discussion 642-3.
PMID: 14759451 [PubMed - indexed for MEDLINE]

3: Bedi A, Flaker GC. Related Articles, Links

How do HMG-CoA reductase inhibitors prevent stroke?
Am J Cardiovasc Drugs. 2002;2(1):7-14.
PMID: 14727994 [PubMed - in process]

4: Yasuda S, Atsumi T, Ieko M, Matsuura E, Kobayashi K, Inagaki J, Kato H, Tanaka H, Yamakado M, Akino M, Saitou H, Amasaki Y, Jodo S, Amengual O, Koike T Related Articles, Links

Nicked beta2-glycoprotein I: A marker of cerebral infarct and a novel role in the negative feedback pathway of extrinsic fibrinolysis.
Blood. 2004 Jan 15 [Epub ahead of print]
PMID: 14726399 [PubMed - as supplied by publisher]

5: Malyszko J, Malyszko JS, Mysliwiec M. Related Articles, Links

Endothelial Cell Injury Markers in Chronic Renal Failure on Conservative Treatment and Continuous Ambulatory Peritoneal Dialysis.
Kidney Blood Press Res. 2004 [Epub ahead of print]
PMID: 14691349 [PubMed - as supplied by publisher]

6: Gautier S, Petrault O, Gele P, Laprais M, Bastide M, Bauters A, Deplanque D, Jude B, Caron J, Bordet R. Related Articles, Links

Involvement of thrombolysis in recombinant tissue plasminogen activator-induced cerebral hemorrhages and effect on infarct volume and postischemic endothelial function.
Stroke. 2003 Dec;34(12):2975-9. Epub 2003 Nov 13.
PMID: 14615621 [PubMed - indexed for MEDLINE]

7: Ozawa H, Abiko Y, Akimoto T. Related Articles, Links

[A 50-year history of new drugs in Japan-the development and trends of hemostatics and antithrombotic drugs]
Yakushigaku Zasshi. 2003;38(1):93-105. Japanese.
PMID: 14570069 [PubMed - indexed for MEDLINE]

8: Stief TW, Bunder R, Richter A, Maisch B, Renz H, Fareed J. Related Articles, Links

In vitro simulation of therapeutic plasmatic fibrinolysis.

h cb h g e e e fcg e ch b e

Clin Appl Thromb Hemost. 2003 Jul;9(3):211-20.
PMID: 14507109 [PubMed - indexed for MEDLINE]

9: Nagai N, Demarsin E, Van Hoef B, Wouters S, Cingolani D, Laroche Y, Collen D. Related Articles, Links

Recombinant human microplasmin: production and potential therapeutic properties.
J Thromb Haemost. 2003 Feb;1(2):307-13.
PMID: 12871505 [PubMed - indexed for MEDLINE]

10: Marcovina SM, Koschinsky ML. Related Articles, Links

Evaluation of lipoprotein(a) as a prothrombotic factor: progress from bench to bedside.
Curr Opin Lipidol. 2003 Aug;14(4):361-6.
PMID: 12865733 [PubMed - in process]

11: Sironi L, Maria Calvio A, Bellosta S, Lodetti B, Guerrini U, Monetti M, Tremoli E, Mussoni L. Related Articles, Links

Endogenous proteolytic activity in a rat model of spontaneous cerebral stroke.
Brain Res. 2003 Jun 6;974(1-2):184-92.
PMID: 12742636 [PubMed - indexed for MEDLINE]

12: Koenig W. Related Articles, Links

Fibrin(ogen) in cardiovascular disease: an update.
Thromb Haemost. 2003 Apr;89(4):601-9. Review.
PMID: 12669113 [PubMed - indexed for MEDLINE]

13: Ouriel K. Related Articles, Links

Comparison of safety and efficacy of the various thrombolytic agents.
Rev Cardiovasc Med. 2002;3 Suppl 2:S17-24. Review.
PMID: 12556739 [PubMed - indexed for MEDLINE]

14: Lapchak PA. Related Articles, Links

Development of thrombolytic therapy for stroke: a perspective.
Expert Opin Investig Drugs. 2002 Nov;11(11):1623-32. Review.
PMID: 12437508 [PubMed - indexed for MEDLINE]

15: Lapchak PA, Araujo DM, Pakola S, Song D, Wei J, Zivin JA. Related Articles, Links

Microplasmin: a novel thrombolytic that improves behavioral outcome after embolic strokes in rabbits.
Stroke. 2002 Sep;33(9):2279-84.
PMID: 12215599 [PubMed - indexed for MEDLINE]

16: Marder VJ, Stewart D. Related Articles, Links

Towards safer thrombolytic therapy.
Semin Hematol. 2002 Jul;39(3):206-16. Review.
PMID: 12124683 [PubMed - indexed for MEDLINE]

17: Antovic J, Bakic M, Zivkovic M, Ilic A, Blomback M. Related Articles, Links

Blood coagulation and fibrinolysis in acute ischaemic and haemorrhagic (intracerebral and subarachnoid haemorrhage) stroke: does decreased plasmin inhibitor indicate increased fibrinolysis in subarachnoid haemorrhage compared to other types of stroke?
Scand J Clin Lab Invest. 2002;62(3):195-9.
PMID: 12088338 [PubMed - indexed for MEDLINE]

18: Molinaro G, Gervais N, Adam A. Related Articles, Links

Biochemical basis of angioedema associated with recombinant tissue plasminogen activator treatment: an in vitro experimental approach.
Stroke. 2002 Jun;33(6):1712-6.
PMID: 12053016 [PubMed - indexed for MEDLINE]

19: Teesalu T, Kulla A, Asser T, Koskiniemi M, Vaheri A. Related Articles, Links

Tissue plasminogen activator as a key effector in neurobiology and neuropathology.
Biochem Soc Trans. 2002 Apr;30(2):183-9. Review.
PMID: 12023848 [PubMed - indexed for MEDLINE]

20: Abrahamsen CT, Barone FC, Campbell WG Jr, Nelson AH, Contino LC, Pullen MA, Grygielko ET, Edwards RM, Laping NJ, Brooks DP. Related Articles, Links

The angiotensin type 1 receptor antagonist, eprosartan, attenuates the progression of renal disease in spontaneously hypertensive stroke-prone rats with accelerated hypertension.
J Pharmacol Exp Ther. 2002 Apr;301(1):21-8.
PMID: 11907153 [PubMed - indexed for MEDLINE]

21: Li Z, Wang H, Li J, Zhang G, Gao C. Related Articles, Links

Basic and clinical study on the antithrombotic mechanism of glycosaminoglycan extracted from sea cucumber.
Chin Med J (Engl). 2000 Aug;113(8):706-11.
PMID: 11776053 [PubMed - indexed for MEDLINE]

22: Dempfle CE, Alesci S, Kucher K, Muller-Peltzer H, Rubsamen K, Borggrefe M. Related Articles, Links

Plasminogen activation without changes in tPA and PAI-1 in response to subcutaneous administration of ancrod.
Thromb Res. 2001 Dec 15;104(6):433-8.
PMID: 11755954 [PubMed - indexed for MEDLINE]

23: Kario K, Matsuo T, Kobayashi H, Hoshide S, Shimada K. Related Articles, Links

Hyperinsulinemia and hemostatic abnormalities are associated with silent lacunar cerebral infarcts in elderly hypertensive subjects.
J Am Coll Cardiol. 2001 Mar 1;37(3):871-7.
PMID: 11693764 [PubMed - indexed for MEDLINE]

24: Kim JA, Hedrick CC, Xie D, Fisher MJ. Related Articles, Links

Adenoviral-mediated transfer of tissue plasminogen activator gene into brain capillary endothelial cells in vitro.
Angiology. 2001 Sep;52(9):627-34.
PMID: 11570662 [PubMed - indexed for MEDLINE]

25: Hosomi N, Lucero J, Heo JH, Koziol JA, Copeland BR, del Zoppo GJ. Related Articles, Links

Rapid differential endogenous plasminogen activator expression after acute middle cerebral artery occlusion.
Stroke. 2001 Jun;32(6):1341-8.
PMID: 11387497 [PubMed - indexed for MEDLINE]

26: Nagai N, De Mol M, Van Hoef B, Verstreken M, Collen D. Related Articles, Links

Depletion of circulating alpha(2)-antiplasmin by intravenous plasmin or immunoneutralization reduces focal cerebral ischemic injury in the absence of arterial recanalization.
Blood. 2001 May 15;97(10):3086-92.
PMID: 11342434 [PubMed - indexed for MEDLINE]

h cb h g e e e fcg e ch b e

27: van der Bom JG, Bots ML, Haverkate F, Meijer P, Hofman A, Kluft C, Grobbee DE — Related Articles, Links

Activation products of the haemostatic system in coronary, cerebrovascular and peripheral arterial disease.
Thromb Haemost. 2001 Feb;85(2):234-9.
PMID: 11246539 [PubMed - indexed for MEDLINE]

28: Lijnen HR. — Related Articles, Links

Gene targeting in hemostasis. Alpha2-antiplasmin.
Front Biosci. 2001 Feb 1;6:D239-47. Review.
PMID: 11171550 [PubMed - indexed for MEDLINE]

29: Tohgi H, Konno S, Takahashi S, Koizumi D, Kondo R, Takahashi H. — Related Articles, Links

Activated coagulation/fibrinolysis system and platelet function in acute thrombotic stroke patients with increased C-reactive protein levels.
Thromb Res. 2000 Dec 1;100(5):373-9.
PMID: 11150578 [PubMed - indexed for MEDLINE]

30: Sands H, Tuma RF. — Related Articles, Links

LEX 032: a novel recombinant human protein for the treatment of ischaemic reperfusion injury.
Expert Opin Investig Drugs. 1999 Nov;8(11):1907-1916.
PMID: 11139833 [PubMed - as supplied by publisher]

31: Beschorner R, Schluesener HJ, Nguyen TD, Magdolen V, Luther T, Pedal I, Mattern R, Meyermann R, Schwab JM. — Related Articles, Links

Lesion-associated accumulation of uPAR/CD87- expressing infiltrating granulocytes, activated microglial cells/macrophages and upregulation by endothelial cells following TBI and FCI in humans.
Neuropathol Appl Neurobiol. 2000 Dec;26(6):522-7.
PMID: 11123718 [PubMed - indexed for MEDLINE]

32: Kataoka S, Hirose G, Hori A, Shirakawa T, Saigan T. — Related Articles, Links

Activation of thrombosis and fibrinolysis following brain infarction.
J Neurol Sci. 2000 Dec 1;181(1-2):82-8.
PMID: 11099716 [PubMed - indexed for MEDLINE]

33: Lounes KC, Soria C, Mirshahi SS, Desvignes P, Mirshahi M, Bertrand O, Bonnet P, Koopman J, Soria J. — Related Articles, Links

Fibrinogen Ales: a homozygous case of dysfibrinogenemia (gamma-Asp (330)-->Val) characterized by a defective fibrin polymerization site "a".
Blood. 2000 Nov 15;96(10):3473-9.
PMID: 11071644 [PubMed - indexed for MEDLINE]

34: Kurabayashi H, Tamura J, Naruse T, Kubota K. — Related Articles, Links

Possible existence of platelet activation before the onset of cerebral infarction.
Atherosclerosis. 2000 Nov;153(1):203-7.
PMID: 11058716 [PubMed - indexed for MEDLINE]

35: Pfefferkorn T, Wiessner C, Allegrini PR, Staufer B, Vosko MR, Liebetrau M, Bueltemeier G, Kloss CU, Hamann GF. — Related Articles, Links

Plasminogen activation in experimental permanent focal cerebral ischemia.
Brain Res. 2000 Nov 3;882(1-2):19-25.
PMID: 11056180 [PubMed - indexed for MEDLINE]

36: Tucker HM, Kihiko-Ehmann M, Wright S, Rydel RE, Estus S. — Related Articles, Links

Tissue plasminogen activator requires plasminogen to modulate amyloid-

beta neurotoxicity and deposition.
J Neurochem. 2000 Nov;75(5):2172-7.
PMID: 11032907 [PubMed - indexed for MEDLINE]

37: Dempfle CE, Argiriou S, Kucher K, Muller-Peltzer H, Rubsamen K, Heene DL. Related Articles, Links

Analysis of fibrin formation and proteolysis during intravenous administration of ancrod.
Blood. 2000 Oct 15;96(8):2793-802.
PMID: 11023513 [PubMed - indexed for MEDLINE]

38: Gingrich MB, Traynelis SF. Related Articles, Links

Serine proteases and brain damage - is there a link?
Trends Neurosci. 2000 Sep;23(9):399-407. Review.
PMID: 10941185 [PubMed - indexed for MEDLINE]

39: Cote R, Wolfson C, Solymoss S, Mackey A, Leclerc JR, Simard D, Rouah F, Bourque F, Leger B. Related Articles, Links

Hemostatic markers in patients at risk of cerebral ischemia.
Stroke. 2000 Aug;31(8):1856-62.
PMID: 10926947 [PubMed - indexed for MEDLINE]

40: Matsuo T, Kobayashi H, Kario K, Suzuki S. Related Articles, Links

Fibrin D-dimer in thrombogenic disorders.
Semin Thromb Hemost. 2000;26(1):101-7. Review.
PMID: 10805290 [PubMed - indexed for MEDLINE]

41: Pfefferkorn T, Staufer B, Liebetrau M, Bultemeier G, Vosko MR, Zimmermann C, Hamann GF. Related Articles, Links

Plasminogen activation in focal cerebral ischemia and reperfusion.
J Cereb Blood Flow Metab. 2000 Feb;20(2):337-42.
PMID: 10698071 [PubMed - indexed for MEDLINE]

42: Hamann GF, del Zoppo GJ, von Kummer R. Related Articles, Links

Hemorrhagic transformation of cerebral infarction--possible mechanisms.
Thromb Haemost. 1999 Sep;82 Suppl 1:92-4. Review.
PMID: 10695495 [PubMed - indexed for MEDLINE]

43: Dietzmann K, von Bossanyi P, Krause D, Wittig H, Mawrin C, Kirches E. Related Articles, Links

Expression of the plasminogen activator system and the inhibitors PAI-1 and PAI-2 in posttraumatic lesions of the CNS and brain injuries following dramatic circulatory arrests: an immunohistochemical study.
Pathol Res Pract. 2000;196(1):15-21.
PMID: 10674268 [PubMed - indexed for MEDLINE]

44: Hamann GF, del Zoppo GJ, von Kummer R. Related Articles, Links

[Mechanisms for the development of intracranial hemorrhage. Possible implications for thrombolysis in cerebral infarct]
Nervenarzt. 1999 Dec;70(12):1116-20. Review. German.
PMID: 10637820 [PubMed - indexed for MEDLINE]

45: Nagai N, Vanlinthout I, Collen D. Related Articles, Links

Comparative effects of tissue plasminogen activator, streptokinase, and staphylokinase on cerebral ischemic infarction and pulmonary clot lysis in hamster models.
Circulation. 1999 Dec 21-28;100(25):2541-6.
PMID: 10604893 [PubMed - indexed for MEDLINE]

46: Ince B, Bayram C, Harmanci H, Ulutin T. Related Articles, Links

Hemostatic markers in ischemic stroke of undetermined etiology.
Thromb Res. 1999 Nov 1;96(3):169-74.
PMID: 10588458 [PubMed - indexed for MEDLINE]

47: Absher PM, Hendley E, Jaworski DM, Taatjes DJ, Sobel BE. Related Articles, Links

Impairment of the blood-brain barrier: a potential surrogate delineating the determinants of cerebral bleeding caused by fibrinolytic drugs.
Coron Artery Dis. 1999 Sep;10(6):413-20.
PMID: 10474793 [PubMed - indexed for MEDLINE]

48: Feinberg WM, Macy E, Cornell ES, Nightingale SD, Pearce LA, Tracy RP, Bovill EG. Related Articles, Links

Plasmin-alpha2-antiplasmin complex in patients with atrial fibrillation. Stroke Prevention in Atrial Fibrillation Investigators.
Thromb Haemost. 1999 Jul;82(1):100-3.
PMID: 10456461 [PubMed - indexed for MEDLINE]

49: Steins MB, Padro T, Li CX, Mesters RM, Ostermann H, Hammel D, Scheld HH, Berdel WE, Kienast J. Related Articles, Links

Overexpression of tissue-type plasminogen activator in atherosclerotic human coronary arteries.
Atherosclerosis. 1999 Jul;145(1):173-80.
PMID: 10428308 [PubMed - indexed for MEDLINE]

50: Bots ML, Breteler MM, van Kooten F, Haverkate F, Meijer P, Koudstaal PJ, Grobbee DE, Kluft C Related Articles, Links

Coagulation and fibrinolysis markers and risk of dementia. The Dutch Vascular Factors in Dementia Study.
Haemostasis. 1998 May-Aug;28(3-4):216-22.
PMID: 10420069 [PubMed - indexed for MEDLINE]

51: Kim YH, Park JH, Hong SH, Koh JY. Related Articles, Links

Nonproteolytic neuroprotection by human recombinant tissue plasminogen activator.
Science. 1999 Apr 23;284(5414):647-50.
PMID: 10213688 [PubMed - indexed for MEDLINE]

52: Suehiro A, Tsujioka H, Yoshimoto H, Higasa S, Kakishita E. Related Articles, Links

Serum macrophage colony-stimulating factor (M-CSF) level is elevated in patients with old cerebral infarction related to vascular damage.
Am J Hematol. 1999 Mar;60(3):185-90.
PMID: 10072108 [PubMed - indexed for MEDLINE]

53: Misz M, Olah L, Kappelmayer J, Blasko G, Udvardy M, Fekete I, Csepany T, Ajzner E, Csiba L. Related Articles, Links

[Hemostatic abnormalities in ischemic stroke]
Orv Hetil. 1998 Oct 18;139(42):2503-7. Review. Hungarian.
PMID: 9810164 [PubMed - indexed for MEDLINE]

54: Matsuoka Y, Kitamura Y, Taniguchi T. Related Articles, Links

Induction of plasminogen in rat hippocampal pyramidal neurons by kainic acid.
Neurosci Lett. 1998 Aug 14;252(2):119-22.
PMID: 9756336 [PubMed - indexed for MEDLINE]

55: Wang Y, Hand AR, Wang YH, Mina M, Gillies C, Peng T, Cone RE, O'Rourke J. Related Articles, Links

Functional and morphologic evidence of the presence of tissue-plasminogen activator in vascular nerves: implications for a neurologic

control of vessel wall fibrinolysis and rigidity.
J Neurosci Res. 1998 Aug 15;53(4):443-53.
PMID: 9710264 [PubMed - indexed for MEDLINE]

56: Kappelmayer J, Berecki D, Misz M, Olah L, Fekete I, Csiba L, Blasko G. Related Articles, Links

Monocytes express tissue factor in young patients with cerebral ischemia.
Cerebrovasc Dis. 1998 Jul-Aug;8(4):235-9.
PMID: 9684064 [PubMed - indexed for MEDLINE]

57: Reddy DS. Related Articles, Links

Newer thrombolytic drugs for acute myocardial infarction.
Indian J Exp Biol. 1998 Jan;36(1):1-15. Review.
PMID: 9536645 [PubMed - indexed for MEDLINE]

58: Uchiyama S, Yamazaki M, Hara Y, Iwata M. Related Articles, Links

Alterations of platelet, coagulation, and fibrinolysis markers in patients with acute ischemic stroke.
Semin Thromb Hemost. 1997;23(6):535-41.
PMID: 9469626 [PubMed - indexed for MEDLINE]

59: Bell WR Jr. Related Articles, Links

Evaluation of thrombolytic agents.
Drugs. 1997;54 Suppl 3:11-6; discussion 16-7. Review.
PMID: 9360848 [PubMed - indexed for MEDLINE]

60: Tsirka SE. Related Articles, Links

Clinical implications of the involvement of tPA in neuronal cell death.
J Mol Med. 1997 May;75(5):341-7. Review.
PMID: 9181475 [PubMed - indexed for MEDLINE]

61: Sohara H, Amitani S, Kurose M, Miyahara K. Related Articles, Links

Atrial fibrillation activates platelets and coagulation in a time-dependent manner: a study in patients with paroxysmal atrial fibrillation.
J Am Coll Cardiol. 1997 Jan;29(1):106-12.
PMID: 8996302 [PubMed - indexed for MEDLINE]

62: Bouchama A, Bridey F, Hammami MM, Lacombe C, al-Shail E, al-Ohali Y, Combe F, al-Sedairy S, de Prost D. Related Articles, Links

Activation of coagulation and fibrinolysis in heatstroke.
Thromb Haemost. 1996 Dec;76(6):909-15.
PMID: 8972010 [PubMed - indexed for MEDLINE]

63: Yoshikawa H, Maruta T, Yokoji H, Takamori M, Yachie A, Torii Y. Related Articles, Links

Degos' disease: radiological and immunological aspects.
Acta Neurol Scand. 1996 Nov;94(5):353-6.
PMID: 8947289 [PubMed - indexed for MEDLINE]

64: Fullerton T. Related Articles, Links

Treatment of acute ischemic stroke, Part 1.
J Am Pharm Assoc (Wash). 1996 Oct;NS36(10):571-2. Review. No abstract available.
PMID: 8908931 [PubMed - indexed for MEDLINE]

65: Thomas GR, Thibodeaux H, Errett CJ, Badillo JM, Wu DT, Refino CJ, Keyt BA, Bennett WF. Related Articles, Links

Limiting systemic plasminogenolysis reduces the bleeding potential for tissue-type plasminogen activators but not for streptokinase.
Thromb Haemost. 1996 Jun;75(6):915-20.
PMID: 8822586 [PubMed - indexed for MEDLINE]

66: Hernandez Nunez A, Romero Barbero JL, Caceres Sansaloni A, Perez de Oteyza C Related Articles, Links

[Alterations of fibrinolysis in stroke]
An Med Interna. 1996 Mar;13(3):107-10. Spanish.
PMID: 8679836 [PubMed - indexed for MEDLINE]

67: Freitag HJ, Becker VU, Thie A, Tilsner V, Philapitsch A, Schwarz HP, Webhof U, Muller A, Zeumer H. Related Articles, Links

Lys-plasminogen as an adjunct to local intra-arterial fibrinolysis for carotid territory stroke: laboratory and clinical findings.
Neuroradiology. 1996 Feb;38(2):181-5.
PMID: 8692437 [PubMed - indexed for MEDLINE]

68: Zlokovic BV, Wang L, Sun N, Haffke S, Verrall S, Seeds NW, Fisher MJ, Schreiber SS. Related Articles, Links

Expression of tissue plasminogen activator in cerebral capillaries: possible fibrinolytic function of the blood-brain barrier.
Neurosurgery. 1995 Nov;37(5):955-61.
PMID: 8559345 [PubMed - indexed for MEDLINE]

69: Wagstaff AJ, Gillis JC, Goa KL. Related Articles, Links

Alteplase. A reappraisal of its pharmacology and therapeutic use in vascular disorders other than acute myocardial infarction.
Drugs. 1995 Aug;50(2):289-316. Review.
PMID: 8521760 [PubMed - indexed for MEDLINE]

70: Gillis JC, Wagstaff AJ, Goa KL. Related Articles, Links

Alteplase. A reappraisal of its pharmacological properties and therapeutic use in acute myocardial infarction.
Drugs. 1995 Jul;50(1):102-36. Review.
PMID: 7588083 [PubMed - indexed for MEDLINE]

71: Ueda T, Hatakeyama T, Sakaki S, Ohta S, Kumon Y, Uraoka T. Related Articles, Links

Changes in coagulation and fibrinolytic system after local intra-arterial thrombolysis for acute ischemic stroke.
Neurol Med Chir (Tokyo). 1995 Mar;35(3):136-43.
PMID: 7770106 [PubMed - indexed for MEDLINE]

72: Nagy Z, Kolev K, Csonka E, Pek M, Machovich R. Related Articles, Links

Contraction of human brain endothelial cells induced by thrombogenic and fibrinolytic factors. An in vitro cell culture model.
Stroke. 1995 Feb;26(2):265-70.
PMID: 7831700 [PubMed - indexed for MEDLINE]

73: Reers M, Koschinsky R, Dickneite G, Hoffmann D, Czech J, Stuber W. Related Articles, Links

Synthesis and characterisation of novel thrombin inhibitors based on 4-amidinophenylalanine.
J Enzyme Inhib. 1995;9(1):61-72.
PMID: 8568567 [PubMed - indexed for MEDLINE]

74: Deadman J, Claeson G, Scully MF. Related Articles, Links

Structure/function aspects of neutral P1 residue peptide inhibitors of thrombin.
J Enzyme Inhib. 1995;9(1):29-41.
PMID: 8568564 [PubMed - indexed for MEDLINE]

75: Kido H, Hayashi K, Uchida T, Watanabe M. Related Articles, Links

Low incidence of hemorrhagic infarction following coronary reperfusion with nasaruplase in a canine model of acute myocardial infarction. Comparison with recombinant t-PA.
Jpn Heart J. 1995 Jan;36(1):61-79.
PMID: 7760515 [PubMed - indexed for MEDLINE]

76: Iijima K, Murakami F, Nakamura K, Ikawa S, Yuasa I, Motosumi H, Ohno K, Takeshita K. Related Articles, Links

Hemostatic studies in patients with carbohydrate-deficient glycoprotein syndrome.
Thromb Res. 1994 Oct 15;76(2):193-8.
PMID: 7863468 [PubMed - indexed for MEDLINE]

77: Kohriyama T, Tanaka E, Katayama S, Yamamura Y, Nakamura S. Related Articles, Links

[Antiplatelet therapy in patients with cerebral thrombosis at the chronic phase--assessment of its effect on coagulation and fibrinolytic parameters]
Rinsho Shinkeigaku. 1994 Aug;34(8):771-6. Japanese.
PMID: 7994982 [PubMed - indexed for MEDLINE]

78: Kario K, Matsuo T. Related Articles, Links

High factor-VII activity in the elderly is related to vascular disease through activation of the coagulation system.
J Cardiovasc Risk. 1994 Aug;1(2):165-71.
PMID: 7606630 [PubMed - indexed for MEDLINE]

79: Yamazaki M, Uchiyama S, Maruyama S. Related Articles, Links

Alterations of haemostatic markers in various subtypes and phases of stroke.
Blood Coagul Fibrinolysis. 1993 Oct;4(5):707-12.
PMID: 7507362 [PubMed - indexed for MEDLINE]

80: Puri RN, Colman RW. Related Articles, Links

Reocclusion after thrombolytic therapy: strategies for inhibiting thrombin-induced platelet aggregation.
Blood Coagul Fibrinolysis. 1993 Jun;4(3):465-78. Review.
PMID: 8329574 [PubMed - indexed for MEDLINE]

81: Guan KJ. Related Articles, Links

[Changes in the fibrinolytic activity in hypertension and acute cerebral infarction]
Zhonghua Xin Xue Guan Bing Za Zhi. 1993 Jun;21(3):150-2, 186-7. Chinese.
PMID: 8243228 [PubMed - indexed for MEDLINE]

82: Ono N, Koyama T, Suehiro A, Oku K, Fujikake K, Kakishita E. Related Articles, Links

Influence of atrial fibrillation on coagulo-fibrinolytic markers in patients with cerebral infarction.
Int Angiol. 1992 Oct-Dec;11(4):298-303.
PMID: 1284251 [PubMed - indexed for MEDLINE]

83: Komberg A, Francis CW, Marder VJ. Related Articles, Links

Plasma crosslinked fibrin polymers: quantitation based on tissue plasminogen activator conversion to D-dimer and measurement in normal and patients with acute thrombotic disorders.
Blood. 1992 Aug 1;80(3):709-17.
PMID: 1386260 [PubMed - indexed for MEDLINE]

84: Benedict CR, Mueller S, Anderson HV, Willerson JT. Related Articles, Links

Thrombolytic therapy: a state of the art review.
Hosp Pract (Off Ed). 1992 Jun 15;27(6):61-72. Review.
PMID: 1534563 [PubMed - indexed for MEDLINE]

85: Furlan AJ, Lucas FV, Craciun R, Wohl RC. Related Articles, Links

Stroke in a young adult with familial plasminogen disorder.
Stroke. 1991 Dec;22(12):1598-602.
PMID: 1962336 [PubMed - indexed for MEDLINE]

86: Ono N, Koyama T, Suehiro A, Oku K, Fujikake K, Kakishita E. Related Articles, Links

Clinical significance of new coagulation and fibrinolytic markers in ischemic stroke patients.
Stroke. 1991 Nov;22(11):1369-73.
PMID: 1836283 [PubMed - indexed for MEDLINE]

87: Cole PL. Related Articles, Links

Thrombolytic therapy: then and now.
Heart Lung. 1991 Sep;20(5 Pt 2):542-51.
PMID: 1910023 [PubMed - indexed for MEDLINE]

88: Di Minno G, Martinez J, Cirillo F, Cerbone AM, Silver MJ, Colucci M, Margaglione M, Tauro R, Semeraro N, Quattrone A, et al. Related Articles, Links

A role for platelets and thrombin in the juvenile stroke of two siblings with defective thrombin-adsorbing capacity of fibrin(ogen).
Arterioscler Thromb. 1991 Jul-Aug;11(4):785-96.
PMID: 1829631 [PubMed - indexed for MEDLINE]

89: Takano K, Yamaguchi T, Kato H, Omae T. Related Articles, Links

Activation of coagulation in acute cardioembolic stroke.
Stroke. 1991 Jan;22(1):12-6.
PMID: 1987667 [PubMed - indexed for MEDLINE]

90: Iijima K, Fukuda C, Nakamura K. Related Articles, Links

Measurements of tissue factor-like activity in plasma of patients with DIC.
Thromb Res. 1991 Jan 1;61(1):29-38.
PMID: 1826974 [PubMed - indexed for MEDLINE]

91: Shirokov EA. Related Articles, Links

[Diagnosis and treatment of coagulopathic syndromes in ischemic stroke]
Zh Nevropatol Psikhiatr Im S S Korsakova. 1991;91(7):23-4. Russian.
PMID: 1661474 [PubMed - indexed for MEDLINE]

92: Verstraete M. Related Articles, Links

Thrombolytic treatment in acute myocardial infarction.
Circulation. 1990 Sep;82(3 Suppl):II96-109. Review.
PMID: 2118432 [PubMed - indexed for MEDLINE]

93: Takano K, Yamaguchi T, Okada Y, Uchida K, Kisiel W, Kato H. Related Articles, Links

Hypercoagulability in acute ischemic stroke: analysis of the extrinsic coagulation reactions in plasma by a highly sensitive automated method.
Thromb Res. 1990 Jun 1;58(5):481-91.
PMID: 2368033 [PubMed - indexed for MEDLINE]

94: Verstraete M. Related Articles, Links

[Thrombolytic therapy in acute myocardial infarct]
Recenti Prog Med. 1990 Apr;81(4):287-98. Review. Italian.
PMID: 2198644 [PubMed - indexed for MEDLINE]

☐ **95:** Marongiu F, Mamusa AM, Mameli G, Conti M, Sorano GG, Biondi G, Farci P, Balestrieri A. Related Articles, Links

Subclinical activation of fibrinolysis in atherosclerotic disease detected by B beta 15-42 assay.
Ric Clin Lab. 1989 Apr-Jun;19(2):157-63.
PMID: 2528202 [PubMed - indexed for MEDLINE]

☐ **96:** Iijima K. Related Articles, Links

[Hemostatic tests for the diagnosis of thrombosis. Activated coagulation and fibrinolytic factors. Detection of the protease/inhibitor complex]
Rinsho Byori. 1988 Jun;36(6):623-6. Japanese. No abstract available.
PMID: 2974894 [PubMed - indexed for MEDLINE]

☐ **97:** van der Laarse A, Kerkhof PL, Vermeer F, Serruys PW, Hermens WT, Verheugt FW, Bar FW, Krauss XH, van der Wall EE, Simoons ML. Related Articles, Links

Relation between infarct size and left ventricular performance assessed in patients with first acute myocardial infarction randomized to intracoronary thrombolytic therapy or to conventional treatment.
Am J Cardiol. 1988 Jan 1;61(1):1-7.
PMID: 2962483 [PubMed - indexed for MEDLINE]

☐ **98:** Papadopoulos SM, Chandler WF, Salamat MS, Topol EJ, Sackellares JC. Related Articles, Links

Recombinant human tissue-type plasminogen activator therapy in acute thromboembolic stroke.
J Neurosurg. 1987 Sep;67(3):394-8.
PMID: 3112328 [PubMed - indexed for MEDLINE]

☐ **99:** Bell W. Related Articles, Links

Objectives of thrombolytic therapy in acute myocardial infarction.
Am J Med. 1987 Aug 24;83(2A):11-4.
PMID: 3631113 [PubMed - indexed for MEDLINE]

☐ **100:** Moriyama H, Minami S, Okamoto K, Tsuchiya T, Tsuji K, Higashi T. Related Articles, Links

[Problems in measuring the activity of alpha 2-plasmin inhibitor in the urokinase therapy]
Rinsho Byori. 1987 Apr;35(4):465-7. Japanese. No abstract available.
PMID: 3613164 [PubMed - indexed for MEDLINE]

☐ **101:** Nomura M, Fukui R, Miyagi Y, Shiga Y, Uwatoko M, Nakano H, Abo Y, Chikamatsu H, Hishida H, Mizuno Y. Related Articles, Links

[The effects of intravenous urokinase administration in patients with acute myocardial infarction]
J Cardiogr Suppl. 1986;(10):23-33. Japanese.
PMID: 2953826 [PubMed - indexed for MEDLINE]

☐ **102:** Kanmatsuse K, Kajiwara N, Onikura S, Satoh Y, Andoh T. Related Articles, Links

Indications for and limitations of coronary thrombolysis.
Jpn Circ J. 1985 Jun;49(6):597-604.
PMID: 3162042 [PubMed - indexed for MEDLINE]

☐ **103:** Mathey DG, Schofer J, Sheehan FH, Becher H, Tilsner V, Dodge HT. Related Articles, Links

Intravenous urokinase in acute myocardial infarction.
Am J Cardiol. 1985 Apr 1;55(8):878-82.
PMID: 3984876 [PubMed - indexed for MEDLINE]

☐ **104:** Matsushima A, Shimizu A, Takahama Y, Tsukada T, Inada Y. Related Articles, Links

Determination of fragment D-dimer derivatives in serum reactive with antiserum against human fragment D-dimer.
Blut. 1984 Aug;49(2):101-5.
PMID: 6235873 [PubMed - indexed for MEDLINE]

105: Ganz W. Related Articles, Links

Intracoronary thrombolysis in acute myocardial infarction.
Am J Cardiol. 1983 Jul 20;52(2):92A-95A.
PMID: 6223519 [PubMed - indexed for MEDLINE]

106: Lane DA, Wolff S, Ireland H, Gawel M, Foadi M. Related Articles, Links

Activation of coagulation and fibrinolytic systems following stroke.
Br J Haematol. 1983 Apr;53(4):655-8.
PMID: 6219694 [PubMed - indexed for MEDLINE]

107: Takemoto Y, Fukuda A, Tanaka S, Tanabe J, Ikeda H, Fujii C, Kohama A. Related Articles, Links

[Correlation between coagulation and fibrinolysis in patient with cerebrovascular accident at acute stage]
No To Shinkei. 1982 Oct;34(10):1007-10. Japanese.
PMID: 7150448 [PubMed - indexed for MEDLINE]

108: Shefer DG, Krupin EN, Shmushkevich LS, Shtuts VN, Khor'iakov GI. Related Articles, Links

[Experience in emergency diagnosis and treatment of stroke]
Zh Nevropatol Psikhiatr Im S S Korsakova. 1972;72(8):1159-64. Russian. No abstract available.
PMID: 4263310 [PubMed - indexed for MEDLINE]

Display Summary Show: 500 Sort Send to Text

Items 1-108 of 108 One page.

Write to the Help Desk
NCBI | NLM | NIH
Department of Health & Human Services
Freedom of Information Act | Disclaimer

Apr 6 2004 10:25:18

h cb h g e e e fcg e ch b e

NCBI PubMed National Library of Medicine NLM

Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Boo

Search PubMed for plasmin AND review AND antiplasmin Go Clear

Limits Preview/Index History Clipboard Details

About Entrez

Text Version

Entrez PubMed
Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby

Related Resources
Order Documents
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

Privacy Policy

Display Summary Show: 500 Sort Send to Text

Items 1-92 of 92 One page.

1: Huntington JA. Related Articles, Links

Mechanisms of glycosaminoglycan activation of the serpins in hemostasis.
J Thromb Haemost. 2003 Jul;1(7):1535-49. Review.
PMID: 12871289 [PubMed - indexed for MEDLINE]

2: Nakahara M, Koyama T. Related Articles, Links

[Congenital plasmin inhibitor deficiencies: basic concepts and clinical applications]
Rinsho Ketsueki. 2003 Mar;44(3):149-58. Review. Japanese. No abstract available.
PMID: 12722341 [PubMed - indexed for MEDLINE]

3: Hellgren M. Related Articles, Links

Hemostasis during normal pregnancy and puerperium.
Semin Thromb Hemost. 2003 Apr;29(2):125-30. Review.
PMID: 12709915 [PubMed - indexed for MEDLINE]

4: Marder VJ, Stewart D. Related Articles, Links

Towards safer thrombolytic therapy.
Semin Hematol. 2002 Jul;39(3):206-16. Review.
PMID: 12124683 [PubMed - indexed for MEDLINE]

5: Lijnen HR. Related Articles, Links

Matrix metalloproteinases and cellular fibrinolytic activity.
Biochemistry (Mosc). 2002 Jan;67(1):92-8. Review.
PMID: 11841344 [PubMed - indexed for MEDLINE]

6: Mammen EF. Related Articles, Links

Disseminated intravascular coagulation (DIC).
Clin Lab Sci. 2000 Fall;13(4):239-45. Review.
PMID: 11586511 [PubMed - indexed for MEDLINE]

7: Favier R, Aoki N, de Moerloose P. Related Articles, Links

Congenital alpha(2)-plasmin inhibitor deficiencies: a review.
Br J Haematol. 2001 Jul;114(1):4-10. Review. No abstract available.
PMID: 11472338 [PubMed - indexed for MEDLINE]

8: Lee KN, Lee CS, Tae WC, Jackson KW, Christiansen VJ, McKee PA. Related Articles, Links

Crosslinking of alpha 2-antiplasmin to fibrin.
Ann N Y Acad Sci. 2001;936:335-9. Review.
PMID: 11460490 [PubMed - indexed for MEDLINE]

9: Lijnen HR. Related Articles, Links

Elements of the fibrinolytic system.
Ann N Y Acad Sci. 2001;936:226-36. Review.
PMID: 11460480 [PubMed - indexed for MEDLINE]

h cb h g e e e fcg e ch b e

10: Lijnen HR. Related Articles, Links

Gene targeting in hemostasis. Alpha2-antiplasmin.
Front Biosci. 2001 Feb 1;6:D239-47. Review.
PMID: 11171550 [PubMed - indexed for MEDLINE]

11: Booth NA. Related Articles, Links

Fibrinolysis and thrombosis.
Baillieres Best Pract Res Clin Haematol. 1999 Sep;12(3):423-33. Review.
PMID: 10856979 [PubMed - indexed for MEDLINE]

12: Stief TW, Fareed J. Related Articles, Links

The antithrombotic factor singlet oxygen/light (1O2/h nu).
Clin Appl Thromb Hemost. 2000 Jan;6(1):22-30. Review.
PMID: 10726045 [PubMed - indexed for MEDLINE]

13: Maruyama I. Related Articles, Links

[t-PA-PAI-1 complex]
Nippon Rinsho. 1999 Sep;57 Suppl:688-90. Review. Japanese. No abstract available.
PMID: 10543214 [PubMed - indexed for MEDLINE]

14: Yoshikawa Y. Related Articles, Links

[Alpha 2-plasmin inhibitor-plasmin complex]
Nippon Rinsho. 1999 Sep;57 Suppl:685-7. Review. Japanese. No abstract available.
PMID: 10543213 [PubMed - indexed for MEDLINE]

15: Kinoshita T. Related Articles, Links

[Alpha 2-plasmin inhibitor]
Nippon Rinsho. 1999 Sep;57 Suppl:682-4. Review. Japanese. No abstract available.
PMID: 10543212 [PubMed - indexed for MEDLINE]

16: Hoffmeister HM, Heller W, Seipel L. Related Articles, Links

[Blood coagulation and fibrinolysis in arteriosclerosis]
Z Kardiol. 1999 May;88(5):315-23. Review. German.
PMID: 10413853 [PubMed - indexed for MEDLINE]

17: Yoshinaga H, Hirosawa S. Related Articles, Links

[Congenital deficiency of alpha 2-plasmin inhibitor]
Ryoikibetsu Shokogun Shirizu. 1998;(21 Pt 2):488-90. Review. Japanese. No abstract available.
PMID: 9833551 [PubMed - indexed for MEDLINE]

18: Misz M, Olah L, Kappelmayer J, Blasko G, Udvardy M, Fekete I, Csepany T, Ajzner E, Csiba L. Related Articles, Links

[Hemostatic abnormalities in ischemic stroke]
Orv Hetil. 1998 Oct 18;139(42):2503-7. Review. Hungarian.
PMID: 9810164 [PubMed - indexed for MEDLINE]

19: Mustonen P, Lepantalo M, Lassila R. Related Articles, Links

Physical exertion induces thrombin formation and fibrin degradation in patients with peripheral atherosclerosis.
Arterioscler Thromb Vasc Biol. 1998 Feb;18(2):244-9. Review.
PMID: 9484989 [PubMed - indexed for MEDLINE]

20: Plesner T, Behrendt N, Ploug M. Related Articles, Links

Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR.
Stem Cells. 1997;15(6):398-408. Review.
PMID: 9402652 [PubMed - indexed for MEDLINE]

h cb h g e e e fcg e ch b e

21: Suehiro A. Related Articles, Links

[Effect of thrombolytic agents on platelets and blood coagulation system]
Rinsho Byori. 1997 Oct;45(10):951-6. Review. Japanese.
PMID: 9369072 [PubMed - indexed for MEDLINE]

22: Pfeiffer A, Spranger J, Meyer-Schwickerath R, Schatz H. Related Articles, Links

Growth factor alterations in advanced diabetic retinopathy: a possible role of blood retina barrier breakdown.
Diabetes. 1997 Sep;46 Suppl 2:S26-30. Review.
PMID: 9285495 [PubMed - indexed for MEDLINE]

23: Lijnen HR, Collen D. Related Articles, Links

Endothelium in hemostasis and thrombosis.
Prog Cardiovasc Dis. 1997 Jan-Feb;39(4):343-50. Review.
PMID: 9050819 [PubMed - indexed for MEDLINE]

24: Muszbek L, Adany R, Mikkola H. Related Articles, Links

Novel aspects of blood coagulation factor XIII. I. Structure, distribution, activation, and function.
Crit Rev Clin Lab Sci. 1996 Oct;33(5):357-421. Review.
PMID: 8922891 [PubMed - indexed for MEDLINE]

25: Fukuda C, Iijima K, Nakamura K. Related Articles, Links

[Clinical usefulness of the measurements of plasmin-alpha 2-plasmin inhibitor complex and plasma tissue factor activity in patients with disseminated intravascular coagulation]
Rinsho Byori. 1996 Aug;44(8):750-6. Review. Japanese.
PMID: 8816061 [PubMed - indexed for MEDLINE]

26: Kuwajima M, Iijima K. Related Articles, Links

[Recent advances in laboratory approaches to hematologic disorders]
Rinsho Byori. 1996 Aug;44(8):727-8. Review. Japanese.
PMID: 8816057 [PubMed - indexed for MEDLINE]

27: McDonagh J, Fukue H. Related Articles, Links

Determinants of substrate specificity for factor XIII.
Semin Thromb Hemost. 1996;22(5):369-76. Review.
PMID: 8989819 [PubMed - indexed for MEDLINE]

28: Dietrich W. Related Articles, Links

Reducing thrombin formation during cardiopulmonary bypass: is there a benefit of the additional anticoagulant action of aprotinin?
J Cardiovasc Pharmacol. 1996;27 Suppl 1:S50-7. Review.
PMID: 8938284 [PubMed - indexed for MEDLINE]

29: Prandota J, Kotecki L. Related Articles, Links

[Plasma proteinase inhibitors and their clinical significance]
Pediatr Pol. 1995 Aug;70(8):667-72. Review. Polish. No abstract available.
PMID: 8668369 [PubMed - indexed for MEDLINE]

30: Collen D, Lijnen HR. Related Articles, Links

Molecular basis of fibrinolysis, as relevant for thrombolytic therapy.
Thromb Haemost. 1995 Jul;74(1):167-71. Review.
PMID: 8578451 [PubMed - indexed for MEDLINE]

31: Lijnen HR, Collen D. Related Articles, Links

Mechanisms of physiological fibrinolysis.

Baillieres Clin Haematol. 1995 Jun;8(2):277-90. Review.
PMID: 7549063 [PubMed - indexed for MEDLINE]

32: Yoshikawa Y, Sakata Y. Related Articles, Links

[alpha 2-Plasmin inhibitor-plasmin complex (PIC)]
Nippon Rinsho. 1995 Mar;53 Su Pt 2:55-8. Review. Japanese. No abstract available.
PMID: 8753179 [PubMed - indexed for MEDLINE]

33: Kramer MD, Schaefer B, Reinartz J. Related Articles, Links

Plasminogen activation by human keratinocytes: molecular pathways and cell-biological consequences.
Biol Chem Hoppe Seyler. 1995 Mar;376(3):131-41. Review.
PMID: 7612190 [PubMed - indexed for MEDLINE]

34: Udrardy M, Schwartzott D, Jackson K, McKee PA. Related Articles, Links

[A new thrombocyte aggregation-inhibiting and fibrinolysis-promoting synthetic molecule: RGDF (Arg-Gly-Asp-Phe) coupled with the carboxyterminal antiplasmin peptide]
Orv Hetil. 1995 Jan 15;136(3):129-33. Review. Hungarian.
PMID: 7870410 [PubMed - indexed for MEDLINE]

35: Lijnen HR. Related Articles, Links

Mechanism of action and thrombolytic potential of staphylokinase.
Verh K Acad Geneeskd Belg. 1995;57(4):303-14. Review.
PMID: 8571666 [PubMed - indexed for MEDLINE]

36: Zawilska K. Related Articles, Links

[Progress in the detection of intravascular activation of fibrinolysis]
Acta Haematol Pol. 1995;26(1):33-8. Review. Polish.
PMID: 7747560 [PubMed - indexed for MEDLINE]

37: Collen D, Lijnen HR, Vanderschueren S. Related Articles, Links

Staphylokinase: fibrinolytic properties and current experience in patients with occlusive arterial thrombosis.
Verh K Acad Geneeskd Belg. 1995;57(3):183-96; discussion 196-8. Review.
PMID: 7483814 [PubMed - indexed for MEDLINE]

38: Declerck PJ, Juhan-Vague I, Felez J, Wiman B. Related Articles, Links

Pathophysiology of fibrinolysis.
J Intern Med. 1994 Oct;236(4):425-32. Review. No abstract available.
PMID: 7523565 [PubMed - indexed for MEDLINE]

39: Collen D, Lijnen HR. Related Articles, Links

Staphylokinase, a fibrin-specific plasminogen activator with therapeutic potential?
Blood. 1994 Aug 1;84(3):680-6. Review. No abstract available.
PMID: 7519069 [PubMed - indexed for MEDLINE]

40: Scherer R, Paar D, Stocker L, Kox WJ. Related Articles, Links

[Diagnosis and therapy of disseminated intravascular coagulation]
Anaesthesist. 1994 Jun;43(6):347-54. Review. German.
PMID: 8048768 [PubMed - indexed for MEDLINE]

41: Samlaska CP, Winfield EA. Related Articles, Links

Pentoxifylline.
J Am Acad Dermatol. 1994 Apr;30(4):603-21. Review.
PMID: 8157787 [PubMed - indexed for MEDLINE]

h cb h g e e e fcg e ch b e

42: Edelberg J, Pizzo SV. Related Articles, Links

Lipoprotein (a) regulates plasmin generation and inhibition.
Chem Phys Lipids. 1994 Jan;67-68:363-8. Review.
PMID: 8187236 [PubMed - indexed for MEDLINE]

43: Angles-Cano E. Related Articles, Links

Overview on fibrinolysis: plasminogen activation pathways on fibrin and cell surfaces.
Chem Phys Lipids. 1994 Jan;67-68:353-62. Review.
PMID: 8187235 [PubMed - indexed for MEDLINE]

44: Deppisch R, Haug U, Gohl H, Ritz E. Related Articles, Links

Role of proteinase/antiproteinase inhibitor disequilibrium in the bioincompatibility induced by artificial surfaces.
Nephrol Dial Transplant. 1994;9 Suppl 3:17-23. Review.
PMID: 7521027 [PubMed - indexed for MEDLINE]

45: Munkvad S. Related Articles, Links

Fibrinolysis in patients with acute ischaemic heart disease. With particular reference to systemic effects of tissue-type plasminogen activator treatment on fibrinolysis, coagulation and complement pathways.
Dan Med Bull. 1993 Sep;40(4):383-408. Review.
PMID: 8222763 [PubMed - indexed for MEDLINE]

46: Menashi S, Lu H, Soria C, Legrand Y. Related Articles, Links

Endothelial cell proteases: physiological role and regulation.
Baillieres Clin Haematol. 1993 Sep;6(3):559-76. Review.
PMID: 7517736 [PubMed - indexed for MEDLINE]

47: Garcia Frade LJ, Garcia Avello A. Related Articles, Links

[Analysis of the fibrinolytic response on disseminated intravascular coagulation]
Sangre (Barc). 1993 Jun;38(3):221-4. Review. Spanish. No abstract available.
PMID: 7692611 [PubMed - indexed for MEDLINE]

48: Nakahara K. Related Articles, Links

[New clinical tests in diagnosis of hematologic diseases]
Nippon Naika Gakkai Zasshi. 1993 Apr 10;82(4):529-33. Review. Japanese. No abstract available.
PMID: 8340662 [PubMed - indexed for MEDLINE]

49: Koyama T, Aoki N. Related Articles, Links

[Progress in diagnosis of disseminated intravascular coagulation (DIC)--diagnostic criteria of DIC]
Nippon Rinsho. 1993 Jan;51(1):43-9. Review. Japanese.
PMID: 8433527 [PubMed - indexed for MEDLINE]

50: Koike K, Fujimaki M. Related Articles, Links

[New useful parameters or makers in diagnosis and condition. Analysis of disseminated intravascular coagulation--mainly molecular markers]
Nippon Rinsho. 1993 Jan;51(1):37-42. Review. Japanese.
PMID: 8433526 [PubMed - indexed for MEDLINE]

51: Ohsato K, Okamoto K. Related Articles, Links

[Advancement in the diagnosis of disseminated intravascular coagulation for the surgeon]
Nippon Rinsho. 1993 Jan;51(1):50-5. Review. Japanese.

PMID: 8381885 [PubMed - indexed for MEDLINE]

52: Kramer MD, Hansch GM, Rother KO. Related Articles, Links

Complement and plasminogen: pathways in inflammation.
Behring Inst Mitt. 1992 Apr;(91):145-56. Review.
PMID: 1524563 [PubMed - indexed for MEDLINE]

53: Boiadzhiian KhP. Related Articles, Links

[Methods of studying alpha 2-antiplasmin activity]
Vopr Med Khim. 1991 Sep-Oct;37(5):92-4. Review. Russian.
PMID: 1722061 [PubMed - indexed for MEDLINE]

54: Plow EF, Felez J, Miles LA. Related Articles, Links

Cellular regulation of fibrinolysis.
Thromb Haemost. 1991 Jul 12;66(1):32-6. Review.
PMID: 1656542 [PubMed - indexed for MEDLINE]

55: Plow EF, Miles LA. Related Articles, Links

Plasminogen receptors in the mediation of pericellular proteolysis.
Cell Differ Dev. 1990 Dec 2;32(3):293-8. Review.
PMID: 1965955 [PubMed - indexed for MEDLINE]

56: Gram J. Related Articles, Links

The haemostatic balance in groups of thrombosis-prone patients. With particular reference to fibrinolysis in patients with myocardial infarction.
Dan Med Bull. 1990 Jun;37(3):210-34. Review.
PMID: 2192835 [PubMed - indexed for MEDLINE]

57: Aoki N. Related Articles, Links

Molecular genetics of alpha 2 plasmin inhibitor.
Adv Exp Med Biol. 1990;281:195-200. Review.
PMID: 2102612 [PubMed - indexed for MEDLINE]

58: Francis RB Jr. Related Articles, Links

Clinical disorders of fibrinolysis: a critical review.
Blut. 1989 Jul;59(1):1-14. Review.
PMID: 2526671 [PubMed - indexed for MEDLINE]

59: Hirosawa S. Related Articles, Links

Genomic organization of the human alpha 2-plasmin inhibitor.
Nippon Ketsueki Gakkai Zasshi. 1988 Dec;51(8):1665-9. Review. No abstract available.
PMID: 3073621 [PubMed - indexed for MEDLINE]

60: Saito H. Related Articles, Links

Alpha 2-plasmin inhibitor and its deficiency states.
J Lab Clin Med. 1988 Dec;112(6):671-8. Review. No abstract available.
PMID: 3057093 [PubMed - indexed for MEDLINE]

61: Gaffney PJ. Related Articles, Links

Standardization of plasminogen assays.
Haemostasis. 1988;18 Suppl 1:47-60. Review.
PMID: 3280425 [PubMed - indexed for MEDLINE]

62: Vinazzer H. Related Articles, Links

Basics and practice in evaluating plasminogen.
Haemostasis. 1988;18 Suppl 1:41-5. Review.
PMID: 3280424 [PubMed - indexed for MEDLINE]

63: Anderle K, Frohlich A. Related Articles, Links

Review of studies with plasminogen concentrates and proposals for further therapeutic strategies with plasminogen concentrates.
Haemostasis. 1988;18 Suppl 1:165-75. Review.
PMID: 3280422 [PubMed - indexed for MEDLINE]

64: Ranby M, Brandstrom A. Related Articles, Links

Biological control of tissue plasminogen activator-mediated fibrinolysis.
Enzyme. 1988;40(2-3):130-43. Review.
PMID: 3139402 [PubMed - indexed for MEDLINE]

65: Collen D. Related Articles, Links

Fibrin-specific thrombolytic agents.
Klin Wochenschr. 1988;66 Suppl 12:15-23. Review.
PMID: 3126344 [PubMed - indexed for MEDLINE]

66: Collen D. Related Articles, Links

Fibrin-specific thrombolytic agents.
Schweiz Med Wochenschr. 1987 Nov 14;117(46):1791-8. Review.
PMID: 3122317 [PubMed - indexed for MEDLINE]

67: Lill H. Related Articles, Links

[Biochemical and physiologic principles of tissue-type plasminogen activator]
Z Gesamte Inn Med. 1987 Sep 1;42(17):478-86. Review. German.
PMID: 3120429 [PubMed - indexed for MEDLINE]

68: Muller R, Musikic P. Related Articles, Links

Hemorheology in surgery--a review.
Angiology. 1987 Aug;38(8):581-92. Review.
PMID: 3307545 [PubMed - indexed for MEDLINE]

69: Yoshikawa Y, Sakata Y. Related Articles, Links

[alpha 2-Plasmin inhibitor]
Rinsho Byori. 1987 Apr;Spec No 70:210-6. Review. Japanese. No abstract available.
PMID: 3302391 [PubMed - indexed for MEDLINE]

70: Francis CW, Marder VJ. Related Articles, Links

Physiologic regulation and pathologic disorders of fibrinolysis.
Hum Pathol. 1987 Mar;18(3):263-74. Review.
PMID: 3546075 [PubMed - indexed for MEDLINE]

71: Collen D. Related Articles, Links

Molecular mechanisms of fibrinolysis and their application to fibrin-specific thrombolytic therapy.
J Cell Biochem. 1987 Feb;33(2):77-86. Review.
PMID: 3553213 [PubMed - indexed for MEDLINE]

72: Nilsson IM. Related Articles, Links

Coagulation and fibrinolysis.
Scand J Gastroenterol Suppl. 1987;137:11-8. Review.
PMID: 3321400 [PubMed - indexed for MEDLINE]

73: Verstraete M, Collen D. Related Articles, Links

Thrombolytic therapy in the eighties.
Blood. 1986 Jun;67(6):1529-41. Review. No abstract available.
PMID: 2423156 [PubMed - indexed for MEDLINE]

74: Francis CW, Marder VJ. Related Articles, Links

Concepts of clot lysis.
Annu Rev Med. 1986;37:187-204. Review.
PMID: 2939790 [PubMed - indexed for MEDLINE]

75: Collen D, Lijnen HR. Related Articles, Links

The fibrinolytic system in man.
Crit Rev Oncol Hematol. 1986;4(3):249-301. Review.
PMID: 2420482 [PubMed - indexed for MEDLINE]

76: Piliavskaia AS, Kudinov SA. Related Articles, Links

[Current views on structure and function of alpha2-antiplasmin.]
Ukr Biokhim Zh. 1985 Mar-Apr;57(2):93-103. Review. Russian.
PMID: 3159139 [PubMed - indexed for MEDLINE]

77: Mimuro J, Aoki N. Related Articles, Links

[Analysis of alpha 2-plasmin inhibitor]
Rinsho Byori. 1985 Feb;Spec No 61:97-105. Review. Japanese. No abstract available.
PMID: 2860263 [PubMed - indexed for MEDLINE]

78: Collen D, Lijnen HR. Related Articles, Links

New approaches to thrombolytic therapy.
Arteriosclerosis. 1984 Nov-Dec;4(6):579-85. Review.
PMID: 6439177 [PubMed - indexed for MEDLINE]

79: Kane KK. Related Articles, Links

Fibrinolysis--a review.
Ann Clin Lab Sci. 1984 Nov-Dec;14(6):443-9. Review.
PMID: 6239587 [PubMed - indexed for MEDLINE]

80: Veremeenko KN, Kizim AI. Related Articles, Links

[Molecular mechanisms of fibrinolysis and perspectives of thrombolytic therapy]
Vopr Med Khim. 1984 Sep-Oct;30(5):13-22. Review. Russian.
PMID: 6084892 [PubMed - indexed for MEDLINE]

81: Kluft C, Nieuwenhuis HK, Vellenga E. Related Articles, Links

Congenital deficiencies in alpha 2-antiplasmin.
Ric Clin Lab. 1984 Jul-Sep;14(3):507-13. Review. No abstract available.
PMID: 6240760 [PubMed - indexed for MEDLINE]

82: Lijnen HR, Collen D. Related Articles, Links

The pathophysiological role of fibrinolysis inhibitors.
Ric Clin Lab. 1984 Jul-Sep;14(3):499-505. Review. No abstract available.
PMID: 6084295 [PubMed - indexed for MEDLINE]

83: Marder VJ, Francis CW. Related Articles, Links

An assessment of regional versus systemic thrombolytic treatment of peripheral and coronary artery thrombosis.
Prog Hemost Thromb. 1984;7:325-56. Review. No abstract available.
PMID: 6241729 [PubMed - indexed for MEDLINE]

84: Lijnen HR. Related Articles, Links

Fibrinolysis: molecular mechanism and pathophysiological aspects.
Sangre (Barc). 1984;29(4-C):755-61. Review. No abstract available.
PMID: 6240123 [PubMed - indexed for MEDLINE]

85: Reiner AP, Bell WR. Related Articles, Links

h cb h g e e e fcg e ch b e

The fibrinolytic system in man.
Crit Rev Oncol Hematol. 1984;2(1):33-81. Review.
PMID: 6085039 [PubMed - indexed for MEDLINE]

86: Clemmensen I, Andersen RB. Related Articles, Links

The fibrinolytic system and its relation to inflammatory diseases.
Semin Arthritis Rheum. 1982 May;11(4):390-8. Review. No abstract available.
PMID: 6179164 [PubMed - indexed for MEDLINE]

87: Lijnen HR, Collen D. Related Articles, Links

Interaction of plasminogen activators and inhibitors with plasminogen and fibrin.
Semin Thromb Hemost. 1982 Jan;8(1):2-10. Review. No abstract available.
PMID: 6460318 [PubMed - indexed for MEDLINE]

88: Collen D. Related Articles, Links

On the regulation and control of fibrinolysis. Edward Kowalski Memorial Lecture.
Thromb Haemost. 1980 Jun 18;43(2):77-89. Review. No abstract available.
PMID: 6450468 [PubMed - indexed for MEDLINE]

89: Collen D. Related Articles, Links

Natural inhibitors of fibrinolysis.
J Clin Pathol Suppl (R Coll Pathol). 1980;14:24-30. Review. No abstract available.
PMID: 6448870 [PubMed - indexed for MEDLINE]

90: Mannucci PM. Related Articles, Links

Progress in fibrinolysis.
Ric Clin Lab. 1979 Jul-Sep;9(3):223-33. Review.
PMID: 161815 [PubMed - indexed for MEDLINE]

91: Vermylen JG, Chamone DA. Related Articles, Links

The role of the fibrinolytic system in thromboembolism.
Prog Cardiovasc Dis. 1979 Jan-Feb;21(4):255-66. Review.
PMID: 154121 [PubMed - indexed for MEDLINE]

92: Collen D, Wiman B. Related Articles, Links

Fast-acting plasmin inhibitor in human plasma.
Blood. 1978 Apr;51(4):563-9. Review.
PMID: 147116 [PubMed - indexed for MEDLINE]

Display Summary Show: 500 Sort Send to Text

Items 1-92 of 92 One page.

Write to the Help Desk
NCBI | NLM | NIH
Department of Health & Human Services
Freedom of Information Act | Disclaimer

Apr 6 2004 10:25:18

h cb h g e e e fcg e ch b e

NCBI

PubMed

National Library of Medicine NLM

Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Boo

Search PubMed for alpha-2-antiplasmin AND plasmin AND stroke Go Clear

Limits Preview/Index History Clipboard Details

About Entrez

Text Version

Entrez PubMed
Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby

Related Resources
Order Documents
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

Privacy Policy

Display Summary Show: 500 Sort Send to Text

Items 1-18 of 18 One page.

1: Nagai N, De Mol M, Van Hoef B, Verstreken M, Collen D. Related Articles, Links

Depletion of circulating alpha(2)-antiplasmin by intravenous plasmin or immunoneutralization reduces focal cerebral ischemic injury in the absence of arterial recanalization.
Blood. 2001 May 15;97(10):3086-92.
PMID: 11342434 [PubMed - indexed for MEDLINE]

2: van der Bom JG, Bots ML, Haverkate F, Meijer P, Hofman A, Kluft C, Grobbee DE. Related Articles, Links

Activation products of the haemostatic system in coronary, cerebrovascular and peripheral arterial disease.
Thromb Haemost. 2001 Feb;85(2):234-9.
PMID: 11246539 [PubMed - indexed for MEDLINE]

3: Lijnen HR. Related Articles, Links

Gene targeting in hemostasis. Alpha2-antiplasmin.
Front Biosci. 2001 Feb 1;6:D239-47. Review.
PMID: 11171550 [PubMed - indexed for MEDLINE]

4: Kataoka S, Hirose G, Hori A, Shirakawa T, Saigan T. Related Articles, Links

Activation of thrombosis and fibrinolysis following brain infarction.
J Neurol Sci. 2000 Dec 1;181(1-2):82-8.
PMID: 11099716 [PubMed - indexed for MEDLINE]

5: Dempfle CE, Argiriou S, Kucher K, Muller-Peltzer H, Rubsamen K, Heene DL. Related Articles, Links

Analysis of fibrin formation and proteolysis during intravenous administration of ancrod.
Blood. 2000 Oct 15;96(8):2793-802.
PMID: 11023513 [PubMed - indexed for MEDLINE]

6: Cote R, Wolfson C, Solymoss S, Mackey A, Leclerc JR, Simard D, Rouah F, Bourque F, Leger B. Related Articles, Links

Hemostatic markers in patients at risk of cerebral ischemia.
Stroke. 2000 Aug;31(8):1856-62.
PMID: 10926947 [PubMed - indexed for MEDLINE]

7: Nagai N, Vanlinthout I, Collen D. Related Articles, Links

Comparative effects of tissue plasminogen activator, streptokinase, and staphylokinase on cerebral ischemic infarction and pulmonary clot lysis in hamster models.
Circulation. 1999 Dec 21-28;100(25):2541-6.
PMID: 10604893 [PubMed - indexed for MEDLINE]

8: Feinberg WM, Macy E, Cornell ES, Nightingale SD, Pearce LA, Tracy RP, Bovill EG. Related Articles, Links

Plasmin-alpha2-antiplasmin complex in patients with atrial fibrillation. Stroke Prevention in Atrial Fibrillation Investigators.

h cb h g e e e fcg e ch b e

Thromb Haemost. 1999 Jul;82(1):100-3.
PMID: 10456461 [PubMed - indexed for MEDLINE]

9: Bots ML, Breteler MM, van Kooten F, Haverkate F, Meijer P, Koudstaal PJ, Grobbee DE, Kluft C. Related Articles, Links

Coagulation and fibrinolysis markers and risk of dementia. The Dutch Vascular Factors in Dementia Study.
Haemostasis. 1998 May-Aug;28(3-4):216-22.
PMID: 10420069 [PubMed - indexed for MEDLINE]

10: Misz M, Olah L, Kappelmayer J, Blasko G, Udvardy M, Fekete I, Csepany T, Ajzner E, Csiba L. Related Articles, Links

[Hemostatic abnormalities in ischemic stroke]
Orv Hetil. 1998 Oct 18;139(42):2503-7. Review. Hungarian.
PMID: 9810164 [PubMed - indexed for MEDLINE]

11: Yamazaki M, Uchiyama S, Maruyama S. Related Articles, Links

Alterations of haemostatic markers in various subtypes and phases of stroke.
Blood Coagul Fibrinolysis. 1993 Oct;4(5):707-12.
PMID: 7507362 [PubMed - indexed for MEDLINE]

12: Ono N, Koyama T, Suehiro A, Oku K, Fujikake K, Kakishita E. Related Articles, Links

Influence of atrial fibrillation on coagulo-fibrinolytic markers in patients with cerebral infarction.
Int Angiol. 1992 Oct-Dec;11(4):298-303.
PMID: 1284251 [PubMed - indexed for MEDLINE]

13: Ono N, Koyama T, Suehiro A, Oku K, Fujikake K, Kakishita E. Related Articles, Links

Clinical significance of new coagulation and fibrinolytic markers in ischemic stroke patients.
Stroke. 1991 Nov;22(11):1369-73.
PMID: 1836283 [PubMed - indexed for MEDLINE]

14: Iijima K, Fukuda C, Nakamura K. Related Articles, Links

Measurements of tissue factor-like activity in plasma of patients with DIC.
Thromb Res. 1991 Jan 1;61(1):29-38.
PMID: 1826974 [PubMed - indexed for MEDLINE]

15: Takano K, Yamaguchi T, Okada Y, Uchida K, Kisiel W, Kato H. Related Articles, Links

Hypercoagulability in acute ischemic stroke: analysis of the extrinsic coagulation reactions in plasma by a highly sensitive automated method.
Thromb Res. 1990 Jun 1;58(5):481-91.
PMID: 2368033 [PubMed - indexed for MEDLINE]

16: Iijima K. Related Articles, Links

[Hemostatic tests for the diagnosis of thrombosis. Activated coagulation and fibrinolytic factors. Detection of the protease/inhibitor complex]
Rinsho Byori. 1988 Jun;36(6):623-6. Japanese. No abstract available.
PMID: 2974894 [PubMed - indexed for MEDLINE]

17: Moriyama H, Minami S, Okamoto K, Tsuchiya T, Tsuji K, Higashi T Related Articles, Links

[Problems in measuring the activity of alpha 2-plasmin inhibitor in the urokinase therapy]
Rinsho Byori. 1987 Apr;35(4):465-7. Japanese. No abstract available.
PMID: 3613164 [PubMed - indexed for MEDLINE]

18: Takemoto Y, Fukuda A, Tanaka S, Tanabe J, Ikeda H, Fujii C, Kohama A. Related Articles, Links

h cb h g e e e fcg e ch b e

[Correlation between coagulation and fibrinolysis in patient with cerebrovascular accident at acute stage]
No To Shinkei. 1982 Oct;34(10):1007-10. Japanese.
PMID: 7150448 [PubMed - indexed for MEDLINE]

Write to the Help Desk
NCBI | NLM | NIH
Department of Health & Human Services
Freedom of Information Act | Disclaimer

Apr 6 2004 10:25:18

h cb h g e e e fcg e ch b e

NCBI PubMed National Library of Medicine NLM

Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Book

Search PubMed for miniplasmin Go Clear

Limits Preview/Index History Clipboard Details

About Entrez

Text Version

Entrez PubMed
Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby

Related Resources
Order Documents
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

Privacy Policy

Display Summary Show: 500 Sort Send to Text

Items 1-43 of 43 One page.

1: Kido H, Chen Y, Yamada H, Okumura Y. Related Articles, Links

[Host cellular proteases trigger the infectivity of the influenza virus in the airway and brain]
Nippon Yakurigaku Zasshi. 2003 Jul;122(1):45-53. Review. Japanese.
PMID: 12843572 [PubMed - indexed for MEDLINE]

2: Yao D, Kuwajima M, Kido H. Related Articles, Links

Pathologic mechanisms of influenza encephalitis with an abnormal expression of inflammatory cytokines and accumulation of mini-plasmin.
J Med Invest. 2003 Feb;50(1-2):1-8. Review.
PMID: 12630563 [PubMed - indexed for MEDLINE]

3: Murakami M, Towatari T, Ohuchi M, Shiota M, Akao M, Okumura Y, Parry MA, Kido H Related Articles, Links

Mini-plasmin found in the epithelial cells of bronchioles triggers infection by broad-spectrum influenza A viruses and Sendai virus.
Eur J Biochem. 2001 May;268(10):2847-55.
PMID: 11358500 [PubMed - indexed for MEDLINE]

4: Nagai N, De Mol M, Van Hoef B, Verstreken M, Collen D. Related Articles, Links

Depletion of circulating alpha(2)-antiplasmin by intravenous plasmin or immunoneutralization reduces focal cerebral ischemic injury in the absence of arterial recanalization.
Blood. 2001 May 15;97(10):3086-92.
PMID: 11342434 [PubMed - indexed for MEDLINE]

5: Rajamohan G, Dikshit KL. Related Articles, Links

Role of the N-terminal region of staphylokinase (SAK): evidence for the participation of the N-terminal region of SAK in the enzyme-substrate complex formation.
FEBS Lett. 2000 Jun 2;474(2-3):151-8.
PMID: 10838076 [PubMed - indexed for MEDLINE]

6: Kido H, Murakami M, Oba K, Chen Y, Towatari T. Related Articles, Links

Cellular proteinases trigger the infectivity of the influenza A and Sendai viruses.
Mol Cells. 1999 Jun 30;9(3):235-44. Review.
PMID: 10420980 [PubMed - indexed for MEDLINE]

7: Nagy Z, Kolev K, Csonka E, Vastag M, Machovich R. Related Articles, Links

Perturbation of the integrity of the blood-brain barrier by fibrinolytic enzymes.
Blood Coagul Fibrinolysis. 1998 Sep;9(6):471-8.
PMID: 9818996 [PubMed - indexed for MEDLINE]

8: Vastag M, Skopal J, Kramer J, Kolev K, Voko Z, Csonka E, Machovich R, Nagy Z. Related Articles, Links

Endothelial cells cultured from human brain microvessels produce complement proteins factor H, factor B, C1 inhibitor, and C4.
Immunobiology. 1998 Jul;199(1):5-13.
PMID: 9717663 [PubMed - indexed for MEDLINE]

9: Komorowicz E, Kolev K, Machovich R. Related Articles, Links

Fibrinolysis with des-kringle derivatives of plasmin and its modulation by plasma protease inhibitors.
Biochemistry. 1998 Jun 23;37(25):9112-8.
PMID: 9636057 [PubMed - indexed for MEDLINE]

10: Komorowicz E, Kolev K, Lerant I, Machovich R. Related Articles, Links

Flow rate-modulated dissolution of fibrin with clot-embedded and circulating proteases.
Circ Res. 1998 Jun 1;82(10):1102-8.
PMID: 9622163 [PubMed - indexed for MEDLINE]

11: Selim TE, Ghoneim HR, Uknis AB, Colman RW, DeLa Cadena RA. Related Articles, Links

High-molecular-mass and low-molecular-mass kininogens block plasmin-induced platelet aggregation by forming a complex with kringle 5 of plasminogen/plasmin.
Eur J Biochem. 1997 Dec 1;250(2):532-8.
PMID: 9428707 [PubMed - indexed for MEDLINE]

12: Duboscq C, Genoud V, Parborell MF, Kordich LC. Related Articles, Links

Impaired clot lysis by rt-PA catalyzed mini-plasminogen activation.
Thromb Res. 1997 Jun 15;86(6):505-13.
PMID: 9219330 [PubMed - indexed for MEDLINE]

13: Lijnen HR, Lasters I, Verstreken M, Collen D, Jespers L. Related Articles, Links

Screening panels of monoclonal antibodies using phage-displayed antigen.
Anal Biochem. 1997 Jun 1;248(2):211-5.
PMID: 9177746 [PubMed - indexed for MEDLINE]

14: Kolev K, Tenekedjiev K, Komorowicz E, Machovich R. Related Articles, Links

Functional evaluation of the structural features of proteases and their substrate in fibrin surface degradation.
J Biol Chem. 1997 May 23;272(21):13666-75.
PMID: 9153217 [PubMed - indexed for MEDLINE]

15: Nagy Z, Vastag M, Skopal J, Kolev K, Machovich R, Kramer J, Karadi I, Toth M. Related Articles, Links

Human brain microvessel endothelial cell culture as a model system to study vascular factors of ischemic brain.
Keio J Med. 1996 Sep;45(3):200-6.
PMID: 8897762 [PubMed - indexed for MEDLINE]

16: Kolev K, Komorowicz E, Owen WG, Machovich R. Related Articles, Links

Quantitative comparison of fibrin degradation with plasmin, miniplasmin, neurophil leukocyte elastase and cathepsin G.
Thromb Haemost. 1996 Jan;75(1):140-6.
PMID: 8713793 [PubMed - indexed for MEDLINE]

17: Christensen S, Sottrup-Jensen L, Christensen U. Related Articles, Links

Stopped-flow fluorescence kinetics of bovine alpha 2-antiplasmin inhibition of bovine midiplasmin.
Biochem J. 1995 Jan 1;305 (Pt 1):97-102.

h cb h g e e e fcg e ch b e

PMID: 7529997 [PubMed - indexed for MEDLINE]

18: Kolev K, Komorowicz E, Machovich R. Related Articles, Links

Heparin modulation of the fibrinolytic activity of plasmin, miniplasmin and neutrophil leukocyte elastase in the presence of plasma protease inhibitors.
Blood Coagul Fibrinolysis. 1994 Dec;5(6):905-11.
PMID: 7534486 [PubMed - indexed for MEDLINE]

19: Kolev K, Lerant I, Tenekejiev K, Machovich R. Related Articles, Links

Regulation of fibrinolytic activity of neutrophil leukocyte elastase, plasmin, and miniplasmin by plasma protease inhibitors.
J Biol Chem. 1994 Jun 24;269(25):17030-4.
PMID: 7516329 [PubMed - indexed for MEDLINE]

20: Teuten AJ, Cooper A, Smith RA, Dobson CM. Related Articles, Links

Binding of a substrate analogue can induce co-operative structure in the plasmin serine-proteinase domain.
Biochem J. 1993 Jul 15;293 (Pt 2):567-72.
PMID: 8343136 [PubMed - indexed for MEDLINE]

21: Anonick PK, Yoo JK, Webb DJ, Gonias SL. Related Articles, Links

Characterization of the antiplasmin activity of human thrombospondin-1 in solution.
Biochem J. 1993 Feb 1;289 (Pt 3):903-9.
PMID: 7679575 [PubMed - indexed for MEDLINE]

22: Metelitsyna IP, Petretskaia OS, Rodin SS, Andrianov SI. Related Articles, Links

[Thrombolytic effect of plasmin, miniplasmin and fibrinolysin in simulated intraocular hemorrhage]
Ukr Biokhim Zh. 1993 Jan-Feb;65(1):93-7. Russian.
PMID: 8351749 [PubMed - indexed for MEDLINE]

23: Anonick PK, Vasudevan J, Gonias SL. Related Articles, Links

Antifibrinolytic activities of alpha-N-acetyl-L-lysine methyl ester, epsilon-aminocaproic acid, and tranexamic acid. Importance of kringle interactions and active site inhibition.
Arterioscler Thromb. 1992 Jun;12(6):708-16.
PMID: 1375508 [PubMed - indexed for MEDLINE]

24: Andrianov SI, Makogonenko EM, Kudinov SA. Related Articles, Links

[Hydrolysis of polymeric fibrin by plasmin, miniplasmin, microplasmin and trypsin]
Ukr Biokhim Zh. 1992 May-Jun;64(3):14-20. Russian.
PMID: 1440960 [PubMed - indexed for MEDLINE]

25: Zolotareva EN, Grinenko TV, Skomorovskaia EV, Kudinov SA. Related Articles, Links

[The effect of arginine on hydrolysis of fibrinogen by plasmin and mini-plasmin]
Ukr Biokhim Zh. 1992 Jan-Feb;64(1):3-9. Russian.
PMID: 1387746 [PubMed - indexed for MEDLINE]

26: Shi GY, Wu DH, Wu HL. Related Articles, Links

Kringle domains and plasmin denaturation.
Biochem Biophys Res Commun. 1991 Jul 15;178(1):360-8.
PMID: 1829887 [PubMed - indexed for MEDLINE]

27: Anonick PK, Gonias SL. Related Articles, Links

h cb h g e e e fcg e ch b e

Soluble fibrin preparations inhibit the reaction of plasmin with alpha 2-macroglobulin. Comparison with alpha 2-antiplasmin and leupeptin.
Biochem J. 1991 Apr 1;275 (Pt 1):53-9.
PMID: 1708234 [PubMed - indexed for MEDLINE]

28: Lu H, Soria C, Li H, Soria J, Lijnen HR, Perrot JY, Caen JP. Related Articles, Links

Role of active center and lysine binding sites of plasmin in plasmin-induced platelet activation and disaggregation.
Thromb Haemost. 1991 Jan 23;65(1):67-72.
PMID: 1827215 [PubMed - indexed for MEDLINE]

29: Anonick PK, Wolf B, Gonias SL. Related Articles, Links

Regulation of plasmin, miniplasmin, and streptokinase-plasmin complex by alpha 2-antiplasmin, alpha 2-macroglobulin, and antithrombin III in the presence of heparin.
Thromb Res. 1990 Aug 1;59(3):449-62.
PMID: 1700488 [PubMed - indexed for MEDLINE]

30: Gonias SL, Young WW Jr, Fox JW. Related Articles, Links

Cleavage of recombinant murine interferon-gamma by plasmin and miniplasmin.
J Interferon Res. 1989 Oct;9(5):517-29.
PMID: 2529320 [PubMed - indexed for MEDLINE]

31: Geary WA, Gonias SL. Related Articles, Links

Inactivation of alpha 2-antiplasmin by limited reaction with cis-dichlorodiammineplatinum (II)
Biochim Biophys Acta. 1989 Jan 19;994(1):1-6. Erratum in: Biochim Biophys Acta 1989 May 1;995(3):301.
PMID: 2521201 [PubMed - indexed for MEDLINE]

32: Gonias SL, Figler NL. Related Articles, Links

Alpha 2-macroglobulin is the primary inhibitor of miniplasmin in vitro and in vivo in the mouse. Comparison with alpha 2-antiplasmin in simultaneous reaction experiments.
Biochem J. 1988 Oct 15;255(2):725-30.
PMID: 2462416 [PubMed - indexed for MEDLINE]

33: Sugiyama N, Iwamoto M, Abiko Y. Related Articles, Links

Effects of kringles derived from human plasminogen on fibrinolysis in vitro.
Thromb Res. 1987 Aug 15;47(4):459-68.
PMID: 2821651 [PubMed - indexed for MEDLINE]

34: Siostrzonek P, Jung M, Bailer H, Herold C, Dudczak R, Ehringer H, Schubiger A. Related Articles, Links

[Scintigraphic studies with J123 miniplasmin in patients with suspected deep venous thrombosis of the leg: comparison of the diagnostic value of J123 miniplasmin scintigraphy and Tc99m plasmin test]
Vasa. 1987;16(2):140-8. German. No abstract available.
PMID: 2955604 [PubMed - indexed for MEDLINE]

35: Kastrikina TF, Taran LD, Kudinov SA. Related Articles, Links

Kinetic characteristics of fibrinogen and fibrin hydrolysis by plasmin 1 and 2 and miniplasmin.
Thromb Res. 1986 Mar 1;41(5):681-8.
PMID: 2938303 [PubMed - indexed for MEDLINE]

36: Kastrikina TF, Taran LD, Kudinov SA. Related Articles, Links

[Hydrolytic properties of plasmin 1 and 2 and miniplasmin]
Dokl Akad Nauk SSSR. 1984 Sep-Oct;278(1):240-2. Russian. No abstract available.
PMID: 6237895 [PubMed - indexed for MEDLINE]

37: Morris JP, Castellino FJ. Related Articles, Links

The role of the lysine binding sites of human plasmin in the hydrolysis of human fibrinogen.
Biochim Biophys Acta. 1983 Apr 14;744(1):99-104.
PMID: 6219709 [PubMed - indexed for MEDLINE]

38: Kluft C, Traas DW, Jie AF, Hoegee-de Nobel E. Related Articles, Links

The suitability of various plasmin preparations for the functional assay of alpha 2-antiplasmin in plasma.
Thromb Haemost. 1982 Dec 27;48(3):320-4.
PMID: 6219471 [PubMed - indexed for MEDLINE]

39: Ney KA, Pizzo SV. Related Articles, Links

Fibrinolysis and fibrinogenolysis by Val442-plasmin.
Biochim Biophys Acta. 1982 Nov 9;708(2):218-24.
PMID: 6216916 [PubMed - indexed for MEDLINE]

40: Petersen LC, Clemmensen I. Related Articles, Links

Kinetics of plasmin inhibition in the presence of a synthetic tripeptide substrate. The reaction with pancreatic trypsin inhibitor and two forms of alpha 2-plasmin inhibitor.
Biochem J. 1981 Oct 1;199(1):121-7.
PMID: 6175313 [PubMed - indexed for MEDLINE]

41: Suenson E, Thorsen S. Related Articles, Links

Secondary-site binding of Glu-plasmin, Lys-plasmin and miniplasmin to fibrin.
Biochem J. 1981 Sep 1;197(3):619-28. No abstract available.
PMID: 6459779 [PubMed - indexed for MEDLINE]

42: Powell JR, Castellino FJ. Related Articles, Links

Activation of human neo-plasminogen-Val442 by urokinase and streptokinase and a kinetic characterization of neoplasmin-Val442.
J Biol Chem. 1980 Jun 10;255(11):5329-35. No abstract available.
PMID: 6445361 [PubMed - indexed for MEDLINE]

43: Christensen U, Sottrup-Jensen L, Magnusson S, Petersen TE, Clemmensen I Related Articles, Links

Enzymic properties of the neo-plasmin-Val-422 (miniplasmin).
Biochim Biophys Acta. 1979 Apr 12;567(2):472-81. No abstract available.
PMID: 36160 [PubMed - indexed for MEDLINE]

Display Summary Show: 500 Sort Send to Text

Items 1-43 of 43 One page.

Write to the Help Desk
NCBI | NLM | NIH
Department of Health & Human Services
Freedom of Information Act | Disclaimer

Apr 6 2004 10:25:18

h cb h g e e e fcg e ch b e

NCBI

PubMed

National Library of Medicine NLM

Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Boo

Search PubMed for microplasmin Go Clear

Limits Preview/Index History Clipboard Details

About Entrez

Text Version

Entrez PubMed
Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby

Related Resources
Order Documents
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

Privacy Policy

Display Summary Show: 500 Sort Send to Text

Items 1-27 of 27 One page.

1: Gandorfer A, Rohleder M, Sethi C, Eckle D, Welge-Lussen U, Kampik A, Luthert P, Charteris D. Related Articles, Links

Posterior vitreous detachment induced by microplasmin.
Invest Ophthalmol Vis Sci. 2004 Feb;45(2):641-7.
PMID: 14744909 [PubMed - indexed for MEDLINE]

2: Nagai N, Demarsin E, Van Hoef B, Wouters S, Cingolani D, Laroche Y, Collen D. Related Articles, Links

Recombinant human microplasmin: production and potential therapeutic properties.
J Thromb Haemost. 2003 Feb;1(2):307-13.
PMID: 12871505 [PubMed - indexed for MEDLINE]

3: Lapchak PA. Related Articles, Links

Development of thrombolytic therapy for stroke: a perspective.
Expert Opin Investig Drugs. 2002 Nov;11(11):1623-32. Review.
PMID: 12437508 [PubMed - indexed for MEDLINE]

4: Lapchak PA, Araujo DM, Pakola S, Song D, Wei J, Zivin JA. Related Articles, Links

Microplasmin: a novel thrombolytic that improves behavioral outcome after embolic strokes in rabbits.
Stroke. 2002 Sep;33(9):2279-84.
PMID: 12215599 [PubMed - indexed for MEDLINE]

5: Turner RB, Liu L, Sazonova IY, Reed GL. Related Articles, Links

Structural elements that govern the substrate specificity of the clot-dissolving enzyme plasmin.
J Biol Chem. 2002 Sep 6;277(36):33068-74. Epub 2002 Jun 21.
PMID: 12080056 [PubMed - indexed for MEDLINE]

6: Gladysheva IP, Sazonova IY, Chowdhry SA, Liu L, Turner RB, Reed GL. Related Articles, Links

Chimerism reveals a role for the streptokinase Beta -domain in nonproteolytic active site formation, substrate, and inhibitor interactions.
J Biol Chem. 2002 Jul 26;277(30):26846-51. Epub 2002 May 16.
PMID: 12016220 [PubMed - indexed for MEDLINE]

7: Wu DH, Shi GY, Chuang WJ, Hsu JM, Young KC, Chang CW, Wu HL. Related Articles, Links

Coiled coil region of streptokinase gamma-domain is essential for plasminogen activation.
J Biol Chem. 2001 May 4;276(18):15025-33. Epub 2001 Jan 31.
PMID: 11278293 [PubMed - indexed for MEDLINE]

8: Liu L, Sazonova IY, Turner RB, Chowdhry SA, Tsai J, Houng AK, Reed GL. Related Articles, Links

Leucine 42 in the fibronectin motif of streptokinase plays a critical role in fibrin-independent plasminogen activation.

h cb h g e e e fcg e ch b e

J Biol Chem. 2000 Dec 1;275(48):37686-91.
PMID: 10961989 [PubMed - indexed for MEDLINE]

9: Parry MA, Zhang XC, Bode I. Related Articles, Links

Molecular mechanisms of plasminogen activation: bacterial cofactors provide clues.
Trends Biochem Sci. 2000 Feb;25(2):53-9. Review.
PMID: 10664583 [PubMed - indexed for MEDLINE]

10: Rester U, Bode W, Moser M, Parry MA, Huber R, Auerswald E. Related Articles, Links

Structure of the complex of the antistasin-type inhibitor bdellastasin with trypsin and modelling of the bdellastasin-microplasmin system.
J Mol Biol. 1999 Oct 15;293(1):93-106.
PMID: 10512718 [PubMed - indexed for MEDLINE]

11: Jespers L, Lijnen HR, Vanwetswinkel S, Van Hoef B, Brepoels K, Collen D, De Maeyer M. Related Articles, Links

Guiding a docking mode by phage display: selection of correlated mutations at the staphylokinase-plasmin interface.
J Mol Biol. 1999 Jul 9;290(2):471-9.
PMID: 10390345 [PubMed - indexed for MEDLINE]

12: Jespers L, Vanwetswinkel S, Lijnen HR, Van Herzeele N, Van Hoef B, Demarsin E, Collen D, De Maeyer M. Related Articles, Links

Structural and functional basis of plasminogen activation by staphylokinase.
Thromb Haemost. 1999 Apr;81(4):479-85.
PMID: 10235424 [PubMed - indexed for MEDLINE]

13: Wang S, Reed GL, Hedstrom L. Related Articles, Links

Deletion of Ile1 changes the mechanism of streptokinase: evidence for the molecular sexuality hypothesis.
Biochemistry. 1999 Apr 20;38(16):5232-40.
PMID: 10213631 [PubMed - indexed for MEDLINE]

14: Stathakis P, Lay AJ, Fitzgerald M, Schlieker C, Matthias LJ, Hogg PJ. Related Articles, Links

Angiostatin formation involves disulfide bond reduction and proteolysis in kringle 5 of plasmin.
J Biol Chem. 1999 Mar 26;274(13):8910-6.
PMID: 10085135 [PubMed - indexed for MEDLINE]

15: Parry MA, Fernandez-Catalan C, Bergner A, Huber R, Hopfner KP, Schlott B, Guhrs KH, Bode W. Related Articles, Links

The ternary microplasmin-staphylokinase-microplasmin complex is a proteinase-cofactor-substrate complex in action.
Nat Struct Biol. 1998 Oct;5(10):917-23.
PMID: 9783753 [PubMed - indexed for MEDLINE]

16: Komorowicz E, Kolev K, Machovich R. Related Articles, Links

Fibrinolysis with des-kringle derivatives of plasmin and its modulation by plasma protease inhibitors.
Biochemistry. 1998 Jun 23;37(25):9112-8.
PMID: 9636057 [PubMed - indexed for MEDLINE]

17: de los Santos T, Wang J, Reich E. Related Articles, Links

Structure and function of microplasminogen: reconstitution of microplasminogen and microplasmin from isolated fragments.
Ciba Found Symp. 1997;212:66-76; discussion 76-83.

h cb h g e e e fcg e ch b e

PMID: 9524764 [PubMed - indexed for MEDLINE]

18: Kolev K, Tenekedjiev K, Komorowicz E, Machovich R. Related Articles, Links

Functional evaluation of the structural features of proteases and their substrate in fibrin surface degradation.
J Biol Chem. 1997 May 23;272(21):13666-75.
PMID: 9153217 [PubMed - indexed for MEDLINE]

19: Wang J, Reich E. Related Articles, Links

Structure and function of microplasminogen: II. Determinants of activation by urokinase and by the bacterial activator streptokinase.
Protein Sci. 1995 Sep;4(9):1768-79.
PMID: 8528075 [PubMed - indexed for MEDLINE]

20: Chang WC, Shi GY, Chow YH, Chang LC, Hau JS, Lin MT, Jen CJ, Wing LY, Wu HL. Related Articles, Links

Human plasmin induces a receptor-mediated arachidonate release coupled with G proteins in endothelial cells.
Am J Physiol. 1993 Feb;264(2 Pt 1):C271-81.
PMID: 8383426 [PubMed - indexed for MEDLINE]

21: Shi GY, Hau JS, Wang SJ, Wu IS, Chang BI, Lin MT, Chow YH, Chang WC, Wing LY, Jen CJ, et al. Related Articles, Links

Plasmin and the regulation of tissue-type plasminogen activator biosynthesis in human endothelial cells.
J Biol Chem. 1992 Sep 25;267(27):19363-8.
PMID: 1388168 [PubMed - indexed for MEDLINE]

22: Andrianov SI, Makogonenko EM, Kudinov SA. Related Articles, Links

[Hydrolysis of polymeric fibrin by plasmin, miniplasmin, microplasmin and trypsin]
Ukr Biokhim Zh. 1992 May-Jun;64(3):14-20. Russian.
PMID: 1440960 [PubMed - indexed for MEDLINE]

23: Shi GY, Wu DH, Wu HL. Related Articles, Links

Kringle domains and plasmin denaturation.
Biochem Biophys Res Commun. 1991 Jul 15;178(1):360-8.
PMID: 1829887 [PubMed - indexed for MEDLINE]

24: Shi GY, Change BI, Wu DH, Ha YM, Wu HL. Related Articles, Links

Activation of human and bovine plasminogens by the microplasmin and streptokinase complex.
Thromb Res. 1990 May 1;58(3):317-29.
PMID: 2141198 [PubMed - indexed for MEDLINE]

25: Shi GY, Wu HL. Related Articles, Links

Isolation and characterization of microplasminogen. A low molecular weight form of plasminogen.
J Biol Chem. 1988 Nov 15;263(32):17071-5.
PMID: 2972717 [PubMed - indexed for MEDLINE]

26: Wu HL, Shi GY, Wohl RC, Bender ML. Related Articles, Links

Structure and formation of microplasmin.
Proc Natl Acad Sci U S A. 1987 Dec;84(24):8793-5.
PMID: 2962191 [PubMed - indexed for MEDLINE]

27: Wu HL, Shi GY, Bender ML. Related Articles, Links

Preparation and purification of microplasmin.

Proc Natl Acad Sci U S A. 1987 Dec;84(23):8292-5.
PMID: 2960974 [PubMed - indexed for MEDLINE]

Write to the Help Desk
NCBI | NLM | NIH
Department of Health & Human Services
Freedom of Information Act | Disclaimer

Apr 6 2004 10:25:18

h cb h g e e e fcg e ch b e

```
Connecting via Winsock to STN
Welcome to STN International!  Enter x:x
* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *
* * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *



FILE 'HOME' ENTERED AT 11:59:44 ON 12 APR 2004

=> file BIOSCIENCE
FILE 'ADISCTI' ENTERED AT 11:59:53 ON 12 APR 2004
COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'ADISINSIGHT' ENTERED AT 11:59:53 ON 12 APR 2004
COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'ADISNEWS' ENTERED AT 11:59:53 ON 12 APR 2004
COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'AGRICOLA' ENTERED AT 11:59:53 ON 12 APR 2004

FILE 'ANABSTR' ENTERED AT 11:59:53 ON 12 APR 2004
COPYRIGHT (c) 2004 THE ROYAL SOCIETY OF CHEMISTRY (RSC)

FILE 'AQUASCI' ENTERED AT 11:59:53 ON 12 APR 2004
COPYRIGHT 2004 FAO (On behalf of the ASFA Advisory Board). All rights reserved.

FILE 'BIOBUSINESS' ENTERED AT 11:59:53 ON 12 APR 2004
COPYRIGHT (C) 2004 Biological Abstracts, Inc. (BIOSIS)

FILE 'BIOCOMMERCE' ENTERED AT 11:59:53 ON 12 APR 2004
COPYRIGHT (C) 2004 BioCommerce Data Ltd. Richmond Surrey, United Kingdom. All rights reserved

FILE 'BIOSIS' ENTERED AT 11:59:53 ON 12 APR 2004
COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'BIOTECHABS' ACCESS NOT AUTHORIZED

FILE 'BIOTECHDS' ENTERED AT 11:59:53 ON 12 APR 2004
COPYRIGHT (C) 2004 THOMSON DERWENT AND INSTITUTE FOR SCIENTIFIC INFORMATION

FILE 'BIOTECHNO' ENTERED AT 11:59:53 ON 12 APR 2004
COPYRIGHT (C) 2004 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'CABA' ENTERED AT 11:59:53 ON 12 APR 2004
COPYRIGHT (C) 2004 CAB INTERNATIONAL (CABI)

FILE 'CANCERLIT' ENTERED AT 11:59:53 ON 12 APR 2004

FILE 'CAPLUS' ENTERED AT 11:59:53 ON 12 APR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CEABA-VTB' ENTERED AT 11:59:53 ON 12 APR 2004
COPYRIGHT (c) 2004 DECHEMA eV

FILE 'CEN' ENTERED AT 11:59:53 ON 12 APR 2004
COPYRIGHT (C) 2004 American Chemical Society (ACS)

FILE 'CIN' ENTERED AT 11:59:53 ON 12 APR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

FILE 'CONFSCI' ENTERED AT 11:59:53 ON 12 APR 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'CROPB' ENTERED AT 11:59:53 ON 12 APR 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'CROPU' ENTERED AT 11:59:53 ON 12 APR 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'DISSABS' ENTERED AT 11:59:53 ON 12 APR 2004
```

COPYRIGHT (C) 2004 ProQuest Information and Learning Company; All Rights Reserved.

FILE 'DDFB' ACCESS NOT AUTHORIZED

FILE 'DDFU' ACCESS NOT AUTHORIZED

FILE 'DGENE' ENTERED AT 11:59:53 ON 12 APR 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'DRUGB' ENTERED AT 11:59:53 ON 12 APR 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'DRUGMONOG2' ENTERED AT 11:59:53 ON 12 APR 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'IMSDRUGNEWS' ENTERED AT 11:59:53 ON 12 APR 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'DRUGU' ENTERED AT 11:59:53 ON 12 APR 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'IMSRESEARCH' ENTERED AT 11:59:53 ON 12 APR 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'EMBAL' ENTERED AT 11:59:53 ON 12 APR 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'EMBASE' ENTERED AT 11:59:53 ON 12 APR 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'ESBIOBASE' ENTERED AT 11:59:53 ON 12 APR 2004
COPYRIGHT (C) 2004 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'FEDRIP' ENTERED AT 11:59:53 ON 12 APR 2004

FILE 'FOMAD' ENTERED AT 11:59:53 ON 12 APR 2004
COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FOREGE' ENTERED AT 11:59:53 ON 12 APR 2004
COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FROSTI' ENTERED AT 11:59:53 ON 12 APR 2004
COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FSTA' ENTERED AT 11:59:53 ON 12 APR 2004
COPYRIGHT (C) 2004 International Food Information Service

FILE 'GENBANK' ENTERED AT 11:59:53 ON 12 APR 2004

FILE 'HEALSAFE' ENTERED AT 11:59:53 ON 12 APR 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'IFIPAT' ENTERED AT 11:59:53 ON 12 APR 2004
COPYRIGHT (C) 2004 IFI CLAIMS(R) Patent Services (IFI)

FILE 'IMSPRODUCT' ENTERED AT 11:59:53 ON 12 APR 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'JICST-EPLUS' ENTERED AT 11:59:53 ON 12 APR 2004
COPYRIGHT (C) 2004 Japan Science and Technology Agency (JST)

FILE 'KOSMET' ENTERED AT 11:59:53 ON 12 APR 2004
COPYRIGHT (C) 2004 International Federation of the Societies of Cosmetics Chemists

FILE 'LIFESCI' ENTERED AT 11:59:53 ON 12 APR 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'MEDICONF' ENTERED AT 11:59:53 ON 12 APR 2004
COPYRIGHT (c) 2004 FAIRBASE Datenbank GmbH, Hannover, Germany

FILE 'MEDLINE' ENTERED AT 11:59:53 ON 12 APR 2004

FILE 'NIOSHTIC' ENTERED AT 11:59:53 ON 12 APR 2004
COPYRIGHT (C) 2004 U.S. Secretary of Commerce on Behalf of the U.S. Government

FILE 'NTIS' ENTERED AT 11:59:53 ON 12 APR 2004

Compiled and distributed by the NTIS, U.S. Department of Commerce.
It contains copyrighted material.
All rights reserved. (2004)

FILE 'NUTRACEUT' ENTERED AT 11:59:53 ON 12 APR 2004
Copyright 2004 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'OCEAN' ENTERED AT 11:59:53 ON 12 APR 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'PASCAL' ENTERED AT 11:59:53 ON 12 APR 2004
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2004 INIST-CNRS. All rights reserved.

FILE 'PCTGEN' ENTERED AT 11:59:53 ON 12 APR 2004
COPYRIGHT (C) 2004 WIPO

FILE 'PHAR' ENTERED AT 11:59:53 ON 12 APR 2004
COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PHARMAML' ENTERED AT 11:59:53 ON 12 APR 2004
Copyright 2004 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'PHIC' ENTERED AT 11:59:53 ON 12 APR 2004
COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PHIN' ENTERED AT 11:59:53 ON 12 APR 2004
COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PROMT' ENTERED AT 11:59:53 ON 12 APR 2004
COPYRIGHT (C) 2004 Gale Group. All rights reserved.

FILE 'RDISCLOSURE' ENTERED AT 11:59:53 ON 12 APR 2004
COPYRIGHT (C) 2004 Kenneth Mason Publications Ltd.

FILE 'SCISEARCH' ENTERED AT 11:59:53 ON 12 APR 2004
COPYRIGHT 2004 THOMSON ISI

FILE 'SYNTHLINE' ENTERED AT 11:59:53 ON 12 APR 2004
COPYRIGHT (C) 2004 Prous Science

FILE 'TOXCENTER' ENTERED AT 11:59:53 ON 12 APR 2004
COPYRIGHT (C) 2004 ACS

FILE 'USPATFULL' ENTERED AT 11:59:53 ON 12 APR 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 11:59:53 ON 12 APR 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'VETB' ENTERED AT 11:59:53 ON 12 APR 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'VETU' ENTERED AT 11:59:53 ON 12 APR 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'WPIDS' ENTERED AT 11:59:53 ON 12 APR 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'WPINDEX' ACCESS NOT AUTHORIZED

=> S plasmin OR miniplasmin OR microplasmin
 33 FILES SEARCHED...
L1 76775 PLASMIN OR MINIPLASMIN OR MICROPLASMIN

=> S L1 AND alpha-2-antiplasmin
 18 FILES SEARCHED...
 30 FILES SEARCHED...
 49 FILES SEARCHED...
L2 4556 L1 AND ALPHA-2-ANTIPLASMIN

=> DUP REM L2
DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT, ADISNEWS, BIOCOMMERCE, DGENE,
DRUGMONOG2, IMSRESEARCH, FEDRIP, FOREGE, GENBANK, IMSPRODUCT, KOSMET,

```
MEDICONF, NUTRACEUT, PCTGEN, PHAR, PHARMAML, RDISCLOSURE, SYNTHLINE'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING IS APPROXIMATELY  36% COMPLETE FOR L2
PROCESSING IS APPROXIMATELY  64% COMPLETE FOR L2
PROCESSING IS APPROXIMATELY  89% COMPLETE FOR L2
PROCESSING COMPLETED FOR L2
L3          2162 DUP REM L2 (2394 DUPLICATES REMOVED)

=> S L3 AND stroke
  26 FILES SEARCHED...
  56 FILES SEARCHED...
L4          268 L3 AND STROKE

=> D L4 1-268

L4   ANSWER 1 OF 268  ADISINSIGHT COPYRIGHT (C) 2004  Adis Data Information BV
     on STN
ACCESSION NUMBER:       2001:679  ADISINSIGHT
SOURCE:                 Adis R&D Insight
DOCUMENT NO:            015809
CHANGE DATE:            Apr 1, 2004
GENERIC NAME:             ***Microplasmin***
SYNONYM:                  ***microPli; Alpha 2 antiplasmin inhibitors research***
  ***                        programme -ThromboGenics; Recombinant human***
  ***                        microplasmin; Recombinant microplasmin;***
  ***                        Research-programme:alpha-2-antiplasmin-inhibitors-***
  ***                        ThromboGenics***
MOLECULAR FORMULA:Unspecified
STRUCTURE:
     STRUCTURE DIAGRAM IS NOT AVAILABLE

EPHMRA ATC CODE:        B1 Antithrombotic Agents; S1X Other Ophthalmologicals
WHO ATC CODE:           B01A Antithrombotic Agents; S01X Other Ophthalmologicals
HIGHEST DEV. PHASE:     Phase I

COMPANY INFORMATION
ORIGINATOR:             University of Leuven (Belgium)
PARENT:                 University of Leuven
LICENSEE:               ThromboGenics
OTHER:                  Thromb-X

OTHER SOURCES:          809021353
WORD COUNT:             448

L4   ANSWER 2 OF 268  BIOSIS  COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN   2003:356871  BIOSIS
DN   PREV200300356871
TI   Characterization of the Kinetics of  ***Plasmin***  -Mediated Fibrin
     Degradation; on the Relationship between Plasma Fibrinogen and Thrombotic
     Complications.
AU   Stewart, Ronald J. [Reprint Author]; Lipson, Sara M. [Reprint Author];
     Nesheim, Michael E. [Reprint Author]
CS   Biochemistry and Medicine, Queen's University, Kingston, ON, Canada
SO   Blood, (November 16 2002) Vol. 100, No. 11, pp. Abstract No. 2737. print.
     Meeting Info.: 44th Annual Meeting of the American Society of Hematology.
     Philadelphia, PA, USA. December 06-10, 2002. American Society of
     Hematology.
     CODEN: BLOOAW. ISSN: 0006-4971.
DT   Conference; (Meeting)
     Conference; Abstract; (Meeting Abstract)
     Conference; (Meeting Poster)
LA   English
ED   Entered STN: 6 Aug 2003
     Last Updated on STN: 6 Aug 2003

L4   ANSWER 3 OF 268  BIOSIS  COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN   2002:198710  BIOSIS
DN   PREV200200198710
TI   Structural elements that govern the substrate specificity of the clot
     dissolving enzyme  ***plasmin***  .
AU   Turner, Ryan B. [Reprint author]; Liu, Lin [Reprint author]; Sazonova,
     Irina Y. [Reprint author]; Reed, Guy L. [Reprint author]
CS   Cardiovascular and Nutrition, Harvard School of Public Health, Boston, MA,
     USA
SO   Blood, (November 16, 2001) Vol. 98, No. 11 Part 1, pp. 255a. print.
     Meeting Info.: 43rd Annual Meeting of the American Society of Hematology,
```

Part 1. Orlando, Florida, USA. December 07-11, 2001. American Society of Hematology.
CODEN: BLOOAW. ISSN: 0006-4971.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
Conference; (Meeting Poster)
LA English
ED Entered STN: 20 Mar 2002
Last Updated on STN: 20 Mar 2002

L4 ANSWER 4 OF 268 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 2001:536608 BIOSIS
DN PREV200100536608
TI Reduction of focal cerebral ischemic injury by depletion of circulating alpha2-antiplasmin.
AU Nagai, N. [Reprint author]; Collen, D. [Reprint author]
CS Ctr. Molec and Vascular Biol, Katholic Univ Leuven, Leuven, Belgium
SO Society for Neuroscience Abstracts, (2001) Vol. 27, No. 1, pp. 1154. print.
Meeting Info.: 31st Annual Meeting of the Society for Neuroscience. San Diego, California, USA. November 10-15, 2001.
ISSN: 0190-5295.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 14 Nov 2001
Last Updated on STN: 25 Feb 2002

L4 ANSWER 5 OF 268 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 2001:275395 BIOSIS
DN PREV200100275395
TI Depletion of circulating alpha2-antiplasmin by intravenous ***plasmin*** or immunoneutralization reduces focal cerebral ischemic injury in the absence of arterial recanalization.
AU Nagai, Nobus; De Mol, Maria; Van Hoef, Berthe; Verstreken, Maria; Collen, Desire [Reprint author]
CS Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, University of Leuven, Herestraat 49, Campus Gasthuisberg O and N, B-3000, Leuven, Belgium
desire.collen@med.kuleuven.ac.be
SO Blood, (May 15, 2001) Vol. 97, No. 10, pp. 3086-3092. print.
CODEN: BLOOAW. ISSN: 0006-4971.
DT Article
LA English
ED Entered STN: 6 Jun 2001
Last Updated on STN: 19 Feb 2002

L4 ANSWER 6 OF 268 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 2001:245674 BIOSIS
DN PREV200100245674
TI Gene targeting in hemostasis. Alpha2-antiplasmin.
AU Lijnen, H. R. [Reprint author]
CS Center for Molecular and Vascular Biology, University of Leuven, Herestraat 49, Campus Gasthuisberg, O and N, B-3000, Leuven, Belgium
SO Frontiers in Bioscience, (Feb. 1, 2001) Vol. 6, No. Cited April 17, 2001, pp. d239-247. http://www.bioscience.org/2001/v6/d/lijnen/fulltext.htm. cited April 24, 2001. http://www.bioscience.org/. online.
DT Article
General Review; (Literature Review)
LA English
ED Entered STN: 23 May 2001
Last Updated on STN: 19 Feb 2002

L4 ANSWER 7 OF 268 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 2001:224287 BIOSIS
DN PREV200100224287
TI Concentration of ***plasmin*** -alfa 2 antiplasmin complexes and other fibrynolitic parameters in ischemic ***stroke*** .
AU Dzianott-Pabijan, D. [Reprint author]; Maslowska, B.; Lewandowska, M.; Kotschy, M.
CS Department of Neurology, Biziel's Hospital in Bydgoszcz, Bydgoszcz, Poland
SO European Journal of Neurology, (November, 2000) Vol. 7, No. Supplement 3, pp. 74. print.
Meeting Info.: 5th Congress of the European Federation of Neurological Societies. Copenhagen, Denmark. October 14-18, 2000. European Federation of Neurological Societies.

ISSN: 1351-5101.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 9 May 2001
Last Updated on STN: 18 Feb 2002

L4 ANSWER 8 OF 268 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 2001:215522 BIOSIS
DN PREV200100215522
TI Composition and method for enhancing fibrinolysis.
AU Reed, Guy L. [Inventor, Reprint author]; Harris, Linda [Inventor]; Bajorath, Jurgen [Inventor]; Matsueda, Gary [Inventor]; Hsu, Mei-Yin [Inventor]; Novotny, Jiri [Inventor]
CS Winchester, MA, USA
ASSIGNEE: General Hospital Corporation; President and Fellows of Harvard College; Bristol-Myers Squibb Company
PI US 6114506 September 05, 2000
SO Official Gazette of the United States Patent and Trademark Office Patents, (Sep. 5, 2000) Vol. 1238, No. 1. e-file.
CODEN: OGUPE7. ISSN: 0098-1133.
DT Patent
LA English
ED Entered STN: 2 May 2001
Last Updated on STN: 18 Feb 2002

L4 ANSWER 9 OF 268 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 1999:370843 BIOSIS
DN PREV199900370843
TI ***Plasmin*** -alpha2-antiplasmin complex in patients with atrial fibrillation.
AU Feinberg, William M.; Macy, Elizabeth; Cornell, Elaine S.; Nightingale, Sarah D.; Pearce, Lesly A.; Tracy, Russell P.; Bovill, Edwin G. [Reprint author]
CS Department of Pathology, University of Vermont, College of Medicine, Burlington, VT, 05405, USA
SO Thrombosis and Haemostasis, (July, 1999) Vol. 82, No. 1, pp. 100-103. print.
CODEN: THHADQ. ISSN: 0340-6245.
DT Article
LA English
ED Entered STN: 9 Sep 1999
Last Updated on STN: 9 Sep 1999

L4 ANSWER 10 OF 268 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 1999:11589 BIOSIS
DN PREV199900011589
TI Haemostatic abnormalities in ischaemic ***stroke*** .
AU Misz, Maria [Reprint author]; Olah, Laszlo; Kappelmayer, Janos; Blasko, Gyorgy; Udvardy, Miklos; Fekete, Istvan; Csepany, Tunde; Ajzner, Eva; Csiba, Laszlo
CS Debreceni, Nagyerdei krt.98. 4012, Debrecen, Hungary
SO Orvosi Hetilap, (Oct. 18, 1998) Vol. 139, No. 42, pp. 2503-2507. print.
CODEN: ORHEAG. ISSN: 0030-6002.
DT Article
LA Hungarian
ED Entered STN: 11 Jan 1999
Last Updated on STN: 11 Jan 1999

L4 ANSWER 11 OF 268 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 1997:138001 BIOSIS
DN PREV199799437204
TI ***Plasmin*** - ***alpha*** - ***2*** - ***antiplasmin*** levels in patients with atrial fibrillation.
AU Feinberg, William M. [Reprint author]; Macy, Elizabeth M.; Nightingale, Sarah D.; Cornell, Elaine S.; Pearce, Lesly A.; Bovill, Edwin G.
CS Dep. Neurol., Univ. Arizona Health Sci. Cent., Tucson, AZ, USA
SO Stroke, (1997) Vol. 28, No. 1, pp. 242.
Meeting Info.: 22nd International Joint Conference on Stroke and Cerebral Circulation. Anaheim, California, USA. February 6-8, 1997.
CODEN: SJCCA7. ISSN: 0039-2499.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 2 Apr 1997
Last Updated on STN: 2 Apr 1997

L4 ANSWER 12 OF 268 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 1997:60784 BIOSIS
DN PREV199799359987
TI Activation of coagulation and fibrinolysis in heatstroke.
AU Bouchama, Abderrezak [Reprint author]; Bridey, Francoise; Hammani, Muhammad M.; Lacombe, Catherine; Al-Shail, Essam; Al-Ohali, Yazid; Combe, Frederic; Al-Sedairy, Sultan; De Prost, Dominique
CS Dep. Med., King Faisal Specialist Hosp. Res. Cent., Riyadh 11211, Saudi Arabia
SO Thrombosis and Haemostasis, (1996) Vol. 76, No. 6, pp. 909-915.
CODEN: THHADQ. ISSN: 0340-6245.
DT Article
LA English
ED Entered STN: 11 Feb 1997
Last Updated on STN: 11 Feb 1997

L4 ANSWER 13 OF 268 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 1994:72612 BIOSIS
DN PREV199497085612
TI Alterations of haemostatic markers in various subtypes and phases of ***stroke*** .
AU Yamazaki, M. [Reprint author]; Uchiyama, S.; Maruyama, S.
CS Dep. Neurol., Neurol. Inst., Tokyo Women's Med. Coll., 8-1 Kawada-cho, Shinjuku-ku, Tokyo 162, Japan
SO Blood Coagulation and Fibrinolysis, (1993) Vol. 4, No. 5, pp. 707-712.
CODEN: BLFIE7. ISSN: 0957-5235.
DT Article
LA English
ED Entered STN: 22 Feb 1994
Last Updated on STN: 27 Apr 1994

L4 ANSWER 14 OF 268 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 1993:271199 BIOSIS
DN PREV199396001424
TI Influence of atrial fibrillation on coagulo-fibrinolytic markers in patients with cerebral infarction.
AU Ono, Noriko; Koyama, Tetsuji; Suehiro, Akira; Oku, Ken-Ichi; Fujikake, Kunihiko; Kakishita, Eizo
CS II Dep. Intern. Med., Hyogo College Med., 1-1 Mukogawa-Cho, Nishinomiya-Shi, Hyogo 663, Japan
SO International Angiology, (1992) Vol. 11, No. 4, pp. 298-303.
ISSN: 0392-9590.
DT Article
LA English
ED Entered STN: 9 Jun 1993
Last Updated on STN: 3 Jan 1995

L4 ANSWER 15 OF 268 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 1992:45299 BIOSIS
DN PREV199293025274; BA93:25274
TI CLINICAL SIGNIFICANCE OF NEW COAGULATION AND FIBRINOLYTIC MARKERS IN ISCHEMIC ***STROKE*** PATIENTS.
AU ONO N [Reprint author]; KOYAMA T; SUEHIRO A; OKU K-I; FUJIKAKE K; KAKISHITA E
CS SECONE DEP INTERNAL MED, HYOGO COLL MED, 1-1 MUKOGAWACKO, JPN
SO Stroke, (1991) Vol. 22, No. 11, pp. 1369-1373.
CODEN: SJCCA7. ISSN: 0039-2499.
DT Article
FS BA
LA ENGLISH
ED Entered STN: 13 Jan 1992
Last Updated on STN: 13 Jan 1992

L4 ANSWER 16 OF 268 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 1990:351457 BIOSIS
DN PREV199090048036; BA90:48036
TI HYPERCOAGULABILITY IN ACUTE ISCHEMIC ***STROKE*** ANALYSIS OF THE EXTRINSIC COAGULATION REACTIONS IN PLASMA BY A HIGHLY SENSITIVE AUTOMATED METHOD.
AU TAKANO K [Reprint author]; YAMAGUCHI T; OKADA Y; UCHIDA K; KISIEL W; KATO H
CS RES INST, OSAKA, JAPAN
SO Thrombosis Research, (1990) Vol. 58, No. 5, pp. 481-492.
CODEN: THBRAA. ISSN: 0049-3848.
DT Article

FS BA
LA ENGLISH
ED Entered STN: 7 Aug 1990
Last Updated on STN: 7 Aug 1990

L4 ANSWER 17 OF 268 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 1982:308390 BIOSIS
DN PREV198274080870; BA74:80870
TI HEMOSTASIS IN ISCHEMIC CEREBRO VASCULAR DISEASE 3. ABNORMALITIES IN VASCULAR PLASMINOGEN ACTIVATORS ANTI ACTIVATORS AND ALPHA-2 ANTI ***PLASMIN*** .
AU METTINGER K L [Reprint author]; EGBERG N
CS DEP NEUROL, KAROLINSKA INST, KAROLINSKA HOSP, S-104 01 STOCKHOLM, SWEDEN
SO Thrombosis Research, (1982) Vol. 26, No. 3, pp. 203-210.
CODEN: THBRAA. ISSN: 0049-3848.
DT Article
FS BA
LA ENGLISH

L4 ANSWER 18 OF 268 BIOTECHDS COPYRIGHT 2004 THOMSON DERWENT/ISI on STN
AN 2003-18348 BIOTECHDS
TI New immunogenic molecule that binds circulating or fibrin crosslinked ***alpha*** - ***2*** ***antiplasmins*** , useful for treating pulmonary embolism, myocardial infarction, thrombosis, ***stroke*** , coronary syndrome, or angina pectoris in a patient; monoclonal antibody, chimeric antibody and humanized antibody production by hybridoma cell culture for use in therapy
AU REED G L
PA GEN HOSPITAL CORP
PI US 2003031664 13 Feb 2003
AI US 2001-977283 16 Oct 2001
PRAI US 2001-977283 16 Oct 2001; US 1996-26356 20 Sep 1996
DT Patent
LA English
OS WPI: 2003-466215 [44]

L4 ANSWER 19 OF 268 BIOTECHNO COPYRIGHT 2004 Elsevier Science B.V. on STN
AN 2003:37070129 BIOTECHNO
TI In vitro simulation of therapeutic plasmatic fibrinolysis
AU Stief T.W.; Bunder R.; Richter A.; Maisch B.; Renz H.; Fareed J.
CS Dr. T.W. Stief, Department of Clinical Chemistry, Hosp. of Philipps-University Marburg, D-35033 Marburg, Germany.
E-mail: thstief@med.uni-marburg.de
SO Clinical and Applied Thrombosis/Hemostasis, (2003), 9/3 (211-220), 22 reference(s)
CODEN: CATHF0 ISSN: 1076-0296
DT Journal; Article
CY United States
LA English
SL English

L4 ANSWER 20 OF 268 BIOTECHNO COPYRIGHT 2004 Elsevier Science B.V. on STN
AN 2000:30770375 BIOTECHNO
TI Analysis of fibrin formation and proteolysis during intravenous administration of ancrod
AU Dempfle C.-E.; Argiriou S.; Kucher K.; Muller-Peltzer H.; Rubsamen K.; Heene D.L.
CS C.-E. Dempfle, Universitatsklinikum Mannheim, I. Med. Klinik, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany.
E-mail: dempfle@verw.ma.uni-heidelberg.de
SO Blood, (15 OCT 2000), 96/8 (2793-2802), 32 reference(s)
CODEN: BLOOAW ISSN: 0006-4971
DT Journal; Article
CY United States
LA English
SL English

L4 ANSWER 21 OF 268 BIOTECHNO COPYRIGHT 2004 Elsevier Science B.V. on STN
AN 1997:27488851 BIOTECHNO
TI Evaluation of thrombolytic agents
AU Bell W.R. Jr.; Markland F.S. Jr.
CS Prof. W.R. Bell Jr., Department of Medicine, Johns Hopkins Univ. School Medicine, Blalock Building, 600 North Wolfe Street, Baltimore, MD 21287-4928, United States.
SO Drugs, (1997), 54/SUPPL. 3 (11-17), 0 reference(s)
CODEN: DRUGAY ISSN: 0012-6667

DT Journal; Conference Article
CY New Zealand
LA English
SL English

L4 ANSWER 22 OF 268 BIOTECHNO COPYRIGHT 2004 Elsevier Science B.V. on STN
AN 1995:25109075 BIOTECHNO
TI Changes in coagulation and fibrinolytic system after local intra-arterial thrombolysis for acute ischemic ***stroke***
AU Ueda T.; Hatakeyama T.; Sakaki S.; Ohta S.; Kumon Y.; Uraoka T.
CS Department of Neurological Surgery, Ehime University School of Medicine, Shingenobu-cho,Onsen-gun, Ehime 791-02, Japan.
SO Neurologia Medico-Chirurgica, (1995), 35/3 (136-143)
CODEN: NMCHBN ISSN: 0387-2572
DT Journal; Article
CY Japan
LA English
SL English

L4 ANSWER 23 OF 268 BIOTECHNO COPYRIGHT 2004 Elsevier Science B.V. on STN
AN 1993:23163552 BIOTECHNO
TI Coagulation-fibrinolysis system in poststroke patients receiving antiplatelet medication
AU Tohgi H.; Takahashi H.; Chiba K.; Tamura K.
CS Department of Neurology, Iwate Medical University, 19-1 Uchimaru,Morioka 020, Japan.
SO Stroke, (1993), 24/6 (801-804)
CODEN: SJCCA7 ISSN: 0039-2499
DT Journal; Article
CY United States
LA English
SL English

L4 ANSWER 24 OF 268 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:836505 CAPLUS
DN 139:304173
TI Diagnostic markers of ***stroke*** and cerebral injury and methods of use thereof
IN Valkirs, Gunars E.; Dahlen, Jeffery; Kirchick, Howard J.; Buechler, Kenneth F.
PA USA
SO U.S. Pat. Appl. Publ., 45 pp., Cont.-in-part of U.S. Ser. No. 225,082.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003199000	A1	20031023	US 2003-371149	20030220
	WO 2003016910	A1	20030227	WO 2002-US26604	20020820
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003119064	A1	20030626	US 2002-225082	20020820
PRAI	US 2001-313775P	P	20010820		
	US 2001-334964P	P	20011130		
	US 2002-346485P	P	20020102		
	US 2002-225082	A2	20020820		
	WO 2002-US26604	A2	20020820		

L4 ANSWER 25 OF 268 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:154702 CAPLUS
DN 138:166265
TI Diagnostic markers of ***stroke*** and cerebral injury and methods of use thereof
IN Valkirs, Gunars E.; Dahlen, Jeffrey R.; Buechler, Kenneth F.; Kirchick, Howard J.
PA Biosite, Inc., USA

SO PCT Int. Appl., 86 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003016910	A1	20030227	WO 2002-US26604	20020820
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003199000	A1	20031023	US 2003-371149	20030220
	US 2003219734	A1	20031127	US 2003-419059	20030417
PRAI	US 2001-313775P	P	20010820		
	US 2001-334964P	P	20011130		
	US 2002-346485P	P	20020102		
	US 2001-835298	A2	20010413		
	US 2001-288871P	P	20010504		
	US 2001-315642P	P	20010828		
	US 2002-139086	A2	20020504		
	US 2002-225082	A2	20020820		
	WO 2002-US26604	A2	20020820		

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 26 OF 268 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:107339 CAPLUS
DN 136:167289
TI Preparation of lactam inhibitors of factor Xa which are useful for the treatment of thrombosis
IN Stein, Philip D.; Shi, Yan; O'Connor, Stephen P.; Li, Chi
PA Bristol-Myers Squibb Company, USA
SO PCT Int. Appl., 66 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002010159	A1	20020207	WO 2001-US23932	20010730
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2002045616	A1	20020418	US 2001-916941	20010727
	US 6511973	B2	20030128		
	EP 1305309	A1	20030502	EP 2001-961808	20010730
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004507464	T2	20040311	JP 2002-515888	20010730
PRAI	US 2000-222498P	P	20000802		
	WO 2001-US23932	W	20010730		

OS MARPAT 136:167289
RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 27 OF 268 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2000:598412 CAPLUS
DN 134:99019
TI Hemostatic markers in patients at risk of cerebral ischemia
AU Cote, Robert; Wolfson, Christina; Solymoss, Susan; Mackey, Ariane; Leclerc, Jacques R.; Simard, Denis; Rouah, Fabrice; Bourque, France; Leger, Barbara

CS Division of Neurology, Montreal General Hospital, Montreal, QC, H3G 1A4, Can.
SO Stroke (2000), 31(8), 1856-1862
CODEN: SJCCA7; ISSN: 0039-2499
PB Lippincott Williams & Wilkins
DT Journal
LA English
RE.CNT 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 28 OF 268 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2000:227534 CAPLUS
DN 132:264103
TI Use of compounds that reduce alpha2-antiplasmin in vivo for the preparation of a composition for the treatment of ischemic ***stroke***
IN Nobuo, Nagia; Collen, Desire Jose
PA Leuven Research & Development VZW, Belg.
SO PCT Int. Appl., 26 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000018436	A1	20000406	WO 1999-EP7405	19990924
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1062953	A1	20001227	EP 1999-202004	19990622
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	CA 2344317	AA	20000406	CA 1999-2344317	19990924
	AU 9962005	A1	20000417	AU 1999-62005	19990924
	EP 1117437	A1	20010725	EP 1999-948942	19990924
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2002525340	T2	20020813	JP 2000-571953	19990924
PRAI	EP 1998-203280	A	19980929		
	EP 1999-202004	A	19990622		
	WO 1999-EP7405	W	19990924		

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 29 OF 268 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2000:157050 CAPLUS
DN 132:332881
TI Thrombolytic Properties of Leukocytes from Peripheral Blood in Healthy Subjects and in Patients with Acute Cerebral Ischemia
AU Lichy, C.; Wagner, S.; Hacke, W.; Grau, A. J.
CS Department of Neurology, University of Heidelberg, Heidelberg, Germany
SO Thrombosis Research (2000), 98(1), 29-37
CODEN: THBRAA; ISSN: 0049-3848
PB Elsevier Science Inc.
DT Journal
LA English
RE.CNT 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 30 OF 268 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1998:197619 CAPLUS
DN 128:252995
TI Antibodies to .alpha.2 anti- ***plasmin*** as aids for increasing the efficiency of fibrinolysis in the treatment of clotting disorders
IN Reed, Guy L.
PA Reed, Guy L., USA
SO PCT Int. Appl., 112 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9812329	A2	19980326	WO 1997-US16122	19970919
	W: AU, CA, JP				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9744134	A1	19980414	AU 1997-44134	19970919
	AU 734997	B2	20010628		
	EP 937146	A2	19990825	EP 1997-942435	19970919
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	US 6114506	A	20000905	US 1997-933983	19970919
	JP 2001515345	T2	20010918	JP 1998-514755	19970919
	US 2003017147	A1	20030123	US 1997-934000	19970919
	US 2003031664	A1	20030213	US 2001-977283	20011016
PRAI	US 1996-26356P	P	19960920		
	US 1997-934000	A3	19970919		
	WO 1997-US16122	W	19970919		

L4 ANSWER 31 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ABU89696 Protein DGENE
TI Novel immunologic molecule that binds to both human and nonhuman circulating alpha2-antiplasmins and human and non-human fibrin crosslinked alpha2-antiplasmins, useful for treating pulmonary embolism, thrombosis -
IN Reed G L
PA (REED-I) REED G L.
PI US 2003017147 A1 20030123 48p
AI US 1997-934000 19970919
PRAI US 1996-26356P 19960920
DT Patent
LA English
OS 2003-438927 [41]
DESC ***Alpha*** - ***2*** ***antiplasmin*** antibody heavy chain consensus sequence.

L4 ANSWER 32 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ABU89695 Protein DGENE
TI Novel immunologic molecule that binds to both human and nonhuman circulating alpha2-antiplasmins and human and non-human fibrin crosslinked alpha2-antiplasmins, useful for treating pulmonary embolism, thrombosis -
IN Reed G L
PA (REED-I) REED G L.
PI US 2003017147 A1 20030123 48p
AI US 1997-934000 19970919
PRAI US 1996-26356P 19960920
DT Patent
LA English
OS 2003-438927 [41]
DESC Human ***alpha*** - ***2*** ***antiplasmin*** antibody heavy chain consensus sequence #2.

L4 ANSWER 33 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ABU89694 Protein DGENE
TI Novel immunologic molecule that binds to both human and nonhuman circulating alpha2-antiplasmins and human and non-human fibrin crosslinked alpha2-antiplasmins, useful for treating pulmonary embolism, thrombosis -
IN Reed G L
PA (REED-I) REED G L.
PI US 2003017147 A1 20030123 48p
AI US 1997-934000 19970919
PRAI US 1996-26356P 19960920
DT Patent
LA English
OS 2003-438927 [41]
DESC Murine ***alpha*** - ***2*** ***antiplasmin*** antibody heavy chain consensus sequence.

L4 ANSWER 34 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ABU89693 Protein DGENE
TI Novel immunologic molecule that binds to both human and nonhuman circulating alpha2-antiplasmins and human and non-human fibrin crosslinked alpha2-antiplasmins, useful for treating pulmonary embolism, thrombosis -
IN Reed G L

PA (REED-I) REED G L.
PI US 2003017147 A1 20030123 48p
AI US 1997-934000 19970919
PRAI US 1996-26356P 19960920
DT Patent
LA English
OS 2003-438927 [41]
DESC Human ***alpha*** - ***2*** ***antiplasmin*** antibody heavy chain consensus sequence #1.

L4 ANSWER 35 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ABU89692 Protein DGENE
TI Novel immunologic molecule that binds to both human and nonhuman circulating alpha2-antiplasmins and human and non-human fibrin crosslinked alpha2-antiplasmins, useful for treating pulmonary embolism, thrombosis -
IN Reed G L
PA (REED-I) REED G L.
PI US 2003017147 A1 20030123 48p
AI US 1997-934000 19970919
PRAI US 1996-26356P 19960920
DT Patent
LA English
OS 2003-438927 [41]
DESC ***Alpha*** - ***2*** ***antiplasmin*** antibody light chain consensus sequence.

L4 ANSWER 36 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ABU89691 Protein DGENE
TI Novel immunologic molecule that binds to both human and nonhuman circulating alpha2-antiplasmins and human and non-human fibrin crosslinked alpha2-antiplasmins, useful for treating pulmonary embolism, thrombosis -
IN Reed G L
PA (REED-I) REED G L.
PI US 2003017147 A1 20030123 48p
AI US 1997-934000 19970919
PRAI US 1996-26356P 19960920
DT Patent
LA English
OS 2003-438927 [41]
DESC Human ***alpha*** - ***2*** ***antiplasmin*** antibody light chain consensus sequence.

L4 ANSWER 37 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ABU89690 Protein DGENE
TI Novel immunologic molecule that binds to both human and nonhuman circulating alpha2-antiplasmins and human and non-human fibrin crosslinked alpha2-antiplasmins, useful for treating pulmonary embolism, thrombosis -
IN Reed G L
PA (REED-I) REED G L.
PI US 2003017147 A1 20030123 48p
AI US 1997-934000 19970919
PRAI US 1996-26356P 19960920
DT Patent
LA English
OS 2003-438927 [41]
DESC Murine ***alpha*** - ***2*** ***antiplasmin*** antibody light chain consensus sequence.

L4 ANSWER 38 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ABU89689 Protein DGENE
TI Novel immunologic molecule that binds to both human and nonhuman circulating alpha2-antiplasmins and human and non-human fibrin crosslinked alpha2-antiplasmins, useful for treating pulmonary embolism, thrombosis -
IN Reed G L
PA (REED-I) REED G L.
PI US 2003017147 A1 20030123 48p
AI US 1997-934000 19970919
PRAI US 1996-26356P 19960920
DT Patent
LA English
OS 2003-438927 [41]
DESC ***Alpha*** - ***2*** ***antiplasmin*** antibody light chain

sFv fragment sFv77A3-2 linker.

L4 ANSWER 39 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ABU89688 Protein DGENE
TI Novel immunologic molecule that binds to both human and nonhuman circulating alpha2-antiplasmins and human and non-human fibrin crosslinked alpha2-antiplasmins, useful for treating pulmonary embolism, thrombosis -
IN Reed G L
PA (REED-I) REED G L.
PI US 2003017147 A1 20030123 48p
AI US 1997-934000 19970919
PRAI US 1996-26356P 19960920
DT Patent
LA English
OS 2003-438927 [41]
DESC ***Alpha*** - ***2*** ***antiplasmin*** antibody light chain sFv fragment sFv77A3-1 linker.

L4 ANSWER 40 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ABU89687 Protein DGENE
TI Novel immunologic molecule that binds to both human and nonhuman circulating alpha2-antiplasmins and human and non-human fibrin crosslinked alpha2-antiplasmins, useful for treating pulmonary embolism, thrombosis -
IN Reed G L
PA (REED-I) REED G L.
PI US 2003017147 A1 20030123 48p
AI US 1997-934000 19970919
PRAI US 1996-26356P 19960920
DT Patent
LA English
OS 2003-438927 [41]
CR N-PSDB: ACA89798
DESC ***Alpha*** - ***2*** ***antiplasmin*** antibody 77A3-2 heavy chain.

L4 ANSWER 41 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ABU89686 Protein DGENE
TI Novel immunologic molecule that binds to both human and nonhuman circulating alpha2-antiplasmins and human and non-human fibrin crosslinked alpha2-antiplasmins, useful for treating pulmonary embolism, thrombosis -
IN Reed G L
PA (REED-I) REED G L.
PI US 2003017147 A1 20030123 48p
AI US 1997-934000 19970919
PRAI US 1996-26356P 19960920
DT Patent
LA English
OS 2003-438927 [41]
CR N-PSDB: ACA89797
DESC ***Alpha*** - ***2*** ***antiplasmin*** antibody 77A3-1 heavy chain.

L4 ANSWER 42 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ABU89685 Protein DGENE
TI Novel immunologic molecule that binds to both human and nonhuman circulating alpha2-antiplasmins and human and non-human fibrin crosslinked alpha2-antiplasmins, useful for treating pulmonary embolism, thrombosis -
IN Reed G L
PA (REED-I) REED G L.
PI US 2003017147 A1 20030123 48p
AI US 1997-934000 19970919
PRAI US 1996-26356P 19960920
DT Patent
LA English
OS 2003-438927 [41]
CR N-PSDB: ACA89796
DESC ***Alpha*** - ***2*** ***antiplasmin*** antibody 77A3-1 and 77A3-2 light chain.

L4 ANSWER 43 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ABU89684 Protein DGENE
TI Novel immunologic molecule that binds to both human and nonhuman

circulating alpha2-antiplasmins and human and non-human fibrin crosslinked alpha2-antiplasmins, useful for treating pulmonary embolism, thrombosis -
IN Reed G L
PA (REED-I) REED G L.
PI US 2003017147 A1 20030123 48p
AI US 1997-934000 19970919
PRAI US 1996-26356P 19960920
DT Patent
LA English
OS 2003-438927 [41]
CR N-PSDB: ACA89795
DESC ***Alpha*** - ***2*** ***antiplasmin*** antibody 77A3 heavy chain variable region.

L4 ANSWER 44 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ABU89683 Protein DGENE
TI Novel immunologic molecule that binds to both human and nonhuman circulating alpha2-antiplasmins and human and non-human fibrin crosslinked alpha2-antiplasmins, useful for treating pulmonary embolism, thrombosis -
IN Reed G L
PA (REED-I) REED G L.
PI US 2003017147 A1 20030123 48p
AI US 1997-934000 19970919
PRAI US 1996-26356P 19960920
DT Patent
LA English
OS 2003-438927 [41]
CR N-PSDB: ACA89794
DESC ***Alpha*** - ***2*** ***antiplasmin*** antibody 70B11 heavy chain variable region.

L4 ANSWER 45 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ABU89682 Protein DGENE
TI Novel immunologic molecule that binds to both human and nonhuman circulating alpha2-antiplasmins and human and non-human fibrin crosslinked alpha2-antiplasmins, useful for treating pulmonary embolism, thrombosis -
IN Reed G L
PA (REED-I) REED G L.
PI US 2003017147 A1 20030123 48p
AI US 1997-934000 19970919
PRAI US 1996-26356P 19960920
DT Patent
LA English
OS 2003-438927 [41]
CR N-PSDB: ACA89793
DESC ***Alpha*** - ***2*** ***antiplasmin*** antibody 49C9 heavy chain variable region.

L4 ANSWER 46 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ABU89681 Protein DGENE
TI Novel immunologic molecule that binds to both human and nonhuman circulating alpha2-antiplasmins and human and non-human fibrin crosslinked alpha2-antiplasmins, useful for treating pulmonary embolism, thrombosis -
IN Reed G L
PA (REED-I) REED G L.
PI US 2003017147 A1 20030123 48p
AI US 1997-934000 19970919
PRAI US 1996-26356P 19960920
DT Patent
LA English
OS 2003-438927 [41]
CR N-PSDB: ACA89792
DESC ***Alpha*** - ***2*** ***antiplasmin*** antibody 77A3 light chain variable region.

L4 ANSWER 47 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ABU89680 Protein DGENE
TI Novel immunologic molecule that binds to both human and nonhuman circulating alpha2-antiplasmins and human and non-human fibrin crosslinked alpha2-antiplasmins, useful for treating pulmonary embolism, thrombosis -
IN Reed G L

PA (REED-I) REED G L.
PI US 2003017147 A1 20030123 48p
AI US 1997-934000 19970919
PRAI US 1996-26356P 19960920
DT Patent
LA English
OS 2003-438927 [41]
CR N-PSDB: ACA89791
DESC ***Alpha*** - ***2*** ***antiplasmin*** antibody 70B11 light chain variable region.

L4 ANSWER 48 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ABU89679 Protein DGENE
TI Novel immunologic molecule that binds to both human and nonhuman circulating alpha2-antiplasmins and human and non-human fibrin crosslinked alpha2-antiplasmins, useful for treating pulmonary embolism, thrombosis -
IN Reed G L
PA (REED-I) REED G L.
PI US 2003017147 A1 20030123 48p
AI US 1997-934000 19970919
PRAI US 1996-26356P 19960920
DT Patent
LA English
OS 2003-438927 [41]
CR N-PSDB: ACA89790
DESC ***Alpha*** - ***2*** ***antiplasmin*** antibody 49C9 light chain variable region.

L4 ANSWER 49 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ABU89678 Peptide DGENE
TI Novel immunologic molecule that binds to both human and nonhuman circulating alpha2-antiplasmins and human and non-human fibrin crosslinked alpha2-antiplasmins, useful for treating pulmonary embolism, thrombosis -
IN Reed G L
PA (REED-I) REED G L.
PI US 2003017147 A1 20030123 48p
AI US 1997-934000 19970919
PRAI US 1996-26356P 19960920
DT Patent
LA English
OS 2003-438927 [41]
DESC ***Alpha*** - ***2*** ***antiplasmin*** antibody 77A3 light chain amino terminus.

L4 ANSWER 50 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ABU89677 Peptide DGENE
TI Novel immunologic molecule that binds to both human and nonhuman circulating alpha2-antiplasmins and human and non-human fibrin crosslinked alpha2-antiplasmins, useful for treating pulmonary embolism, thrombosis -
IN Reed G L
PA (REED-I) REED G L.
PI US 2003017147 A1 20030123 48p
AI US 1997-934000 19970919
PRAI US 1996-26356P 19960920
DT Patent
LA English
OS 2003-438927 [41]
DESC ***Alpha*** - ***2*** ***antiplasmin*** antibody 70B11 light chain amino terminus.

L4 ANSWER 51 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ABU89676 Peptide DGENE
TI Novel immunologic molecule that binds to both human and nonhuman circulating alpha2-antiplasmins and human and non-human fibrin crosslinked alpha2-antiplasmins, useful for treating pulmonary embolism, thrombosis -
IN Reed G L
PA (REED-I) REED G L.
PI US 2003017147 A1 20030123 48p
AI US 1997-934000 19970919
PRAI US 1996-26356P 19960920
DT Patent
LA English

OS 2003-438927 [41]
DESC ***Alpha*** - ***2*** ***antiplasmin*** antibody 49C9 light chain amino terminus.

L4 ANSWER 52 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAW46303 Protein DGENE
TI Chimeric and humanised antibodies which bind to and inhibit circulating alpha-2-anti- ***plasmin*** - useful for, e.g. enhancing fibrinolysis for treatment of pulmonary embolism(s) and heart attack(s)
IN Bajorath J; Harris L; Hsu M; Matsueda G; Novotny J; Reed G L
PA (BAJO-I) BAJORATH J.
(HARR-I) HARRIS L.
(HSUM-I) HSU M.
(MATS-I) MATSUEDA G.
(NOVO-I) NOVOTNY J.
(REED-I) REED G L.
PI WO 9812334 A2 19980326 103p
AI WO 1997-US16123 19970919
PRAI US 1996-26356 19960920
DT Patent
LA English
OS 1998-217271 [19]
CR N-PSDB: AAV26389
DESC Murine MAb 77A3 heavy chain variable region.

L4 ANSWER 53 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAW46302 Protein DGENE
TI Chimeric and humanised antibodies which bind to and inhibit circulating alpha-2-anti- ***plasmin*** - useful for, e.g. enhancing fibrinolysis for treatment of pulmonary embolism(s) and heart attack(s)
IN Bajorath J; Harris L; Hsu M; Matsueda G; Novotny J; Reed G L
PA (BAJO-I) BAJORATH J.
(HARR-I) HARRIS L.
(HSUM-I) HSU M.
(MATS-I) MATSUEDA G.
(NOVO-I) NOVOTNY J.
(REED-I) REED G L.
PI WO 9812334 A2 19980326 103p
AI WO 1997-US16123 19970919
PRAI US 1996-26356 19960920
DT Patent
LA English
OS 1998-217271 [19]
CR N-PSDB: AAV26388
DESC Murine MAb 70B11 heavy chain variable region.

L4 ANSWER 54 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAW46301 Protein DGENE
TI Chimeric and humanised antibodies which bind to and inhibit circulating alpha-2-anti- ***plasmin*** - useful for, e.g. enhancing fibrinolysis for treatment of pulmonary embolism(s) and heart attack(s)
IN Bajorath J; Harris L; Hsu M; Matsueda G; Novotny J; Reed G L
PA (BAJO-I) BAJORATH J.
(HARR-I) HARRIS L.
(HSUM-I) HSU M.
(MATS-I) MATSUEDA G.
(NOVO-I) NOVOTNY J.
(REED-I) REED G L.
PI WO 9812334 A2 19980326 103p
AI WO 1997-US16123 19970919
PRAI US 1996-26356 19960920
DT Patent
LA English
OS 1998-217271 [19]
CR N-PSDB: AAV26387
DESC Murine MAb 49C9 heavy chain variable region.

L4 ANSWER 55 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAW46300 Protein DGENE
TI Chimeric and humanised antibodies which bind to and inhibit circulating alpha-2-anti- ***plasmin*** - useful for, e.g. enhancing fibrinolysis for treatment of pulmonary embolism(s) and heart attack(s)
IN Bajorath J; Harris L; Hsu M; Matsueda G; Novotny J; Reed G L
PA (BAJO-I) BAJORATH J.
(HARR-I) HARRIS L.
(HSUM-I) HSU M.

(MATS-I) MATSUEDA G.
(NOVO-I) NOVOTNY J.
(REED-I) REED G L.
PI WO 9812334 A2 19980326 103p
AI WO 1997-US16123 19970919
PRAI US 1996-26356 19960920
DT Patent
LA English
OS 1998-217271 [19]
CR N-PSDB: AAV26386
DESC Murine MAb 77A3 light chain variable region.

L4 ANSWER 56 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAW46299 Protein DGENE
TI Chimeric and humanised antibodies which bind to and inhibit circulating alpha-2-anti- ***plasmin*** - useful for, e.g. enhancing fibrinolysis for treatment of pulmonary embolism(s) and heart attack(s)
IN Bajorath J; Harris L; Hsu M; Matsueda G; Novotny J; Reed G L
PA (BAJO-I) BAJORATH J.
(HARR-I) HARRIS L.
(HSUM-I) HSU M.
(MATS-I) MATSUEDA G.
(NOVO-I) NOVOTNY J.
(REED-I) REED G L.
PI WO 9812334 A2 19980326 103p
AI WO 1997-US16123 19970919
PRAI US 1996-26356 19960920
DT Patent
LA English
OS 1998-217271 [19]
CR N-PSDB: AAV26385
DESC Murine MAb 70B11 light chain variable region.

L4 ANSWER 57 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAW53199 Protein DGENE
TI Chimeric and humanised antibodies which bind to and inhibit circulating alpha2-anti- ***plasmin*** - useful for, e.g. enhancing fibrinolysis for treatment of pulmonary embolism(s) and heart attack(s)
IN Reed G L
PA (REED-I) REED G L.
PI WO 9812329 A2 19980326 103p
AI WO 1997-US16122 19970919
PRAI US 1996-26356 19960920
DT Patent
LA English
OS 1998-217268 [19]
CR N-PSDB: AAV21670
DESC Humanised antibody 77A3-2 heavy chain.

L4 ANSWER 58 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAW53198 Protein DGENE
TI Chimeric and humanised antibodies which bind to and inhibit circulating alpha2-anti- ***plasmin*** - useful for, e.g. enhancing fibrinolysis for treatment of pulmonary embolism(s) and heart attack(s)
IN Reed G L
PA (REED-I) REED G L.
PI WO 9812329 A2 19980326 103p
AI WO 1997-US16122 19970919
PRAI US 1996-26356 19960920
DT Patent
LA English
OS 1998-217268 [19]
CR N-PSDB: AAV21669
DESC Humanised antibody 77A3-1 heavy chain.

L4 ANSWER 59 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAW53197 Protein DGENE
TI Chimeric and humanised antibodies which bind to and inhibit circulating alpha2-anti- ***plasmin*** - useful for, e.g. enhancing fibrinolysis for treatment of pulmonary embolism(s) and heart attack(s)
IN Reed G L
PA (REED-I) REED G L.
PI WO 9812329 A2 19980326 103p
AI WO 1997-US16122 19970919
PRAI US 1996-26356 19960920
DT Patent

LA English
OS 1998-217268 [19]
CR N-PSDB: AAV21668
DESC Humanised antibody 77A3-1 and 77A3-2 light chain.

L4 ANSWER 60 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAW53196 Protein DGENE
TI Chimeric and humanised antibodies which bind to and inhibit circulating alpha2-anti- ***plasmin*** - useful for, e.g. enhancing fibrinolysis for treatment of pulmonary embolism(s) and heart attack(s)
IN Reed G L
PA (REED-I) REED G L.
PI WO 9812329 A2 19980326 103p
AI WO 1997-US16122 19970919
PRAI US 1996-26356 19960920
DT Patent
LA English
OS 1998-217268 [19]
CR N-PSDB: AAV21667
DESC Murine MAb 77A3 heavy chain variable region.

L4 ANSWER 61 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAW53195 Protein DGENE
TI Chimeric and humanised antibodies which bind to and inhibit circulating alpha2-anti- ***plasmin*** - useful for, e.g. enhancing fibrinolysis for treatment of pulmonary embolism(s) and heart attack(s)
IN Reed G L
PA (REED-I) REED G L.
PI WO 9812329 A2 19980326 103p
AI WO 1997-US16122 19970919
PRAI US 1996-26356 19960920
DT Patent
LA English
OS 1998-217268 [19]
CR N-PSDB: AAV21666
DESC Murine MAb 70B11 heavy chain variable region.

L4 ANSWER 62 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAW46296 Protein DGENE
TI Chimeric and humanised antibodies which bind to and inhibit circulating alpha-2-anti- ***plasmin*** - useful for, e.g. enhancing fibrinolysis for treatment of pulmonary embolism(s) and heart attack(s)
IN Bajorath J; Harris L; Hsu M; Matsueda G; Novotny J; Reed G L
PA (BAJO-I) BAJORATH J.
(HARR-I) HARRIS L.
(HSUM-I) HSU M.
(MATS-I) MATSUEDA G.
(NOVO-I) NOVOTNY J.
(REED-I) REED G L.
PI WO 9812334 A2 19980326 103p
AI WO 1997-US16123 19970919
PRAI US 1996-26356 19960920
DT Patent
LA English
OS 1998-217271 [19]
DESC Linker 2 used for constructing humanised antibody 77A3-2.

L4 ANSWER 63 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAW46295 Protein DGENE
TI Chimeric and humanised antibodies which bind to and inhibit circulating alpha-2-anti- ***plasmin*** - useful for, e.g. enhancing fibrinolysis for treatment of pulmonary embolism(s) and heart attack(s)
IN Bajorath J; Harris L; Hsu M; Matsueda G; Novotny J; Reed G L
PA (BAJO-I) BAJORATH J.
(HARR-I) HARRIS L.
(HSUM-I) HSU M.
(MATS-I) MATSUEDA G.
(NOVO-I) NOVOTNY J.
(REED-I) REED G L.
PI WO 9812334 A2 19980326 103p
AI WO 1997-US16123 19970919
PRAI US 1996-26356 19960920
DT Patent
LA English
OS 1998-217271 [19]
DESC Linker 1 used for constructing humanised antibody 77A3-1.

L4 ANSWER 64 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAW46306 Protein DGENE
TI Chimeric and humanised antibodies which bind to and inhibit circulating alpha-2-anti- ***plasmin*** - useful for, e.g. enhancing fibrinolysis for treatment of pulmonary embolism(s) and heart attack(s)
IN Bajorath J; Harris L; Hsu M; Matsueda G; Novotny J; Reed G L
PA (BAJO-I) BAJORATH J.
(HARR-I) HARRIS L.
(HSUM-I) HSU M.
(MATS-I) MATSUEDA G.
(NOVO-I) NOVOTNY J.
(REED-I) REED G L.
PI WO 9812334 A2 19980326 103p
AI WO 1997-US16123 19970919
PRAI US 1996-26356 19960920
DT Patent
LA English
OS 1998-217271 [19]
CR N-PSDB: AAV26392
DESC Humanised antibody 77A3-2 heavy chain.

L4 ANSWER 65 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAW46305 Protein DGENE
TI Chimeric and humanised antibodies which bind to and inhibit circulating alpha-2-anti- ***plasmin*** - useful for, e.g. enhancing fibrinolysis for treatment of pulmonary embolism(s) and heart attack(s)
IN Bajorath J; Harris L; Hsu M; Matsueda G; Novotny J; Reed G L
PA (BAJO-I) BAJORATH J.
(HARR-I) HARRIS L.
(HSUM-I) HSU M.
(MATS-I) MATSUEDA G.
(NOVO-I) NOVOTNY J.
(REED-I) REED G L.
PI WO 9812334 A2 19980326 103p
AI WO 1997-US16123 19970919
PRAI US 1996-26356 19960920
DT Patent
LA English
OS 1998-217271 [19]
CR N-PSDB: AAV26391
DESC Humanised antibody 77A3-1 heavy chain.

L4 ANSWER 66 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAW46304 Protein DGENE
TI Chimeric and humanised antibodies which bind to and inhibit circulating alpha-2-anti- ***plasmin*** - useful for, e.g. enhancing fibrinolysis for treatment of pulmonary embolism(s) and heart attack(s)
IN Bajorath J; Harris L; Hsu M; Matsueda G; Novotny J; Reed G L
PA (BAJO-I) BAJORATH J.
(HARR-I) HARRIS L.
(HSUM-I) HSU M.
(MATS-I) MATSUEDA G.
(NOVO-I) NOVOTNY J.
(REED-I) REED G L.
PI WO 9812334 A2 19980326 103p
AI WO 1997-US16123 19970919
PRAI US 1996-26356 19960920
DT Patent
LA English
OS 1998-217271 [19]
CR N-PSDB: AAV26390
DESC Humanised antibody 77A3-1 and 77A3-2 light chain.

L4 ANSWER 67 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAW53191 Protein DGENE
TI Chimeric and humanised antibodies which bind to and inhibit circulating alpha2-anti- ***plasmin*** - useful for, e.g. enhancing fibrinolysis for treatment of pulmonary embolism(s) and heart attack(s)
IN Reed G L
PA (REED-I) REED G L.
PI WO 9812329 A2 19980326 103p
AI WO 1997-US16122 19970919
PRAI US 1996-26356 19960920
DT Patent
LA English

OS 1998-217268 [19]
CR N-PSDB: AAV21662
DESC Murine MAb 49C9 light chain variable region.

L4 ANSWER 68 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAW46298 Protein DGENE
TI Chimeric and humanised antibodies which bind to and inhibit circulating alpha-2-anti- ***plasmin*** - useful for, e.g. enhancing fibrinolysis for treatment of pulmonary embolism(s) and heart attack(s)
IN Bajorath J; Harris L; Hsu M; Matsueda G; Novotny J; Reed G L
PA (BAJO-I) BAJORATH J.
(HARR-I) HARRIS L.
(HSUM-I) HSU M.
(MATS-I) MATSUEDA G.
(NOVO-I) NOVOTNY J.
(REED-I) REED G L.
PI WO 9812334 A2 19980326 103p
AI WO 1997-US16123 19970919
PRAI US 1996-26356 19960920
DT Patent
LA English
OS 1998-217271 [19]
CR N-PSDB: AAV26384
DESC Murine MAb 49C9 light chain variable region.

L4 ANSWER 69 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAW53193 Protein DGENE
TI Chimeric and humanised antibodies which bind to and inhibit circulating alpha2-anti- ***plasmin*** - useful for, e.g. enhancing fibrinolysis for treatment of pulmonary embolism(s) and heart attack(s)
IN Reed G L
PA (REED-I) REED G L.
PI WO 9812329 A2 19980326 103p
AI WO 1997-US16122 19970919
PRAI US 1996-26356 19960920
DT Patent
LA English
OS 1998-217268 [19]
CR N-PSDB: AAV21664
DESC Murine MAb 77A3 light chain variable region.

L4 ANSWER 70 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAW53192 Protein DGENE
TI Chimeric and humanised antibodies which bind to and inhibit circulating alpha2-anti- ***plasmin*** - useful for, e.g. enhancing fibrinolysis for treatment of pulmonary embolism(s) and heart attack(s)
IN Reed G L
PA (REED-I) REED G L.
PI WO 9812329 A2 19980326 103p
AI WO 1997-US16122 19970919
PRAI US 1996-26356 19960920
DT Patent
LA English
OS 1998-217268 [19]
CR N-PSDB: AAV21663
DESC Murine MAb 70B11 light chain variable region.

L4 ANSWER 71 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAW53194 Protein DGENE
TI Chimeric and humanised antibodies which bind to and inhibit circulating alpha2-anti- ***plasmin*** - useful for, e.g. enhancing fibrinolysis for treatment of pulmonary embolism(s) and heart attack(s)
IN Reed G L
PA (REED-I) REED G L.
PI WO 9812329 A2 19980326 103p
AI WO 1997-US16122 19970919
PRAI US 1996-26356 19960920
DT Patent
LA English
OS 1998-217268 [19]
CR N-PSDB: AAV21665
DESC Murine MAb 49C9 heavy chain variable region.

L4 ANSWER 72 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAW57780 protein DGENE
TI Single-chain variants of tissue plasminogen activator - with basic

residue replaced in serine protease region useful for treating or diagnosing thrombotic disorders
IN Madison E L
PA (SCRI) SCRIPPS RES INST.
PI WO 9821320 A2 19980522 45p
AI WO 1997-US20226 19971112
PRAI US 1996-30655 19961112
DT Patent
LA English
OS 1998-297926 [26]
DESC R275E,K429Y human tissue-type plasminogen activator protein mutant.

L4 ANSWER 73 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAW57779 protein DGENE
TI Single-chain variants of tissue plasminogen activator - with basic residue replaced in serine protease region useful for treating or diagnosing thrombotic disorders
IN Madison E L
PA (SCRI) SCRIPPS RES INST.
PI WO 9821320 A2 19980522 45p
AI WO 1997-US20226 19971112
PRAI US 1996-30655 19961112
DT Patent
LA English
OS 1998-297926 [26]
DESC R275E,H417E human tissue-type plasminogen activator protein mutant.

L4 ANSWER 74 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAW57778 protein DGENE
TI Single-chain variants of tissue plasminogen activator - with basic residue replaced in serine protease region useful for treating or diagnosing thrombotic disorders
IN Madison E L
PA (SCRI) SCRIPPS RES INST.
PI WO 9821320 A2 19980522 45p
AI WO 1997-US20226 19971112
PRAI US 1996-30655 19961112
DT Patent
LA English
OS 1998-297926 [26]
DESC R275E,H417D human tissue-type plasminogen activator protein mutant.

L4 ANSWER 75 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ACA89849 DNA DGENE
TI Novel immunologic molecule that binds to both human and nonhuman circulating alpha2-antiplasmins and human and non-human fibrin crosslinked alpha2-antiplasmins, useful for treating pulmonary embolism, thrombosis -
IN Reed G L
PA (REED-I) REED G L.
PI US 2003017147 A1 20030123 48p
AI US 1997-934000 19970919
PRAI US 1996-26356P 19960920
DT Patent
LA English
OS 2003-438927 [41]
DESC ***Alpha*** - ***2*** ***antiplasmin*** antibody light chain anti-sense primer LH24.

L4 ANSWER 76 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ACA89848 DNA DGENE
TI Novel immunologic molecule that binds to both human and nonhuman circulating alpha2-antiplasmins and human and non-human fibrin crosslinked alpha2-antiplasmins, useful for treating pulmonary embolism, thrombosis -
IN Reed G L
PA (REED-I) REED G L.
PI US 2003017147 A1 20030123 48p
AI US 1997-934000 19970919
PRAI US 1996-26356P 19960920
DT Patent
LA English
OS 2003-438927 [41]
DESC ***Alpha*** - ***2*** ***antiplasmin*** antibody light chain sense primer LH23.

L4 ANSWER 77 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ACA89847 DNA DGENE
TI Novel immunologic molecule that binds to both human and nonhuman circulating alpha2-antiplasmins and human and non-human fibrin crosslinked alpha2-antiplasmins, useful for treating pulmonary embolism, thrombosis -
IN Reed G L
PA (REED-I) REED G L.
PI US 2003017147 A1 20030123 48p
AI US 1997-934000 19970919
PRAI US 1996-26356P 19960920
DT Patent
LA English
OS 2003-438927 [41]
DESC ***Alpha*** - ***2*** ***antiplasmin*** antibody light chain sense primer LH22.

L4 ANSWER 78 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ACA89846 DNA DGENE
TI Novel immunologic molecule that binds to both human and nonhuman circulating alpha2-antiplasmins and human and non-human fibrin crosslinked alpha2-antiplasmins, useful for treating pulmonary embolism, thrombosis -
IN Reed G L
PA (REED-I) REED G L.
PI US 2003017147 A1 20030123 48p
AI US 1997-934000 19970919
PRAI US 1996-26356P 19960920
DT Patent
LA English
OS 2003-438927 [41]
DESC ***Alpha*** - ***2*** ***antiplasmin*** antibody light chain anti-sense primer LH21.

L4 ANSWER 79 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ACA89845 DNA DGENE
TI Novel immunologic molecule that binds to both human and nonhuman circulating alpha2-antiplasmins and human and non-human fibrin crosslinked alpha2-antiplasmins, useful for treating pulmonary embolism, thrombosis -
IN Reed G L
PA (REED-I) REED G L.
PI US 2003017147 A1 20030123 48p
AI US 1997-934000 19970919
PRAI US 1996-26356P 19960920
DT Patent
LA English
OS 2003-438927 [41]
DESC ***Alpha*** - ***2*** ***antiplasmin*** antibody heavy chain sense primer LH36.

L4 ANSWER 80 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ACA89844 DNA DGENE
TI Novel immunologic molecule that binds to both human and nonhuman circulating alpha2-antiplasmins and human and non-human fibrin crosslinked alpha2-antiplasmins, useful for treating pulmonary embolism, thrombosis -
IN Reed G L
PA (REED-I) REED G L.
PI US 2003017147 A1 20030123 48p
AI US 1997-934000 19970919
PRAI US 1996-26356P 19960920
DT Patent
LA English
OS 2003-438927 [41]
DESC ***Alpha*** - ***2*** ***antiplasmin*** antibody heavy chain anti-sense primer LH35.

L4 ANSWER 81 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ACA89843 DNA DGENE
TI Novel immunologic molecule that binds to both human and nonhuman circulating alpha2-antiplasmins and human and non-human fibrin crosslinked alpha2-antiplasmins, useful for treating pulmonary embolism, thrombosis -
IN Reed G L
PA (REED-I) REED G L.

PI US 2003017147 A1 20030123 48p
AI US 1997-934000 19970919
PRAI US 1996-26356P 19960920
DT Patent
LA English
OS 2003-438927 [41]
DESC ***Alpha*** - ***2*** ***antiplasmin*** antibody heavy chain sense primer LH34.

L4 ANSWER 82 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ACA89842 DNA DGENE
TI Novel immunologic molecule that binds to both human and nonhuman circulating alpha2-antiplasmins and human and non-human fibrin crosslinked alpha2-antiplasmins, useful for treating pulmonary embolism, thrombosis -
IN Reed G L
PA (REED-I) REED G L.
PI US 2003017147 A1 20030123 48p
AI US 1997-934000 19970919
PRAI US 1996-26356P 19960920
DT Patent
LA English
OS 2003-438927 [41]
DESC ***Alpha*** - ***2*** ***antiplasmin*** antibody heavy chain anti-sense primer LH33.

L4 ANSWER 83 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ACA89841 DNA DGENE
TI Novel immunologic molecule that binds to both human and nonhuman circulating alpha2-antiplasmins and human and non-human fibrin crosslinked alpha2-antiplasmins, useful for treating pulmonary embolism, thrombosis -
IN Reed G L
PA (REED-I) REED G L.
PI US 2003017147 A1 20030123 48p
AI US 1997-934000 19970919
PRAI US 1996-26356P 19960920
DT Patent
LA English
OS 2003-438927 [41]
DESC ***Alpha*** - ***2*** ***antiplasmin*** antibody heavy chain anti-sense primer LH32.

L4 ANSWER 84 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ACA89840 DNA DGENE
TI Novel immunologic molecule that binds to both human and nonhuman circulating alpha2-antiplasmins and human and non-human fibrin crosslinked alpha2-antiplasmins, useful for treating pulmonary embolism, thrombosis -
IN Reed G L
PA (REED-I) REED G L.
PI US 2003017147 A1 20030123 48p
AI US 1997-934000 19970919
PRAI US 1996-26356P 19960920
DT Patent
LA English
OS 2003-438927 [41]
DESC ***Alpha*** - ***2*** ***antiplasmin*** antibody heavy chain sense primer LH31.

L4 ANSWER 85 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ACA89839 DNA DGENE
TI Novel immunologic molecule that binds to both human and nonhuman circulating alpha2-antiplasmins and human and non-human fibrin crosslinked alpha2-antiplasmins, useful for treating pulmonary embolism, thrombosis -
IN Reed G L
PA (REED-I) REED G L.
PI US 2003017147 A1 20030123 48p
AI US 1997-934000 19970919
PRAI US 1996-26356P 19960920
DT Patent
LA English
OS 2003-438927 [41]
DESC ***Alpha*** - ***2*** ***antiplasmin*** antibody heavy chain anti-sense primer LH30.

L4 ANSWER 86 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ACA89838 DNA DGENE
TI Novel immunologic molecule that binds to both human and nonhuman circulating alpha2-antiplasmins and human and non-human fibrin crosslinked alpha2-antiplasmins, useful for treating pulmonary embolism, thrombosis -
IN Reed G L
PA (REED-I) REED G L.
PI US 2003017147 A1 20030123 48p
AI US 1997-934000 19970919
PRAI US 1996-26356P 19960920
DT Patent
LA English
OS 2003-438927 [41]
DESC ***Alpha*** - ***2*** ***antiplasmin*** antibody heavy chain sense primer LH29.

L4 ANSWER 87 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ACA89837 DNA DGENE
TI Novel immunologic molecule that binds to both human and nonhuman circulating alpha2-antiplasmins and human and non-human fibrin crosslinked alpha2-antiplasmins, useful for treating pulmonary embolism, thrombosis -
IN Reed G L
PA (REED-I) REED G L.
PI US 2003017147 A1 20030123 48p
AI US 1997-934000 19970919
PRAI US 1996-26356P 19960920
DT Patent
LA English
OS 2003-438927 [41]
DESC ***Alpha*** - ***2*** ***antiplasmin*** antibody heavy chain anti-sense primer LH28.

L4 ANSWER 88 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ACA89836 DNA DGENE
TI Novel immunologic molecule that binds to both human and nonhuman circulating alpha2-antiplasmins and human and non-human fibrin crosslinked alpha2-antiplasmins, useful for treating pulmonary embolism, thrombosis -
IN Reed G L
PA (REED-I) REED G L.
PI US 2003017147 A1 20030123 48p
AI US 1997-934000 19970919
PRAI US 1996-26356P 19960920
DT Patent
LA English
OS 2003-438927 [41]
DESC ***Alpha*** - ***2*** ***antiplasmin*** antibody heavy chain sense primer LH27.

L4 ANSWER 89 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ACA89835 DNA DGENE
TI Novel immunologic molecule that binds to both human and nonhuman circulating alpha2-antiplasmins and human and non-human fibrin crosslinked alpha2-antiplasmins, useful for treating pulmonary embolism, thrombosis -
IN Reed G L
PA (REED-I) REED G L.
PI US 2003017147 A1 20030123 48p
AI US 1997-934000 19970919
PRAI US 1996-26356P 19960920
DT Patent
LA English
OS 2003-438927 [41]
DESC ***Alpha*** - ***2*** ***antiplasmin*** antibody heavy chain anti-sense primer LH26.

L4 ANSWER 90 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ACA89834 DNA DGENE
TI Novel immunologic molecule that binds to both human and nonhuman circulating alpha2-antiplasmins and human and non-human fibrin crosslinked alpha2-antiplasmins, useful for treating pulmonary embolism, thrombosis -
IN Reed G L

PA (REED-I) REED G L.
PI US 2003017147 A1 20030123 48p
AI US 1997-934000 19970919
PRAI US 1996-26356P 19960920
DT Patent
LA English
OS 2003-438927 [41]
DESC ***Alpha*** - ***2*** ***antiplasmin*** antibody heavy chain sense primer LH25.

L4 ANSWER 91 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ACA89833 DNA DGENE
TI Novel immunologic molecule that binds to both human and nonhuman circulating alpha2-antiplasmins and human and non-human fibrin crosslinked alpha2-antiplasmins, useful for treating pulmonary embolism, thrombosis -
IN Reed G L
PA (REED-I) REED G L.
PI US 2003017147 A1 20030123 48p
AI US 1997-934000 19970919
PRAI US 1996-26356P 19960920
DT Patent
LA English
OS 2003-438927 [41]
DESC ***Alpha*** - ***2*** ***antiplasmin*** antibody light chain sense primer LH20.

L4 ANSWER 92 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ACA89832 DNA DGENE
TI Novel immunologic molecule that binds to both human and nonhuman circulating alpha2-antiplasmins and human and non-human fibrin crosslinked alpha2-antiplasmins, useful for treating pulmonary embolism, thrombosis -
IN Reed G L
PA (REED-I) REED G L.
PI US 2003017147 A1 20030123 48p
AI US 1997-934000 19970919
PRAI US 1996-26356P 19960920
DT Patent
LA English
OS 2003-438927 [41]
DESC ***Alpha*** - ***2*** ***antiplasmin*** antibody light chain anti-sense primer LH19.

L4 ANSWER 93 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ACA89831 DNA DGENE
TI Novel immunologic molecule that binds to both human and nonhuman circulating alpha2-antiplasmins and human and non-human fibrin crosslinked alpha2-antiplasmins, useful for treating pulmonary embolism, thrombosis -
IN Reed G L
PA (REED-I) REED G L.
PI US 2003017147 A1 20030123 48p
AI US 1997-934000 19970919
PRAI US 1996-26356P 19960920
DT Patent
LA English
OS 2003-438927 [41]
DESC ***Alpha*** - ***2*** ***antiplasmin*** antibody light chain sense primer LH18.

L4 ANSWER 94 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ACA89830 DNA DGENE
TI Novel immunologic molecule that binds to both human and nonhuman circulating alpha2-antiplasmins and human and non-human fibrin crosslinked alpha2-antiplasmins, useful for treating pulmonary embolism, thrombosis -
IN Reed G L
PA (REED-I) REED G L.
PI US 2003017147 A1 20030123 48p
AI US 1997-934000 19970919
PRAI US 1996-26356P 19960920
DT Patent
LA English
OS 2003-438927 [41]
DESC ***Alpha*** - ***2*** ***antiplasmin*** antibody light chain

anti-sense primer LH17.

L4 ANSWER 95 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ACA89829 DNA DGENE
TI Novel immunologic molecule that binds to both human and nonhuman circulating alpha2-antiplasmins and human and non-human fibrin crosslinked alpha2-antiplasmins, useful for treating pulmonary embolism, thrombosis -
IN Reed G L
PA (REED-I) REED G L.
PI US 2003017147 A1 20030123 48p
AI US 1997-934000 19970919
PRAI US 1996-26356P 19960920
DT Patent
LA English
OS 2003-438927 [41]
DESC ***Alpha*** - ***2*** ***antiplasmin*** antibody light chain sense primer LH16.

L4 ANSWER 96 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ACA89828 DNA DGENE
TI Novel immunologic molecule that binds to both human and nonhuman circulating alpha2-antiplasmins and human and non-human fibrin crosslinked alpha2-antiplasmins, useful for treating pulmonary embolism, thrombosis -
IN Reed G L
PA (REED-I) REED G L.
PI US 2003017147 A1 20030123 48p
AI US 1997-934000 19970919
PRAI US 1996-26356P 19960920
DT Patent
LA English
OS 2003-438927 [41]
DESC ***Alpha*** - ***2*** ***antiplasmin*** antibody light chain anti-sense primer LH15.

L4 ANSWER 97 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ACA89827 DNA DGENE
TI Novel immunologic molecule that binds to both human and nonhuman circulating alpha2-antiplasmins and human and non-human fibrin crosslinked alpha2-antiplasmins, useful for treating pulmonary embolism, thrombosis -
IN Reed G L
PA (REED-I) REED G L.
PI US 2003017147 A1 20030123 48p
AI US 1997-934000 19970919
PRAI US 1996-26356P 19960920
DT Patent
LA English
OS 2003-438927 [41]
DESC ***Alpha*** - ***2*** ***antiplasmin*** antibody light chain sense primer LH14.

L4 ANSWER 98 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ACA89826 DNA DGENE
TI Novel immunologic molecule that binds to both human and nonhuman circulating alpha2-antiplasmins and human and non-human fibrin crosslinked alpha2-antiplasmins, useful for treating pulmonary embolism, thrombosis -
IN Reed G L
PA (REED-I) REED G L.
PI US 2003017147 A1 20030123 48p
AI US 1997-934000 19970919
PRAI US 1996-26356P 19960920
DT Patent
LA English
OS 2003-438927 [41]
DESC ***Alpha*** - ***2*** ***antiplasmin*** antibody light chain anti-sense primer LH13.

L4 ANSWER 99 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ACA89825 DNA DGENE
TI Novel immunologic molecule that binds to both human and nonhuman circulating alpha2-antiplasmins and human and non-human fibrin crosslinked alpha2-antiplasmins, useful for treating pulmonary embolism, thrombosis -

IN Reed G L
PA (REED-I) REED G L.
PI US 2003017147 A1 20030123 48p
AI US 1997-934000 19970919
PRAI US 1996-26356P 19960920
DT Patent
LA English
OS 2003-438927 [41]
DESC ***Alpha*** - ***2*** ***antiplasmin*** antibody light chain sense primer LH12.

L4 ANSWER 100 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ACA89824 DNA DGENE
TI Novel immunologic molecule that binds to both human and nonhuman circulating alpha2-antiplasmins and human and non-human fibrin crosslinked alpha2-antiplasmins, useful for treating pulmonary embolism, thrombosis -
IN Reed G L
PA (REED-I) REED G L.
PI US 2003017147 A1 20030123 48p
AI US 1997-934000 19970919
PRAI US 1996-26356P 19960920
DT Patent
LA English
OS 2003-438927 [41]
DESC ***Alpha*** - ***2*** ***antiplasmin*** antibody light chain sense primer LH11.

L4 ANSWER 101 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ACA89823 DNA DGENE
TI Novel immunologic molecule that binds to both human and nonhuman circulating alpha2-antiplasmins and human and non-human fibrin crosslinked alpha2-antiplasmins, useful for treating pulmonary embolism, thrombosis -
IN Reed G L
PA (REED-I) REED G L.
PI US 2003017147 A1 20030123 48p
AI US 1997-934000 19970919
PRAI US 1996-26356P 19960920
DT Patent
LA English
OS 2003-438927 [41]
DESC ***Alpha*** - ***2*** ***antiplasmin*** antibody heavy chain anti-sense primer LH10.

L4 ANSWER 102 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ACA89822 DNA DGENE
TI Novel immunologic molecule that binds to both human and nonhuman circulating alpha2-antiplasmins and human and non-human fibrin crosslinked alpha2-antiplasmins, useful for treating pulmonary embolism, thrombosis -
IN Reed G L
PA (REED-I) REED G L.
PI US 2003017147 A1 20030123 48p
AI US 1997-934000 19970919
PRAI US 1996-26356P 19960920
DT Patent
LA English
OS 2003-438927 [41]
DESC ***Alpha*** - ***2*** ***antiplasmin*** antibody heavy chain anti-sense primer LH9.

L4 ANSWER 103 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ACA89821 DNA DGENE
TI Novel immunologic molecule that binds to both human and nonhuman circulating alpha2-antiplasmins and human and non-human fibrin crosslinked alpha2-antiplasmins, useful for treating pulmonary embolism, thrombosis -
IN Reed G L
PA (REED-I) REED G L.
PI US 2003017147 A1 20030123 48p
AI US 1997-934000 19970919
PRAI US 1996-26356P 19960920
DT Patent
LA English
OS 2003-438927 [41]

DESC ***Alpha*** - ***2*** ***antiplasmin*** antibody heavy chain sense primer LH8.

L4 ANSWER 104 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ACA89820 DNA DGENE
TI Novel immunologic molecule that binds to both human and nonhuman circulating alpha2-antiplasmins and human and non-human fibrin crosslinked alpha2-antiplasmins, useful for treating pulmonary embolism, thrombosis -
IN Reed G L
PA (REED-I) REED G L.
PI US 2003017147 A1 20030123 48p
AI US 1997-934000 19970919
PRAI US 1996-26356P 19960920
DT Patent
LA English
OS 2003-438927 [41]
DESC ***Alpha*** - ***2*** ***antiplasmin*** antibody heavy chain anti-sense primer LH7.

L4 ANSWER 105 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ACA89819 DNA DGENE
TI Novel immunologic molecule that binds to both human and nonhuman circulating alpha2-antiplasmins and human and non-human fibrin crosslinked alpha2-antiplasmins, useful for treating pulmonary embolism, thrombosis -
IN Reed G L
PA (REED-I) REED G L.
PI US 2003017147 A1 20030123 48p
AI US 1997-934000 19970919
PRAI US 1996-26356P 19960920
DT Patent
LA English
OS 2003-438927 [41]
DESC ***Alpha*** - ***2*** ***antiplasmin*** antibody heavy chain sense primer LH6.

L4 ANSWER 106 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ACA89818 DNA DGENE
TI Novel immunologic molecule that binds to both human and nonhuman circulating alpha2-antiplasmins and human and non-human fibrin crosslinked alpha2-antiplasmins, useful for treating pulmonary embolism, thrombosis -
IN Reed G L
PA (REED-I) REED G L.
PI US 2003017147 A1 20030123 48p
AI US 1997-934000 19970919
PRAI US 1996-26356P 19960920
DT Patent
LA English
OS 2003-438927 [41]
DESC ***Alpha*** - ***2*** ***antiplasmin*** antibody heavy chain anti-sense primer LH5.

L4 ANSWER 107 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ACA89817 DNA DGENE
TI Novel immunologic molecule that binds to both human and nonhuman circulating alpha2-antiplasmins and human and non-human fibrin crosslinked alpha2-antiplasmins, useful for treating pulmonary embolism, thrombosis -
IN Reed G L
PA (REED-I) REED G L.
PI US 2003017147 A1 20030123 48p
AI US 1997-934000 19970919
PRAI US 1996-26356P 19960920
DT Patent
LA English
OS 2003-438927 [41]
DESC ***Alpha*** - ***2*** ***antiplasmin*** antibody heavy chain sense primer LH4.

L4 ANSWER 108 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ACA89816 DNA DGENE
TI Novel immunologic molecule that binds to both human and nonhuman circulating alpha2-antiplasmins and human and non-human fibrin crosslinked alpha2-antiplasmins, useful for treating pulmonary embolism,

thrombosis -
IN Reed G L
PA (REED-I) REED G L.
PI US 2003017147 A1 20030123 48p
AI US 1997-934000 19970919
PRAI US 1996-26356P 19960920
DT Patent
LA English
OS 2003-438927 [41]
DESC ***Alpha*** - ***2*** ***antiplasmin*** antibody heavy chain anti-sense primer LH3.

L4 ANSWER 109 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ACA89815 DNA DGENE
TI Novel immunologic molecule that binds to both human and nonhuman circulating alpha2-antiplasmins and human and non-human fibrin crosslinked alpha2-antiplasmins, useful for treating pulmonary embolism, thrombosis -
IN Reed G L
PA (REED-I) REED G L.
PI US 2003017147 A1 20030123 48p
AI US 1997-934000 19970919
PRAI US 1996-26356P 19960920
DT Patent
LA English
OS 2003-438927 [41]
DESC ***Alpha*** - ***2*** ***antiplasmin*** antibody heavy chain sense primer LH2.

L4 ANSWER 110 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ACA89814 DNA DGENE
TI Novel immunologic molecule that binds to both human and nonhuman circulating alpha2-antiplasmins and human and non-human fibrin crosslinked alpha2-antiplasmins, useful for treating pulmonary embolism, thrombosis -
IN Reed G L
PA (REED-I) REED G L.
PI US 2003017147 A1 20030123 48p
AI US 1997-934000 19970919
PRAI US 1996-26356P 19960920
DT Patent
LA English
OS 2003-438927 [41]
DESC ***Alpha*** - ***2*** ***antiplasmin*** antibody heavy chain sense primer LH1.

L4 ANSWER 111 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ACA89813 DNA DGENE
TI Novel immunologic molecule that binds to both human and nonhuman circulating alpha2-antiplasmins and human and non-human fibrin crosslinked alpha2-antiplasmins, useful for treating pulmonary embolism, thrombosis -
IN Reed G L
PA (REED-I) REED G L.
PI US 2003017147 A1 20030123 48p
AI US 1997-934000 19970919
PRAI US 1996-26356P 19960920
DT Patent
LA English
OS 2003-438927 [41]
DESC Human gamma4 gene vector pICHgamma4.1 construction primer #4.

L4 ANSWER 112 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ACA89812 DNA DGENE
TI Novel immunologic molecule that binds to both human and nonhuman circulating alpha2-antiplasmins and human and non-human fibrin crosslinked alpha2-antiplasmins, useful for treating pulmonary embolism, thrombosis -
IN Reed G L
PA (REED-I) REED G L.
PI US 2003017147 A1 20030123 48p
AI US 1997-934000 19970919
PRAI US 1996-26356P 19960920
DT Patent
LA English
OS 2003-438927 [41]

DESC Human gamma4 gene vector pICHgamma4.1 construction primer #3.

L4 ANSWER 113 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ACA89811 DNA DGENE
TI Novel immunologic molecule that binds to both human and nonhuman circulating alpha2-antiplasmins and human and non-human fibrin crosslinked alpha2-antiplasmins, useful for treating pulmonary embolism, thrombosis -
IN Reed G L
PA (REED-I) REED G L.
PI US 2003017147 A1 20030123 48p
AI US 1997-934000 19970919
PRAI US 1996-26356P 19960920
DT Patent
LA English
OS 2003-438927 [41]
DESC Human gamma4 gene vector pICHgamma4.1 construction primer #2.

L4 ANSWER 114 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ACA89810 DNA DGENE
TI Novel immunologic molecule that binds to both human and nonhuman circulating alpha2-antiplasmins and human and non-human fibrin crosslinked alpha2-antiplasmins, useful for treating pulmonary embolism, thrombosis -
IN Reed G L
PA (REED-I) REED G L.
PI US 2003017147 A1 20030123 48p
AI US 1997-934000 19970919
PRAI US 1996-26356P 19960920
DT Patent
LA English
OS 2003-438927 [41]
DESC Human gamma4 gene vector pICHgamma4.1 construction primer #1.

L4 ANSWER 115 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ACA89809 DNA DGENE
TI Novel immunologic molecule that binds to both human and nonhuman circulating alpha2-antiplasmins and human and non-human fibrin crosslinked alpha2-antiplasmins, useful for treating pulmonary embolism, thrombosis -
IN Reed G L
PA (REED-I) REED G L.
PI US 2003017147 A1 20030123 48p
AI US 1997-934000 19970919
PRAI US 1996-26356P 19960920
DT Patent
LA English
OS 2003-438927 [41]
DESC ***Alpha*** - ***2*** ***antiplasmin*** antibody expression vector pD16 oligonucleotide #6.

L4 ANSWER 116 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ACA89808 DNA DGENE
TI Novel immunologic molecule that binds to both human and nonhuman circulating alpha2-antiplasmins and human and non-human fibrin crosslinked alpha2-antiplasmins, useful for treating pulmonary embolism, thrombosis -
IN Reed G L
PA (REED-I) REED G L.
PI US 2003017147 A1 20030123 48p
AI US 1997-934000 19970919
PRAI US 1996-26356P 19960920
DT Patent
LA English
OS 2003-438927 [41]
DESC ***Alpha*** - ***2*** ***antiplasmin*** antibody expression vector pD16 oligonucleotide #5.

L4 ANSWER 117 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ACA89807 DNA DGENE
TI Novel immunologic molecule that binds to both human and nonhuman circulating alpha2-antiplasmins and human and non-human fibrin crosslinked alpha2-antiplasmins, useful for treating pulmonary embolism, thrombosis -
IN Reed G L
PA (REED-I) REED G L.

PI US 2003017147 A1 20030123 48p
AI US 1997-934000 19970919
PRAI US 1996-26356P 19960920
DT Patent
LA English
OS 2003-438927 [41]
DESC ***Alpha*** - ***2*** ***antiplasmin*** antibody expression vector pD16 oligonucleotide #4.

L4 ANSWER 118 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ACA89806 DNA DGENE
TI Novel immunologic molecule that binds to both human and nonhuman circulating alpha2-antiplasmins and human and non-human fibrin crosslinked alpha2-antiplasmins, useful for treating pulmonary embolism, thrombosis -
IN Reed G L
PA (REED-I) REED G L.
PI US 2003017147 A1 20030123 48p
AI US 1997-934000 19970919
PRAI US 1996-26356P 19960920
DT Patent
LA English
OS 2003-438927 [41]
DESC ***Alpha*** - ***2*** ***antiplasmin*** antibody expression vector pD16 oligonucleotide #3.

L4 ANSWER 119 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ACA89805 DNA DGENE
TI Novel immunologic molecule that binds to both human and nonhuman circulating alpha2-antiplasmins and human and non-human fibrin crosslinked alpha2-antiplasmins, useful for treating pulmonary embolism, thrombosis -
IN Reed G L
PA (REED-I) REED G L.
PI US 2003017147 A1 20030123 48p
AI US 1997-934000 19970919
PRAI US 1996-26356P 19960920
DT Patent
LA English
OS 2003-438927 [41]
DESC ***Alpha*** - ***2*** ***antiplasmin*** antibody expression vector pD16 oligonucleotide #2.

L4 ANSWER 120 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ACA89804 DNA DGENE
TI Novel immunologic molecule that binds to both human and nonhuman circulating alpha2-antiplasmins and human and non-human fibrin crosslinked alpha2-antiplasmins, useful for treating pulmonary embolism, thrombosis -
IN Reed G L
PA (REED-I) REED G L.
PI US 2003017147 A1 20030123 48p
AI US 1997-934000 19970919
PRAI US 1996-26356P 19960920
DT Patent
LA English
OS 2003-438927 [41]
DESC ***Alpha*** - ***2*** ***antiplasmin*** antibody expression vector pD16 oligonucleotide #1.

L4 ANSWER 121 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ACA89803 DNA DGENE
TI Novel immunologic molecule that binds to both human and nonhuman circulating alpha2-antiplasmins and human and non-human fibrin crosslinked alpha2-antiplasmins, useful for treating pulmonary embolism, thrombosis -
IN Reed G L
PA (REED-I) REED G L.
PI US 2003017147 A1 20030123 48p
AI US 1997-934000 19970919
PRAI US 1996-26356P 19960920
DT Patent
LA English
OS 2003-438927 [41]
DESC ***Alpha*** - ***2*** ***antiplasmin*** antibody expression vector pD12 oligonucleotide #2.

L4 ANSWER 122 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ACA89802 DNA DGENE
TI Novel immunologic molecule that binds to both human and nonhuman circulating alpha2-antiplasmins and human and non-human fibrin crosslinked alpha2-antiplasmins, useful for treating pulmonary embolism, thrombosis -
IN Reed G L
PA (REED-I) REED G L.
PI US 2003017147 A1 20030123 48p
AI US 1997-934000 19970919
PRAI US 1996-26356P 19960920
DT Patent
LA English
OS 2003-438927 [41]
DESC ***Alpha*** - ***2*** ***antiplasmin*** antibody expression vector pD12 oligonucleotide #1.

L4 ANSWER 123 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ACA89801 DNA DGENE
TI Novel immunologic molecule that binds to both human and nonhuman circulating alpha2-antiplasmins and human and non-human fibrin crosslinked alpha2-antiplasmins, useful for treating pulmonary embolism, thrombosis -
IN Reed G L
PA (REED-I) REED G L.
PI US 2003017147 A1 20030123 48p
AI US 1997-934000 19970919
PRAI US 1996-26356P 19960920
DT Patent
LA English
OS 2003-438927 [41]
DESC ***Alpha*** - ***2*** ***antiplasmin*** antibody RT-PCR 5' primer.

L4 ANSWER 124 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ACA89800 DNA DGENE
TI Novel immunologic molecule that binds to both human and nonhuman circulating alpha2-antiplasmins and human and non-human fibrin crosslinked alpha2-antiplasmins, useful for treating pulmonary embolism, thrombosis -
IN Reed G L
PA (REED-I) REED G L.
PI US 2003017147 A1 20030123 48p
AI US 1997-934000 19970919
PRAI US 1996-26356P 19960920
DT Patent
LA English
OS 2003-438927 [41]
DESC ***Alpha*** - ***2*** ***antiplasmin*** antibody heavy chain RT-PCR 3' primer.

L4 ANSWER 125 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ACA89799 DNA DGENE
TI Novel immunologic molecule that binds to both human and nonhuman circulating alpha2-antiplasmins and human and non-human fibrin crosslinked alpha2-antiplasmins, useful for treating pulmonary embolism, thrombosis -
IN Reed G L
PA (REED-I) REED G L.
PI US 2003017147 A1 20030123 48p
AI US 1997-934000 19970919
PRAI US 1996-26356P 19960920
DT Patent
LA English
OS 2003-438927 [41]
DESC ***Alpha*** - ***2*** ***antiplasmin*** antibody light chain RT-PCR 3' primer.

L4 ANSWER 126 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ACA89798 cDNA DGENE
TI Novel immunologic molecule that binds to both human and nonhuman circulating alpha2-antiplasmins and human and non-human fibrin crosslinked alpha2-antiplasmins, useful for treating pulmonary embolism, thrombosis -
IN Reed G L

PA (REED-I) REED G L.
PI US 2003017147 A1 20030123 48p
AI US 1997-934000 19970919
PRAI US 1996-26356P 19960920
DT Patent
LA English
OS 2003-438927 [41]
CR P-PSDB: ABU89687
DESC ***Alpha*** - ***2*** ***antiplasmin*** antibody 77A3-2 heavy chain cDNA.

L4 ANSWER 127 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ACA89797 cDNA DGENE
TI Novel immunologic molecule that binds to both human and nonhuman circulating alpha2-antiplasmins and human and non-human fibrin crosslinked alpha2-antiplasmins, useful for treating pulmonary embolism, thrombosis -
IN Reed G L
PA (REED-I) REED G L.
PI US 2003017147 A1 20030123 48p
AI US 1997-934000 19970919
PRAI US 1996-26356P 19960920
DT Patent
LA English
OS 2003-438927 [41]
CR P-PSDB: ABU89686
DESC ***Alpha*** - ***2*** ***antiplasmin*** antibody 77A3-1 heavy chain cDNA.

L4 ANSWER 128 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ACA89796 cDNA DGENE
TI Novel immunologic molecule that binds to both human and nonhuman circulating alpha2-antiplasmins and human and non-human fibrin crosslinked alpha2-antiplasmins, useful for treating pulmonary embolism, thrombosis -
IN Reed G L
PA (REED-I) REED G L.
PI US 2003017147 A1 20030123 48p
AI US 1997-934000 19970919
PRAI US 1996-26356P 19960920
DT Patent
LA English
OS 2003-438927 [41]
CR P-PSDB: ABU89685
DESC ***Alpha*** - ***2*** ***antiplasmin*** antibody 77A3-1 and 77A3-2 light chain cDNA.

L4 ANSWER 129 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ACA89795 cDNA DGENE
TI Novel immunologic molecule that binds to both human and nonhuman circulating alpha2-antiplasmins and human and non-human fibrin crosslinked alpha2-antiplasmins, useful for treating pulmonary embolism, thrombosis -
IN Reed G L
PA (REED-I) REED G L.
PI US 2003017147 A1 20030123 48p
AI US 1997-934000 19970919
PRAI US 1996-26356P 19960920
DT Patent
LA English
OS 2003-438927 [41]
CR P-PSDB: ABU89684
DESC ***Alpha*** - ***2*** ***antiplasmin*** antibody 77A3 heavy chain cDNA.

L4 ANSWER 130 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ACA89794 cDNA DGENE
TI Novel immunologic molecule that binds to both human and nonhuman circulating alpha2-antiplasmins and human and non-human fibrin crosslinked alpha2-antiplasmins, useful for treating pulmonary embolism, thrombosis -
IN Reed G L
PA (REED-I) REED G L.
PI US 2003017147 A1 20030123 48p
AI US 1997-934000 19970919
PRAI US 1996-26356P 19960920

DT Patent
LA English
OS 2003-438927 [41]
CR P-PSDB: ABU89683
DESC ***Alpha*** - ***2*** ***antiplasmin*** antibody 70B11 heavy chain cDNA.

L4 ANSWER 131 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ACA89793 cDNA DGENE
TI Novel immunologic molecule that binds to both human and nonhuman circulating alpha2-antiplasmins and human and non-human fibrin crosslinked alpha2-antiplasmins, useful for treating pulmonary embolism, thrombosis -
IN Reed G L
PA (REED-I) REED G L.
PI US 2003017147 A1 20030123 48p
AI US 1997-934000 19970919
PRAI US 1996-26356P 19960920
DT Patent
LA English
OS 2003-438927 [41]
CR P-PSDB: ABU89682
DESC ***Alpha*** - ***2*** ***antiplasmin*** antibody 49C9 heavy chain cDNA.

L4 ANSWER 132 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ACA89792 cDNA DGENE
TI Novel immunologic molecule that binds to both human and nonhuman circulating alpha2-antiplasmins and human and non-human fibrin crosslinked alpha2-antiplasmins, useful for treating pulmonary embolism, thrombosis -
IN Reed G L
PA (REED-I) REED G L.
PI US 2003017147 A1 20030123 48p
AI US 1997-934000 19970919
PRAI US 1996-26356P 19960920
DT Patent
LA English
OS 2003-438927 [41]
CR P-PSDB: ABU89681
DESC ***Alpha*** - ***2*** ***antiplasmin*** antibody 77A3 light chain cDNA.

L4 ANSWER 133 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ACA89791 cDNA DGENE
TI Novel immunologic molecule that binds to both human and nonhuman circulating alpha2-antiplasmins and human and non-human fibrin crosslinked alpha2-antiplasmins, useful for treating pulmonary embolism, thrombosis -
IN Reed G L
PA (REED-I) REED G L.
PI US 2003017147 A1 20030123 48p
AI US 1997-934000 19970919
PRAI US 1996-26356P 19960920
DT Patent
LA English
OS 2003-438927 [41]
CR P-PSDB: ABU89680
DESC ***Alpha*** - ***2*** ***antiplasmin*** antibody 70B11 light chain cDNA.

L4 ANSWER 134 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ACA89790 cDNA DGENE
TI Novel immunologic molecule that binds to both human and nonhuman circulating alpha2-antiplasmins and human and non-human fibrin crosslinked alpha2-antiplasmins, useful for treating pulmonary embolism, thrombosis -
IN Reed G L
PA (REED-I) REED G L.
PI US 2003017147 A1 20030123 48p
AI US 1997-934000 19970919
PRAI US 1996-26356P 19960920
DT Patent
LA English
OS 2003-438927 [41]
CR P-PSDB: ABU89679

DESC ***Alpha*** - ***2*** ***antiplasmin*** antibody 49C9 light chain cDNA.

L4 ANSWER 135 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAV26389 cDNA DGENE
TI Chimeric and humanised antibodies which bind to and inhibit circulating alpha-2-anti- ***plasmin*** - useful for, e.g. enhancing fibrinolysis for treatment of pulmonary embolism(s) and heart attack(s)
IN Bajorath J; Harris L; Hsu M; Matsueda G; Novotny J; Reed G L
PA (BAJO-I) BAJORATH J.
(HARR-I) HARRIS L.
(HSUM-I) HSU M.
(MATS-I) MATSUEDA G.
(NOVO-I) NOVOTNY J.
(REED-I) REED G L.
PI WO 9812334 A2 19980326 103p
AI WO 1997-US16123 19970919
PRAI US 1996-26356 19960920
DT Patent
LA English
OS 1998-217271 [19]
CR P-PSDB: AAW46303
DESC Murine MAb 77A3 heavy chain variable region encoding cDNA.

L4 ANSWER 136 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAV26388 cDNA DGENE
TI Chimeric and humanised antibodies which bind to and inhibit circulating alpha-2-anti- ***plasmin*** - useful for, e.g. enhancing fibrinolysis for treatment of pulmonary embolism(s) and heart attack(s)
IN Bajorath J; Harris L; Hsu M; Matsueda G; Novotny J; Reed G L
PA (BAJO-I) BAJORATH J.
(HARR-I) HARRIS L.
(HSUM-I) HSU M.
(MATS-I) MATSUEDA G.
(NOVO-I) NOVOTNY J.
(REED-I) REED G L.
PI WO 9812334 A2 19980326 103p
AI WO 1997-US16123 19970919
PRAI US 1996-26356 19960920
DT Patent
LA English
OS 1998-217271 [19]
CR P-PSDB: AAW46302
DESC Murine MAb 70B11 heavy chain variable region encoding cDNA.

L4 ANSWER 137 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAV26387 cDNA DGENE
TI Chimeric and humanised antibodies which bind to and inhibit circulating alpha-2-anti- ***plasmin*** - useful for, e.g. enhancing fibrinolysis for treatment of pulmonary embolism(s) and heart attack(s)
IN Bajorath J; Harris L; Hsu M; Matsueda G; Novotny J; Reed G L
PA (BAJO-I) BAJORATH J.
(HARR-I) HARRIS L.
(HSUM-I) HSU M.
(MATS-I) MATSUEDA G.
(NOVO-I) NOVOTNY J.
(REED-I) REED G L.
PI WO 9812334 A2 19980326 103p
AI WO 1997-US16123 19970919
PRAI US 1996-26356 19960920
DT Patent
LA English
OS 1998-217271 [19]
CR P-PSDB: AAW46301
DESC Murine MAb 49C9 heavy chain variable region encoding cDNA.

L4 ANSWER 138 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAV26384 DNA DGENE
TI Chimeric and humanised antibodies which bind to and inhibit circulating alpha-2-anti- ***plasmin*** - useful for, e.g. enhancing fibrinolysis for treatment of pulmonary embolism(s) and heart attack(s)
IN Bajorath J; Harris L; Hsu M; Matsueda G; Novotny J; Reed G L
PA (BAJO-I) BAJORATH J.
(HARR-I) HARRIS L.
(HSUM-I) HSU M.
(MATS-I) MATSUEDA G.

(NOVO-I) NOVOTNY J.
(REED-I) REED G L.
PI WO 9812334 A2 19980326 103p
AI WO 1997-US16123 19970919
PRAI US 1996-26356 19960920
DT Patent
LA English
OS 1998-217271 [19]
CR P-PSDB: AAW46298
DESC Murine MAb 49C9 light chain variable region encoding cDNA.

L4 ANSWER 139 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAV26386 cDNA DGENE
TI Chimeric and humanised antibodies which bind to and inhibit circulating alpha-2-anti- ***plasmin*** - useful for, e.g. enhancing fibrinolysis for treatment of pulmonary embolism(s) and heart attack(s)
IN Bajorath J; Harris L; Hsu M; Matsueda G; Novotny J; Reed G L
PA (BAJO-I) BAJORATH J.
(HARR-I) HARRIS L.
(HSUM-I) HSU M.
(MATS-I) MATSUEDA G.
(NOVO-I) NOVOTNY J.
(REED-I) REED G L.
PI WO 9812334 A2 19980326 103p
AI WO 1997-US16123 19970919
PRAI US 1996-26356 19960920
DT Patent
LA English
OS 1998-217271 [19]
CR P-PSDB: AAW46300
DESC Murine MAb 77A3 light chain variable region encoding cDNA.

L4 ANSWER 140 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAV26385 cDNA DGENE
TI Chimeric and humanised antibodies which bind to and inhibit circulating alpha-2-anti- ***plasmin*** - useful for, e.g. enhancing fibrinolysis for treatment of pulmonary embolism(s) and heart attack(s)
IN Bajorath J; Harris L; Hsu M; Matsueda G; Novotny J; Reed G L
PA (BAJO-I) BAJORATH J.
(HARR-I) HARRIS L.
(HSUM-I) HSU M.
(MATS-I) MATSUEDA G.
(NOVO-I) NOVOTNY J.
(REED-I) REED G L.
PI WO 9812334 A2 19980326 103p
AI WO 1997-US16123 19970919
PRAI US 1996-26356 19960920
DT Patent
LA English
OS 1998-217271 [19]
CR P-PSDB: AAW46299
DESC Murine MAb 70B11 light chain variable region encoding cDNA.

L4 ANSWER 141 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAV21662 DNA DGENE
TI Chimeric and humanised antibodies which bind to and inhibit circulating alpha2-anti- ***plasmin*** - useful for, e.g. enhancing fibrinolysis for treatment of pulmonary embolism(s) and heart attack(s)
IN Reed G L
PA (REED-I) REED G L.
PI WO 9812329 A2 19980326 103p
AI WO 1997-US16122 19970919
PRAI US 1996-26356 19960920
DT Patent
LA English
OS 1998-217268 [19]
DESC Murine MAb 49C9 light chain variable region encoding cDNA.

L4 ANSWER 142 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAV26390 cDNA DGENE
TI Chimeric and humanised antibodies which bind to and inhibit circulating alpha-2-anti- ***plasmin*** - useful for, e.g. enhancing fibrinolysis for treatment of pulmonary embolism(s) and heart attack(s)
IN Bajorath J; Harris L; Hsu M; Matsueda G; Novotny J; Reed G L
PA (BAJO-I) BAJORATH J.
(HARR-I) HARRIS L.

(HSUM-I) HSU M.
(MATS-I) MATSUEDA G.
(NOVO-I) NOVOTNY J.
(REED-I) REED G L.
PI WO 9812334 A2 19980326 103p
AI WO 1997-US16123 19970919
PRAI US 1996-26356 19960920
DT Patent
LA English
OS 1998-217271 [19]
CR P-PSDB: AAW46304
DESC Humanised antibody 77A3-1 and 77A3-2 light chain encoding cDNA.

L4 ANSWER 143 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAV21675 DNA DGENE
TI Chimeric and humanised antibodies which bind to and inhibit circulating alpha2-anti- ***plasmin*** - useful for, e.g. enhancing fibrinolysis for treatment of pulmonary embolism(s) and heart attack(s)
IN Reed G L
PA (REED-I) REED G L.
PI WO 9812329 A2 19980326 103p
AI WO 1997-US16122 19970919
PRAI US 1996-26356 19960920
DT Patent
LA English
OS 1998-217268 [19]
DESC Humanised antibody vector constructing 3' primer 1.

L4 ANSWER 144 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAV21674 DNA DGENE
TI Chimeric and humanised antibodies which bind to and inhibit circulating alpha2-anti- ***plasmin*** - useful for, e.g. enhancing fibrinolysis for treatment of pulmonary embolism(s) and heart attack(s)
IN Reed G L
PA (REED-I) REED G L.
PI WO 9812329 A2 19980326 103p
AI WO 1997-US16122 19970919
PRAI US 1996-26356 19960920
DT Patent
LA English
OS 1998-217268 [19]
DESC Humanised antibody vector constructing 5' primer 1.

L4 ANSWER 145 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAV21673 DNA DGENE
TI Chimeric and humanised antibodies which bind to and inhibit circulating alpha2-anti- ***plasmin*** - useful for, e.g. enhancing fibrinolysis for treatment of pulmonary embolism(s) and heart attack(s)
IN Reed G L
PA (REED-I) REED G L.
PI WO 9812329 A2 19980326 103p
AI WO 1997-US16122 19970919
PRAI US 1996-26356 19960920
DT Patent
LA English
OS 1998-217268 [19]
DESC Murine MAb light chain mRNA amplifying RT-PCR 5' primer.

L4 ANSWER 146 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAV21672 DNA DGENE
TI Chimeric and humanised antibodies which bind to and inhibit circulating alpha2-anti- ***plasmin*** - useful for, e.g. enhancing fibrinolysis for treatment of pulmonary embolism(s) and heart attack(s)
IN Reed G L
PA (REED-I) REED G L.
PI WO 9812329 A2 19980326 103p
AI WO 1997-US16122 19970919
PRAI US 1996-26356 19960920
DT Patent
LA English
OS 1998-217268 [19]
DESC Murine MAb heavy chain mRNA amplifying RT-PCR 3' primer.

L4 ANSWER 147 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAV21671 DNA DGENE
TI Chimeric and humanised antibodies which bind to and inhibit circulating

alpha2-anti- ***plasmin*** - useful for, e.g. enhancing fibrinolysis for treatment of pulmonary embolism(s) and heart attack(s)
IN Reed G L
PA (REED-I) REED G L.
PI WO 9812329 A2 19980326 103p
AI WO 1997-US16122 19970919
PRAI US 1996-26356 19960920
DT Patent
LA English
OS 1998-217268 [19]
DESC Murine MAb light chain mRNA amplifying RT-PCR 3' primer.

L4 ANSWER 148 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAV21670 cDNA DGENE
TI Chimeric and humanised antibodies which bind to and inhibit circulating alpha2-anti- ***plasmin*** - useful for, e.g. enhancing fibrinolysis for treatment of pulmonary embolism(s) and heart attack(s)
IN Reed G L
PA (REED-I) REED G L.
PI WO 9812329 A2 19980326 103p
AI WO 1997-US16122 19970919
PRAI US 1996-26356 19960920
DT Patent
LA English
OS 1998-217268 [19]
CR P-PSDB: AAW53199
DESC Humanised antibody 77A3-2 heavy chain encoding cDNA.

L4 ANSWER 149 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAV21669 cDNA DGENE
TI Chimeric and humanised antibodies which bind to and inhibit circulating alpha2-anti- ***plasmin*** - useful for, e.g. enhancing fibrinolysis for treatment of pulmonary embolism(s) and heart attack(s)
IN Reed G L
PA (REED-I) REED G L.
PI WO 9812329 A2 19980326 103p
AI WO 1997-US16122 19970919
PRAI US 1996-26356 19960920
DT Patent
LA English
OS 1998-217268 [19]
CR P-PSDB: AAW53198
DESC Humanised antibody 77A3-1 heavy chain encoding cDNA.

L4 ANSWER 150 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAV21668 cDNA DGENE
TI Chimeric and humanised antibodies which bind to and inhibit circulating alpha2-anti- ***plasmin*** - useful for, e.g. enhancing fibrinolysis for treatment of pulmonary embolism(s) and heart attack(s)
IN Reed G L
PA (REED-I) REED G L.
PI WO 9812329 A2 19980326 103p
AI WO 1997-US16122 19970919
PRAI US 1996-26356 19960920
DT Patent
LA English
OS 1998-217268 [19]
CR P-PSDB: AAW53197
DESC Humanised antibody 77A3-1 and 77A3-2 light chain encoding cDNA.

L4 ANSWER 151 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAV21667 cDNA DGENE
TI Chimeric and humanised antibodies which bind to and inhibit circulating alpha2-anti- ***plasmin*** - useful for, e.g. enhancing fibrinolysis for treatment of pulmonary embolism(s) and heart attack(s)
IN Reed G L
PA (REED-I) REED G L.
PI WO 9812329 A2 19980326 103p
AI WO 1997-US16122 19970919
PRAI US 1996-26356 19960920
DT Patent
LA English
OS 1998-217268 [19]
CR P-PSDB: AAW53196
DESC Murine MAb 77A3 heavy chain variable region encoding cDNA.

L4 ANSWER 152 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAV21666 cDNA DGENE
TI Chimeric and humanised antibodies which bind to and inhibit circulating alpha2-anti- ***plasmin*** - useful for, e.g. enhancing fibrinolysis for treatment of pulmonary embolism(s) and heart attack(s)
IN Reed G L
PA (REED-I) REED G L.
PI WO 9812329 A2 19980326 103p
AI WO 1997-US16122 19970919
PRAI US 1996-26356 19960920
DT Patent
LA English
OS 1998-217268 [19]
CR P-PSDB: AAW53195
DESC Murine MAb 70B11 heavy chain variable region encoding cDNA.

L4 ANSWER 153 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAV21676 DNA DGENE
TI Chimeric and humanised antibodies which bind to and inhibit circulating alpha2-anti- ***plasmin*** - useful for, e.g. enhancing fibrinolysis for treatment of pulmonary embolism(s) and heart attack(s)
IN Reed G L
PA (REED-I) REED G L.
PI WO 9812329 A2 19980326 103p
AI WO 1997-US16122 19970919
PRAI US 1996-26356 19960920
DT Patent
LA English
OS 1998-217268 [19]
DESC Humanised antibody vector constructing 5' primer 2.

L4 ANSWER 154 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAV32155 DNA DGENE
TI Chimeric and humanised antibodies which bind to and inhibit circulating alpha2-anti- ***plasmin*** - useful for, e.g. enhancing fibrinolysis for treatment of pulmonary embolism(s) and heart attack(s)
IN Reed G L
PA (REED-I) REED G L.
PI WO 9812329 A2 19980326 103p
AI WO 1997-US16122 19970919
PRAI US 1996-26356 19960920
DT Patent
LA English
OS 1998-217268 [19]
DESC Humanised antibody vector constructing antisense primer 2.

L4 ANSWER 155 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAV32154 DNA DGENE
TI Chimeric and humanised antibodies which bind to and inhibit circulating alpha2-anti- ***plasmin*** - useful for, e.g. enhancing fibrinolysis for treatment of pulmonary embolism(s) and heart attack(s)
IN Reed G L
PA (REED-I) REED G L.
PI WO 9812329 A2 19980326 103p
AI WO 1997-US16122 19970919
PRAI US 1996-26356 19960920
DT Patent
LA English
OS 1998-217268 [19]
DESC Humanised antibody vector constructing sense primer 2.

L4 ANSWER 156 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAV32153 DNA DGENE
TI Chimeric and humanised antibodies which bind to and inhibit circulating alpha2-anti- ***plasmin*** - useful for, e.g. enhancing fibrinolysis for treatment of pulmonary embolism(s) and heart attack(s)
IN Reed G L
PA (REED-I) REED G L.
PI WO 9812329 A2 19980326 103p
AI WO 1997-US16122 19970919
PRAI US 1996-26356 19960920
DT Patent
LA English
OS 1998-217268 [19]
DESC Humanised antibody vector constructing antisense primer 1.

L4 ANSWER 157 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAV32152 DNA DGENE
TI Chimeric and humanised antibodies which bind to and inhibit circulating alpha2-anti- ***plasmin*** - useful for, e.g. enhancing fibrinolysis for treatment of pulmonary embolism(s) and heart attack(s)
IN Reed G L
PA (REED-I) REED G L.
PI WO 9812329 A2 19980326 103p
AI WO 1997-US16122 19970919
PRAI US 1996-26356 19960920
DT Patent
LA English
OS 1998-217268 [19]
DESC Humanised antibody vector constructing sense primer 1.

L4 ANSWER 158 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAV32151 DNA DGENE
TI Chimeric and humanised antibodies which bind to and inhibit circulating alpha2-anti- ***plasmin*** - useful for, e.g. enhancing fibrinolysis for treatment of pulmonary embolism(s) and heart attack(s)
IN Reed G L
PA (REED-I) REED G L.
PI WO 9812329 A2 19980326 103p
AI WO 1997-US16122 19970919
PRAI US 1996-26356 19960920
DT Patent
LA English
OS 1998-217268 [19]
DESC Humanised antibody vector constructing 3' primer 3.

L4 ANSWER 159 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAV21678 DNA DGENE
TI Chimeric and humanised antibodies which bind to and inhibit circulating alpha2-anti- ***plasmin*** - useful for, e.g. enhancing fibrinolysis for treatment of pulmonary embolism(s) and heart attack(s)
IN Reed G L
PA (REED-I) REED G L.
PI WO 9812329 A2 19980326 103p
AI WO 1997-US16122 19970919
PRAI US 1996-26356 19960920
DT Patent
LA English
OS 1998-217268 [19]
DESC Humanised antibody vector constructing 5' primer 3.

L4 ANSWER 160 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAV21677 DNA DGENE
TI Chimeric and humanised antibodies which bind to and inhibit circulating alpha2-anti- ***plasmin*** - useful for, e.g. enhancing fibrinolysis for treatment of pulmonary embolism(s) and heart attack(s)
IN Reed G L
PA (REED-I) REED G L.
PI WO 9812329 A2 19980326 103p
AI WO 1997-US16122 19970919
PRAI US 1996-26356 19960920
DT Patent
LA English
OS 1998-217268 [19]
DESC Humanised antibody vector constructing 3' primer 2.

L4 ANSWER 161 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAV26400 DNA DGENE
TI Chimeric and humanised antibodies which bind to and inhibit circulating alpha-2-anti- ***plasmin*** - useful for, e.g. enhancing fibrinolysis for treatment of pulmonary embolism(s) and heart attack(s)
IN Bajorath J; Harris L; Hsu M; Matsueda G; Novotny J; Reed G L
PA (BAJO-I) BAJORATH J.
(HARR-I) HARRIS L.
(HSUM-I) HSU M.
(MATS-I) MATSUEDA G.
(NOVO-I) NOVOTNY J.
(REED-I) REED G L.
PI WO 9812334 A2 19980326 103p
AI WO 1997-US16123 19970919
PRAI US 1996-26356 19960920
DT Patent

LA English
OS 1998-217271 [19]
DESC Humanised antibody vector constructing 5' primer 3.

L4 ANSWER 162 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAV26399 DNA DGENE
TI Chimeric and humanised antibodies which bind to and inhibit circulating alpha-2-anti- ***plasmin*** - useful for, e.g. enhancing fibrinolysis for treatment of pulmonary embolism(s) and heart attack(s)
IN Bajorath J; Harris L; Hsu M; Matsueda G; Novotny J; Reed G L
PA (BAJO-I) BAJORATH J.
(HARR-I) HARRIS L.
(HSUM-I) HSU M.
(MATS-I) MATSUEDA G.
(NOVO-I) NOVOTNY J.
(REED-I) REED G L.
PI WO 9812334 A2 19980326 103p
AI WO 1997-US16123 19970919
PRAI US 1996-26356 19960920
DT Patent
LA English
OS 1998-217271 [19]
DESC Humanised antibody vector constructing 3' primer 2.

L4 ANSWER 163 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAV26398 DNA DGENE
TI Chimeric and humanised antibodies which bind to and inhibit circulating alpha-2-anti- ***plasmin*** - useful for, e.g. enhancing fibrinolysis for treatment of pulmonary embolism(s) and heart attack(s)
IN Bajorath J; Harris L; Hsu M; Matsueda G; Novotny J; Reed G L
PA (BAJO-I) BAJORATH J.
(HARR-I) HARRIS L.
(HSUM-I) HSU M.
(MATS-I) MATSUEDA G.
(NOVO-I) NOVOTNY J.
(REED-I) REED G L.
PI WO 9812334 A2 19980326 103p
AI WO 1997-US16123 19970919
PRAI US 1996-26356 19960920
DT Patent
LA English
OS 1998-217271 [19]
DESC Humanised antibody vector constructing 5' primer 2.

L4 ANSWER 164 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAV26397 DNA DGENE
TI Chimeric and humanised antibodies which bind to and inhibit circulating alpha-2-anti- ***plasmin*** - useful for, e.g. enhancing fibrinolysis for treatment of pulmonary embolism(s) and heart attack(s)
IN Bajorath J; Harris L; Hsu M; Matsueda G; Novotny J; Reed G L
PA (BAJO-I) BAJORATH J.
(HARR-I) HARRIS L.
(HSUM-I) HSU M.
(MATS-I) MATSUEDA G.
(NOVO-I) NOVOTNY J.
(REED-I) REED G L.
PI WO 9812334 A2 19980326 103p
AI WO 1997-US16123 19970919
PRAI US 1996-26356 19960920
DT Patent
LA English
OS 1998-217271 [19]
DESC Humanised antibody vector constructing 3' primer 1.

L4 ANSWER 165 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAV26396 DNA DGENE
TI Chimeric and humanised antibodies which bind to and inhibit circulating alpha-2-anti- ***plasmin*** - useful for, e.g. enhancing fibrinolysis for treatment of pulmonary embolism(s) and heart attack(s)
IN Bajorath J; Harris L; Hsu M; Matsueda G; Novotny J; Reed G L
PA (BAJO-I) BAJORATH J.
(HARR-I) HARRIS L.
(HSUM-I) HSU M.
(MATS-I) MATSUEDA G.
(NOVO-I) NOVOTNY J.
(REED-I) REED G L.

PI WO 9812334 A2 19980326 103p
AI WO 1997-US16123 19970919
PRAI US 1996-26356 19960920
DT Patent
LA English
OS 1998-217271 [19]
DESC Humanised antibody vector constructing 5' primer 1.

L4 ANSWER 166 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAV26395 DNA DGENE
TI Chimeric and humanised antibodies which bind to and inhibit circulating alpha-2-anti- ***plasmin*** - useful for, e.g. enhancing fibrinolysis for treatment of pulmonary embolism(s) and heart attack(s)
IN Bajorath J; Harris L; Hsu M; Matsueda G; Novotny J; Reed G L
PA (BAJO-I) BAJORATH J.
(HARR-I) HARRIS L.
(HSUM-I) HSU M.
(MATS-I) MATSUEDA G.
(NOVO-I) NOVOTNY J.
(REED-I) REED G L.
PI WO 9812334 A2 19980326 103p
AI WO 1997-US16123 19970919
PRAI US 1996-26356 19960920
DT Patent
LA English
OS 1998-217271 [19]
DESC Murine MAb light chain mRNA amplifying RT-PCR 5' primer.

L4 ANSWER 167 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAV26394 DNA DGENE
TI Chimeric and humanised antibodies which bind to and inhibit circulating alpha-2-anti- ***plasmin*** - useful for, e.g. enhancing fibrinolysis for treatment of pulmonary embolism(s) and heart attack(s)
IN Bajorath J; Harris L; Hsu M; Matsueda G; Novotny J; Reed G L
PA (BAJO-I) BAJORATH J.
(HARR-I) HARRIS L.
(HSUM-I) HSU M.
(MATS-I) MATSUEDA G.
(NOVO-I) NOVOTNY J.
(REED-I) REED G L.
PI WO 9812334 A2 19980326 103p
AI WO 1997-US16123 19970919
PRAI US 1996-26356 19960920
DT Patent
LA English
OS 1998-217271 [19]
DESC Murine MAb heavy chain mRNA amplifying RT-PCR 3' primer.

L4 ANSWER 168 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAV26393 DNA DGENE
TI Chimeric and humanised antibodies which bind to and inhibit circulating alpha-2-anti- ***plasmin*** - useful for, e.g. enhancing fibrinolysis for treatment of pulmonary embolism(s) and heart attack(s)
IN Bajorath J; Harris L; Hsu M; Matsueda G; Novotny J; Reed G L
PA (BAJO-I) BAJORATH J.
(HARR-I) HARRIS L.
(HSUM-I) HSU M.
(MATS-I) MATSUEDA G.
(NOVO-I) NOVOTNY J.
(REED-I) REED G L.
PI WO 9812334 A2 19980326 103p
AI WO 1997-US16123 19970919
PRAI US 1996-26356 19960920
DT Patent
LA English
OS 1998-217271 [19]
DESC Murine MAb light chain mRNA amplifying RT-PCR 3' primer.

L4 ANSWER 169 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAV26392 cDNA DGENE
TI Chimeric and humanised antibodies which bind to and inhibit circulating alpha-2-anti- ***plasmin*** - useful for, e.g. enhancing fibrinolysis for treatment of pulmonary embolism(s) and heart attack(s)
IN Bajorath J; Harris L; Hsu M; Matsueda G; Novotny J; Reed G L
PA (BAJO-I) BAJORATH J.
(HARR-I) HARRIS L.

(HSUM-I) HSU M.
(MATS-I) MATSUEDA G.
(NOVO-I) NOVOTNY J.
(REED-I) REED G L.
PI WO 9812334 A2 19980326 103p
AI WO 1997-US16123 19970919
PRAI US 1996-26356 19960920
DT Patent
LA English
OS 1998-217271 [19]
CR P-PSDB: AAW46306
DESC Humanised antibody 77A3-2 heavy chain encoding cDNA.

L4 ANSWER 170 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAV26391 cDNA DGENE
TI Chimeric and humanised antibodies which bind to and inhibit circulating alpha-2-anti- ***plasmin*** - useful for, e.g. enhancing fibrinolysis for treatment of pulmonary embolism(s) and heart attack(s)
IN Bajorath J; Harris L; Hsu M; Matsueda G; Novotny J; Reed G L
PA (BAJO-I) BAJORATH J.
(HARR-I) HARRIS L.
(HSUM-I) HSU M.
(MATS-I) MATSUEDA G.
(NOVO-I) NOVOTNY J.
(REED-I) REED G L.
PI WO 9812334 A2 19980326 103p
AI WO 1997-US16123 19970919
PRAI US 1996-26356 19960920
DT Patent
LA English
OS 1998-217271 [19]
CR P-PSDB: AAW46305
DESC Humanised antibody 77A3-1 heavy chain encoding cDNA.

L4 ANSWER 171 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAV32101 DNA DGENE
TI Chimeric and humanised antibodies which bind to and inhibit circulating alpha-2-anti- ***plasmin*** - useful for, e.g. enhancing fibrinolysis for treatment of pulmonary embolism(s) and heart attack(s)
IN Bajorath J; Harris L; Hsu M; Matsueda G; Novotny J; Reed G L
PA (BAJO-I) BAJORATH J.
(HARR-I) HARRIS L.
(HSUM-I) HSU M.
(MATS-I) MATSUEDA G.
(NOVO-I) NOVOTNY J.
(REED-I) REED G L.
PI WO 9812334 A2 19980326 103p
AI WO 1997-US16123 19970919
PRAI US 1996-26356 19960920
DT Patent
LA English
OS 1998-217271 [19]
DESC Humanised antibody vector constructing 3' primer 3.

L4 ANSWER 172 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAV32105 DNA DGENE
TI Chimeric and humanised antibodies which bind to and inhibit circulating alpha-2-anti- ***plasmin*** - useful for, e.g. enhancing fibrinolysis for treatment of pulmonary embolism(s) and heart attack(s)
IN Bajorath J; Harris L; Hsu M; Matsueda G; Novotny J; Reed G L
PA (BAJO-I) BAJORATH J.
(HARR-I) HARRIS L.
(HSUM-I) HSU M.
(MATS-I) MATSUEDA G.
(NOVO-I) NOVOTNY J.
(REED-I) REED G L.
PI WO 9812334 A2 19980326 103p
AI WO 1997-US16123 19970919
PRAI US 1996-26356 19960920
DT Patent
LA English
OS 1998-217271 [19]
DESC Humanised antibody vector constructing antisense primer 2.

L4 ANSWER 173 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAV32104 DNA DGENE

TI Chimeric and humanised antibodies which bind to and inhibit circulating alpha-2-anti- ***plasmin*** - useful for, e.g. enhancing fibrinolysis for treatment of pulmonary embolism(s) and heart attack(s)
IN Bajorath J; Harris L; Hsu M; Matsueda G; Novotny J; Reed G L
PA (BAJO-I) BAJORATH J.
(HARR-I) HARRIS L.
(HSUM-I) HSU M.
(MATS-I) MATSUEDA G.
(NOVO-I) NOVOTNY J.
(REED-I) REED G L.
PI WO 9812334 A2 19980326 103p
AI WO 1997-US16123 19970919
PRAI US 1996-26356 19960920
DT Patent
LA English
OS 1998-217271 [19]
DESC Humanised antibody vector constructing sense primer 2.

L4 ANSWER 174 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAV32103 DNA DGENE
TI Chimeric and humanised antibodies which bind to and inhibit circulating alpha-2-anti- ***plasmin*** - useful for, e.g. enhancing fibrinolysis for treatment of pulmonary embolism(s) and heart attack(s)
IN Bajorath J; Harris L; Hsu M; Matsueda G; Novotny J; Reed G L
PA (BAJO-I) BAJORATH J.
(HARR-I) HARRIS L.
(HSUM-I) HSU M.
(MATS-I) MATSUEDA G.
(NOVO-I) NOVOTNY J.
(REED-I) REED G L.
PI WO 9812334 A2 19980326 103p
AI WO 1997-US16123 19970919
PRAI US 1996-26356 19960920
DT Patent
LA English
OS 1998-217271 [19]
DESC Humanised antibody vector constructing antisense primer 1.

L4 ANSWER 175 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAV32102 DNA DGENE
TI Chimeric and humanised antibodies which bind to and inhibit circulating alpha-2-anti- ***plasmin*** - useful for, e.g. enhancing fibrinolysis for treatment of pulmonary embolism(s) and heart attack(s)
IN Bajorath J; Harris L; Hsu M; Matsueda G; Novotny J; Reed G L
PA (BAJO-I) BAJORATH J.
(HARR-I) HARRIS L.
(HSUM-I) HSU M.
(MATS-I) MATSUEDA G.
(NOVO-I) NOVOTNY J.
(REED-I) REED G L.
PI WO 9812334 A2 19980326 103p
AI WO 1997-US16123 19970919
PRAI US 1996-26356 19960920
DT Patent
LA English
OS 1998-217271 [19]
DESC Humanised antibody vector constructing sense primer 1.

L4 ANSWER 176 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAV21665 cDNA DGENE
TI Chimeric and humanised antibodies which bind to and inhibit circulating alpha2-anti- ***plasmin*** - useful for, e.g. enhancing fibrinolysis for treatment of pulmonary embolism(s) and heart attack(s)
IN Reed G L
PA (REED-I) REED G L.
PI WO 9812329 A2 19980326 103p
AI WO 1997-US16122 19970919
PRAI US 1996-26356 19960920
DT Patent
LA English
OS 1998-217268 [19]
CR P-PSDB: AAW53194
DESC Murine MAb 49C9 heavy chain variable region encoding cDNA.

L4 ANSWER 177 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAV21664 cDNA DGENE

TI Chimeric and humanised antibodies which bind to and inhibit circulating alpha2-anti- ***plasmin*** - useful for, e.g. enhancing fibrinolysis for treatment of pulmonary embolism(s) and heart attack(s)
IN Reed G L
PA (REED-I) REED G L.
PI WO 9812329 A2 19980326 103p
AI WO 1997-US16122 19970919
PRAI US 1996-26356 19960920
DT Patent
LA English
OS 1998-217268 [19]
CR P-PSDB: AAW53193
DESC Murine MAb 77A3 light chain variable region encoding cDNA.

L4 ANSWER 178 OF 268 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAV21663 cDNA DGENE
TI Chimeric and humanised antibodies which bind to and inhibit circulating alpha2-anti- ***plasmin*** - useful for, e.g. enhancing fibrinolysis for treatment of pulmonary embolism(s) and heart attack(s)
IN Reed G L
PA (REED-I) REED G L.
PI WO 9812329 A2 19980326 103p
AI WO 1997-US16122 19970919
PRAI US 1996-26356 19960920
DT Patent
LA English
OS 1998-217268 [19]
CR P-PSDB: AAW53192
DESC Murine MAb 70B11 light chain variable region encoding cDNA.

L4 ANSWER 179 OF 268 DRUGU COPYRIGHT 2004 THOMSON DERWENT on STN
AN 2002-10698 DRUGU P
TI Plasminogen activation without changes in tPA and PAI-1 in response to subcutaneous administration of ancrod.
AU Dempfle C E; Alesci S; Kucher K; Mueller Peltzer H; Ruebsamen K; Borggrefe M
CS Univ.Heidelberg; Knoll
LO Mannheim; Ludwigshafen, Ger.
SO Thromb.Res. (104, No. 6, 433-38, 2001) 5 Fig. 22 Ref.
CODEN: THBRAA ISSN: 0049-3848
AV Universitaetsklinikum Mannheim, I. Med.Klinik, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany. (email: dempfle@verw.ma.uni-heidelberg.de).
LA English
DT Journal
FA AB; LA; CT
FS Literature

L4 ANSWER 180 OF 268 DRUGU COPYRIGHT 2004 THOMSON DERWENT on STN
AN 1995-11938 DRUGU P S
TI Role of systemic ***plasmin*** in hemorrhagic transformations and peripheral bleeding seen after streptokinase or tissue plasminogen activator.
AU Thibodeaux H; Errett C J; Badillo J M; Keyt B A; Refino C J; Bennett W F; Thomas G R
CS Genentech
LO South San Francisco, Cal., USA
SO Stroke (26, No. 1, 175, 1995) 2 Ref.
CODEN: SJCCA7 ISSN: 0039-2499
AV Department of Cardiovascular Research, Genentech Inc., 460 Point San Bruno Boulevard, South San Francisco, CA 94080, U.S.A.
LA English
DT Journal
FA AB; LA; CT
FS Literature

L4 ANSWER 181 OF 268 DRUGU COPYRIGHT 2004 THOMSON DERWENT on STN
AN 1987-31335 DRUGU C P T S
TI Tissue Plasminogen Activator: A New Thrombolytic Agent.
AU Crabbe S J; Cloninger C C
LO Hershey, Philadelphia, Pennsylvania, United States
SO Clin.Pharm. (6, No. 5, 373-86, 1987) 3 Fig. 2 Tab. 99 Ref.
CODEN: CPHADV ISSN: 0278-2677
AV Department of Pharmacy, Thomas Jefferson University Hospital, 111 South 11th Street, Philadelphia, PA 19107, U.S.A.
LA English
DT Journal

FA AB; LA; CT
FS Literature

L4 ANSWER 182 OF 268 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
AN 2000425268 EMBASE
TI Activation of thrombosis and fibrinolysis following brain infarction.
AU Kataoka S.; Hirose G.; Hori A.; Shirakawa T.; Saigan T.
CS S. Kataoka, Department of Neurology, Kanazawa Medical University, Daigaku 1-1, Uchinada-machi, Kahoku-gun, Ishikawa 920-0293, Japan
SO Journal of the Neurological Sciences, (1 Dec 2000) 181/1-2 (82-88).
Refs: 35
ISSN: 0022-510X CODEN: JNSCAG
PUI S 0022-510X(00)00435-4
CY Netherlands
DT Journal; Article
FS 008 Neurology and Neurosurgery
025 Hematology
LA English
SL English

L4 ANSWER 183 OF 268 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
AN 1998081381 EMBASE
TI Alterations of platelet, coagulation, and fibrinolysis markers in patients with acute ischemic ***stroke*** .
AU Uchiyama S.; Yamazaki M.; Hara Y.; Iwata M.
CS Dr. S. Uchiyama, Department of Neurology, Neurological Institute, Tokyo Women's Medical College, 8-1 Kawada-cho, Shinjuku-ku, Tokyo 162, Japan
SO Seminars in Thrombosis and Hemostasis, (1997) 23/6 (535-541).
Refs: 25
ISSN: 0094-6176 CODEN: STHMBV
CY United States
DT Journal; Conference Article
FS 005 General Pathology and Pathological Anatomy
008 Neurology and Neurosurgery
018 Cardiovascular Diseases and Cardiovascular Surgery
LA English
SL English

L4 ANSWER 184 OF 268 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
AN 92343591 EMBASE
DN 1992343591
TI Changes in blood coagulation and fibrinolysis factors after the onset of ***stroke*** in salt-loading SHRSP.
AU Saito N.; Tamaki T.; Yamamoto S.; Ueda H.
CS Tokyo Research Laboratories, Kowa Co. Ltd,Higashimurayama, Tokyo 189, Japan
SO Japanese Heart Journal, (1992) 33/4 (554).
ISSN: 0021-4868 CODEN: JHEJAR
CY Japan
DT Journal; Conference Article
FS 008 Neurology and Neurosurgery
018 Cardiovascular Diseases and Cardiovascular Surgery
025 Hematology
LA English

L4 ANSWER 185 OF 268 IFIPAT COPYRIGHT 2004 IFI on STN
AN 10374645 IFIPAT;IFIUDB;IFICDB
TI DIAGNOSTIC MARKERS OF ***STROKE*** AND CEREBRAL INJURY AND METHODS OF USE THEREOF
IN Buechler Kenneth F; Dahlen Jeffrey R; Kirchick Howard J; Valkirs Gunars E
PA Unassigned Or Assigned To Individual (68000)
PI US 2003119064 A1 20030626
AI US 2002-225082 20020820
PRAI US 2001-313775P 20010820 (Provisional)
US 2001-334964P 20011130 (Provisional)
US 2002-346485P 20020102 (Provisional)
FI US 2003119064 20030626
DT Utility; Patent Application - First Publication
FS CHEMICAL
APPLICATION
CLMN 44

L4 ANSWER 186 OF 268 IFIPAT COPYRIGHT 2004 IFI on STN

AN 10272745 IFIPAT;IFIUDB;IFICDB
TI COMPOSITION AND METHOD FOR ENHANCING FIBRINOLYSIS; NOVEL ***ALPHA*** - ***2*** - ***ANTIPLASMIN*** - BINDING MOLECULES AND TREATMENT FOR PULMONARY EMBOLISM, MYOCARDIAL INFARCTION, THROMBOSIS OR ***STROKE*** IN A PATIENT
IN REED GUY L
PA Unassigned Or Assigned To Individual (68000)
PI US 2003017147 A1 20030123
AI US 1997-934000 19970919
PRAI US 1996-26356P 19960920 (Provisional)
FI US 2003017147 20030123
DT Utility; Patent Application - First Publication
FS CHEMICAL
APPLICATION
CLMN 35
GI 22 Figure(s).

FIG. 1. Comparison of binding to 125I- ***alpha*** ***2*** - ***antiplasmin*** of monoclonal antibodies 49C9, 70B11, 77A3, RWR and anti-digoxin (control). Wells of a microtiter plate were coated with goat antimouse antibody. The wells were incubated in duplicate with 49C9, 70B11, 77A3, RWR or a control (antidigoxin) MAb (MudgettHunter, M. et al., Mol. Immunol. 22:477-488 (1985)). After a wash, 125I-alpha 2AP (60,000 cpm) was added for an hour. The wells were rinsed and the amount of bound 125I-alpha 2AP was measured in a gamma counter.

FIG. 2. Competition binding assays of monoclonal antibodies 49C9, 70B11, 77A3, RWR and anti-digoxin with immobilized 70B11. Competition radioimmunoassays were performed by coating wells of a microtiter plate with 25 mu l of purified MAb (70B11) in duplicate (10 mu g/ml) for 1 hour. The wells were washed and blocked with 1% BSA for 1 hour. After washing, 25 mu l of a competitor MAb, same MAb or negative control MAb was added to different wells (50 mu g/ml) followed by 25 mu l of 125I- ***alpha*** ***2*** - ***antiplasmin*** (100,000 cpm). After 1 hour incubation, the wells were washed, cut and the radioactivity was measured in a gamma scintillation counter.

FIG. 3. Comparison of amount of lysis by different monoclonal antibodies (or TBS alone) as a function of dose of urokinase. See Example 1, below, for detailed description of the method. The amount of lysis was determined by gamma counting. The percent lysis was defined at 100 x (total supernatant cpm/total clot cpm).

FIG. 4. Dose response studies in the absence or presence of MAb 77A3. Lysis by urokinase is increased approximately 100-fold by 77A3.

FIG. 5. Reduced SDS-polyacrylamide gel electrophoresis of 77A3 purification. Ascites containing 77A3 were harvested and purified. Lane 1, protein standards with molecular mass in kDa (left); lane 2, supernatant after precipitation with 40% ammonium sulfate; lane 3, purified 77A3. The reduced 77A3 immunoglobulin consists of bands of 50 kDa, corresponding to the heavy chain, and 25 kDa, corresponding to the light chain.

FIG. 6. Effect of 77A3 on the rate of lysis of ferret plasma clots in vitro. Ferret plasma clots formed with trace amounts of 125I-labeled human fibrinogen were incubated with 100 mu l of TBS (control) or purified MAb (25 mu g, 77A3 or RWR). Clot lysis was initiated by adding 0.1 unit of rt-PA per tube. The clots were incubated at 37 degrees C. and the amount of lysis was determined by sampling for the release of radiolabeled fibrin degradation products into the supernatant as described (Reed, G. L. III et al., Proc. Natl. Acad. Sci. USA 87:11141118 (1990)).

FIG. 7. Effect of in vivo administration of MAb 77A3 on functional alpha 2AP levels in ferrets. In dose finding experiments, two anesthetized ferrets (A, B) were given 77A3 intravenously (22.5 mg/kg) and the amount of functional alpha 2AP was measured in citrated plasma samples drawn before (time 0) and 1 and 4 hours after infusion. The data represent the mean +-LSD inhibition of alpha 2AP in plasma samples.

FIG. 8. Effect of rt-PA and alpha 2AP inhibition on the lysis of pulmonary emboli in vivo. Anesthetized ferrets were given a heparin bolus (100 U/kg) and 125I-labeled fibrin clots were embolized into the lungs. After embolization, three groups of ferrets were given rt-PA (0, 1, or 2 mg/kg) over 2 hours intravenously (plain bars). Two other groups of ferrets also received rt-PA (1 mg/kg) and a control MAb (antidigoxin, black bar, 22.5 mg/kg) or a MAb that inhibits alpha 2AP (77A3, striped bar, same dose). The graph shows the amount of lysis (mean +-SD) for each treatment group. The number of ferrets in each treatment group is shown, and the P values for differences between groups are indicated.

FIG. 9. Residual fibrinogen levels in animals treated with heparin, rt-PA, and an alpha 2AP inhibitor. Blood samples were collected (on EDTA with aprotinin) from ferrets before pulmonary embolization and at the end of

the experiment. Residual fibrinogen levels were measured as described (Rampling, M. W. and Gaffney, P. J., Clin. Chim. Acta.67:43-52 (1976)). The graph shows the mean +-SD percentage residual fibrinogen level for animals receiving rt-PA alone (0, 1, or 2 mg/kg; plain bars) and those receiving rt-PA and the alpha 2AP inhibitor (striped bar).

FIG. 10. The peptide sequences of the amino terminus of purified light chains from 49C9 (SEQ ID NO:1), 70B11 (SEQ ID NO:2) and 77A3 (SEQ ID NO:3) are shown.

FIG. 11. The cDNA sequence (SEQ ID NO:4) and corresponding deduced amino acid sequence of the signal peptide (amino acids20 to-1 of SEQ ID NO:5) and light chain variable regions (amino acids 1 to 107 of SEQ ID NO:5) of 49C9 are shown.

FIG. 12. The cDNA sequence (SEQ ID NO:6) and corresponding deduced amino acid sequence of the signal peptide (amino acids20 to-1 of SEQ ID NO:7) and light chain variable regions (amino acids 1 to 107 of SEQ ID NO:7) of 70B11 are shown.

FIG. 13. The cDNA sequence (SEQ ID NO:8) and corresponding deduced amino acid sequence of the signal peptide (amino acids20 to-1 of SEQ ID NO:9) and light chain variable regions (amino acids 1 to 107 of SEQ ID NO:9) of 77A3 are shown.

FIG. 14. The cDNA sequence (SEQ ID NO:10) and corresponding deduced amino acid sequence of the signal peptide (amino acids19 to-1 of SEQ ID NO:11) and heavy chain variable regions (amino acids 1-119 of SEQ ID NO:11) of 49C9 are shown.

FIG. 15. The cDNA sequence (SEQ ID NO:12) and corresponding deduced amino acid sequence of the signal peptide (amino acids19 to-1 of SEQ ID NO:13) and heavy chain variable regions (amino acids 1-119 of SEQ ID NO:13) of 70B11 are shown.

FIG. 16. The cDNA sequence (SEQ ID NO:14) and corresponding deduced amino acid sequence of the signal peptide (amino acids19 to-1 of SEQ ID NO:15) and heavy chain variable regions (amino acids 1-119 of SEQ ID NO:15) of 77A3 are shown.

FIG. 17. The cDNA sequence (SEQ ID NO:16) and corresponding amino acid sequence (SEQ ID NO:17) of humanized77A3-1 and humanized 77A3-2 light chain. Positions falling within the CDR loops are shown enclosed within the boxes with solid borders.

FIG. 18. The cDNA sequence (SEQ ID NO:18) and corresponding amino acid sequence (SEQ ID NO:19) of humanized 77A3-1 heavy chain. Positions falling within the CDR loops are shown enclosed within the boxes with solid borders.

FIG. 19. The cDNA sequence (SEQ ID NO:20) and corresponding amino acid sequence (SEQ ID NO:21) of humanized 77A3-2 heavy chain. Positions falling within the CDR loops are shown enclosed within the boxes with solid borders.

FIG. 20. Results of murine 77A3 (X), chimeric 77A3 (circlesolid) and humanized 77A3-1 (*) in the ***plasmin*** assay with chromogenic substrate are shown.

FIG. 21. The amino acid sequences of the light chains are shown: h77A3-1 and h77A3-2 (SEQ ID NO:17); m77A3 (SEQ ID NO:9); m49C9 (SEQ ID NO:5); m70B11 (SEQ ID NO:7); murine consensus (SEQ ID NO:75), which shows the consensus between m77A3, m49C9, and m70B11; 77A3/49C9 consensus (SEQ ID NO:76), which shows the consensus between 77A3 and 49C9; and all (SEQ ID NO:77), which shows the consensus between h77A3-1, h77A3-2, m77A3, m49C9, and m70B11. Positions falling withing the CDR loops are shown enclosed within the boxes.

FIG. 22. The amino acid sequences of the heavy chains are shown. h77A3-1 (SEQ ID NO:19); h77A3-2 (SEQ ID NO:21); m77A3 (SEQ ID NO:15); m49C9 (SEQ ID NO:11); m70B11 (SEQ ID NO:13); humanized consensus (SEQ ID NO:78), which is the consensus between h77A31 and h77A3-2; murine consensus (SEQ ID NO:79), which is the consensus between m77A3, m49C9, and m70B11; 77A3/49C9 consensus (SEQ ID NO:80), which is the consensus between 77A3 and 49C9; and all (SEQ ID NO:81), which is the consensus between h77A3-1, h77A3-2, m77A3, m49C9, and m70B11. Positions falling withing the CDR loops are shown enclosed within the boxes.

L4 ANSWER 187 OF 268 JICST-EPlus COPYRIGHT 2004 JST on STN

AN 980063066 JICST-EPlus

TI Activation of Coagulation in Acute Ischemic ***Stroke*** .

AU TAKANO KENTARO

CS National Sanatorium Fukuoka Higashi Hospital

SO Prog Med, (1997) vol. 17, no. 11, pp. 2964-2968. Journal Code: F0664B
(Fig. 1, Tbl. 4, Ref. 25)
ISSN: 0287-3648

CY Japan

DT Journal; Commentary

LA Japanese

STA New

L4 ANSWER 188 OF 268 PHIN COPYRIGHT 2004 PJB on STN

AN 2003:10738 PHIN
DN B00802604
DED 3 Jun 2003
TI Irish biotech completes Phase I
SO Bioventure-View (2003) No. 1811 p16
DT Newsletter
FS FULL

L4 ANSWER 189 OF 268 PROMT COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 94:141674 PROMT
TITLE: Coagulation Market: Slow Change Ahead -- What We Test for When We Test for Coagulation
SOURCE: Genesis Report-Dx, (Dec 1993) pp. N/A.
ISSN: 1061-2289.
LANGUAGE: English
WORD COUNT: 1764
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L4 ANSWER 190 OF 268 SCISEARCH COPYRIGHT 2004 THOMSON ISI on STN
AN 2002:768056 SCISEARCH
GA The Genuine Article (R) Number: 592JK
TI ***Microplasmin*** . A novel thrombolytic that improves behavioral outcome after embolic ***strokes*** in rabbits
AU Lapchak P A (Reprint); Araujo D M; Pakola S; Song D H; Wei J D; Zivin J A
CS Univ Calif San Diego, Dept Neurosci, MTF 316, 9500 Gilman Dr, La Jolla, CA 92093 USA (Reprint); Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA; VA San Diego Healthcare Syst, San Diego, CA USA; Vet Med Res Fdn, San Diego, CA USA; Thrombogen Ltd, Dublin, Ireland
CYA USA; Ireland
SO STROKE, (SEP 2002) Vol. 33, No. 9, pp. 2279-2284.
Publisher: LIPPINCOTT WILLIAMS & WILKINS, 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA.
ISSN: 0039-2499.
DT Article; Journal
LA English
REC Reference Count: 26
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L4 ANSWER 191 OF 268 USPATFULL on STN
AN 2004:70181 USPATFULL
TI Compositions and methods for selective dissolution of nascent intravascular blood clots
IN Muzykantov, Vladimir R., Warwick, PA, UNITED STATES
Murciano, Juan Carlos, Sevilla, SPAIN
Cines, Douglas, Wynnewood, PA, UNITED STATES
PI US 2004053408 A1 20040318
AI US 2003-611723 A1 20030701 (10)
RLI Continuation-in-part of Ser. No. US 2002-253518, filed on 23 Sep 2002, PENDING Division of Ser. No. US 1999-454666, filed on 3 Dec 1999, GRANTED, Pat. No. US 6488927 Continuation-in-part of Ser. No. WO 1999-US10547, filed on 12 May 1999, PENDING
PRAI US 1998-86262P 19980521 (60)
DT Utility
FS APPLICATION
LN.CNT 976
INCL INCLM: 435/372.000
INCLS: 435/002.000
NCL NCLM: 435/372.000
NCLS: 435/002.000
IC [7]
ICM: C12N005-08
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 192 OF 268 USPATFULL on STN
AN 2004:44232 USPATFULL
TI Anticoagulant and fibrinolytic therapy uning p38 MAP kinase inhibitors
IN Wood, Chester C., Ridgefield, CT, UNITED STATES
van der Poll, Tom, Amsterdam, NETHERLANDS
PA Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT (U.S. corporation)
Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, GERMANY, FEDERAL

REPUBLIC OF (U.S. corporation)
PI US 2004033222 A1 20040219
AI US 2003-630599 A1 20030730 (10)
PRAI US 2002-403422P 20020814 (60)
DT Utility
FS APPLICATION
LN.CNT 4024
INCL INCLM: 424/094.640
INCLS: 514/165.000; 514/012.000; 514/056.000; 514/262.100; 514/456.000
NCL NCLM: 424/094.640
NCLS: 514/165.000; 514/012.000; 514/056.000; 514/262.100; 514/456.000
IC [7]
ICM: A61K038-48
ICS: A61K031-727; A61K031-60; A61K031-519; A61K031-366
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 193 OF 268 USPATFULL on STN
AN 2003:335024 USPATFULL
TI Nucleic acid molecules encoding a transmembrane serine protease 10, the encoded polypeptides and methods based thereon
IN Madison, Edwin L., San Diego, CA, UNITED STATES
Yeh, Jiunn-Chern, San Diego, CA, UNITED STATES
PA Corvas International, Inc. (U.S. corporation)
PI US 2003235900 A1 20031225
AI US 2002-147211 A1 20020514 (10)
PRAI US 2001-291001P 20010514 (60)
DT Utility
FS APPLICATION
LN.CNT 7490
INCL INCLM: 435/226.000
INCLS: 435/069.100; 435/320.100; 435/325.000; 536/023.200
NCL NCLM: 435/226.000
NCLS: 435/069.100; 435/320.100; 435/325.000; 536/023.200
IC [7]
ICM: C12N009-64
ICS: C07H021-04; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 194 OF 268 USPATFULL on STN
AN 2003:312137 USPATFULL
TI Polypeptides related to natriuretic peptides and methods of their identification and use
IN Buechler, Kenneth F., Rancho Santa Fe, CA, UNITED STATES
PA Biosite Incorporated (U.S. corporation)
PI US 2003219734 A1 20031127
AI US 2003-419059 A1 20030417 (10)
RLI Continuation-in-part of Ser. No. US 2001-835298, filed on 13 Apr 2001, PENDING Continuation-in-part of Ser. No. WO 2002-US26604, filed on 20 Aug 2002, PENDING Continuation-in-part of Ser. No. US 2002-139086, filed on 4 May 2002, PENDING
PRAI US 2001-313775P 20010820 (60)
US 2001-334964P 20011130 (60)
US 2002-346485P 20020102 (60)
US 2001-288871P 20010504 (60)
US 2001-315642P 20010828 (60)
DT Utility
FS APPLICATION
LN.CNT 1949
INCL INCLM: 435/005.000
INCLS: 435/007.100; 436/518.000; 702/019.000
NCL NCLM: 435/005.000
NCLS: 435/007.100; 436/518.000; 702/019.000
IC [7]
ICM: C12Q001-70
ICS: G01N033-53; G06F019-00; G01N033-48; G01N033-50; G01N033-543
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 195 OF 268 USPATFULL on STN
AN 2003:282611 USPATFULL
TI Human cDNAs and proteins and uses thereof
IN Bejanin, Stephane, Paris, FRANCE
Tanaka, Hiroaki, Antony, FRANCE
PA GENSET, S.A., Paris, FRANCE (non-U.S. corporation)
PI US 2003198954 A1 20031023
AI US 2001-1142 A1 20011114 (10)
RLI Division of Ser. No. US 2001-924340, filed on 6 Aug 2001, PENDING

PRAI WO 2001-IB1715 20010806
US 2001-305456P 20010713 (60)
US 2001-302277P 20010629 (60)
US 2001-298698P 20010615 (60)
US 2001-293574P 20010525 (60)
DT Utility
FS APPLICATION
LN.CNT 25681
INCL INCLM: 435/006.000
INCLS: 536/023.200
NCL NCLM: 435/006.000
NCLS: 536/023.200
IC [7]
ICM: C12Q001-68
ICS: C07H021-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 196 OF 268 USPATFULL on STN
AN 2003:258605 USPATFULL
TI Nucleic acid molecules encoding serine protease CVSP14, the encoded polypeptides and methods based thereon
IN Madison, Edwin L., San Diego, CA, UNITED STATES
Yeh, Jiunn-Chern, San Diego, CA, UNITED STATES
PA Corvas International, Inc. (non-U.S. corporation)
PI US 2003181658 A1 20030925
AI US 2002-104271 A1 20020320 (10)
PRAI US 2001-278166P 20010322 (60)
DT Utility
FS APPLICATION
LN.CNT 6933
INCL INCLM: 530/350.000
NCL NCLM: 530/350.000
IC [7]
ICM: C07K001-00
ICS: C07K014-00; C07K017-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 197 OF 268 USPATFULL on STN
AN 2003:250479 USPATFULL
TI Method of thrombolysis by local delivery of reversibly inactivated acidified ***plasmin***
IN Jesmok, Gary J., Raleigh, NC, UNITED STATES
Landskroner, Kyle A., Raleigh, NC, UNITED STATES
PI US 2003175264 A1 20030918
AI US 2002-280444 A1 20021025 (10)
RLI Continuation-in-part of Ser. No. US 2002-143157, filed on 10 May 2002, PENDING Continuation of Ser. No. WO 2000-US31115, filed on 14 Nov 2000, PENDING Continuation-in-part of Ser. No. US 1999-438331, filed on 13 Nov 1999, GRANTED, Pat. No. US 6355243
DT Utility
FS APPLICATION
LN.CNT 2120
INCL INCLM: 424/094.640
NCL NCLM: 424/094.640
IC [7]
ICM: A61K038-48
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 198 OF 268 USPATFULL on STN
AN 2003:244219 USPATFULL
TI Human cDNAs and proteins and uses thereof
IN Bejanin, Stephane, Paris, FRANCE
Tanaka, Hiroaki, Antony, FRANCE
PA GENSET, S.A., Paris, FRANCE (non-U.S. corporation)
PI US 2003170628 A1 20030911
AI US 2001-999570 A1 20011114 (9)
RLI Division of Ser. No. US 2001-924340, filed on 6 Aug 2001, PENDING
PRAI WO 2001-IB1715 20010806
US 2001-305456P 20010713 (60)
US 2001-302277P 20010629 (60)
US 2001-298698P 20010615 (60)
US 2001-293574P 20010525 (60)
DT Utility
FS APPLICATION
LN.CNT 25549
INCL INCLM: 435/006.000

INCLS: 435/069.100; 435/007.100; 435/320.100; 435/325.000; 530/350.000;
530/388.100; 536/023.500
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/007.100; 435/320.100; 435/325.000; 530/350.000;
530/388.100; 536/023.500
IC [7]
ICM: C12Q001-68
ICS: G01N033-53; C07H021-04; C12P021-02; C12N005-06; C07K014-47
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 199 OF 268 USPATFULL on STN
AN 2003:238693 USPATFULL
TI Nucleic acid molecules encoding a transmembrane serine protease 9, the
encoded polypeptides and methods based thereon
IN Madison, Edwin, San Diego, CA, UNITED STATES
Ong, Edgar O., San Diego, CA, UNITED STATES
PA Corvas international, Inc. (U.S. corporation)
PI US 2003166851 A1 20030904
AI US 2002-112221 A1 20020327 (10)
PRAI US 2001-279228P 20010327 (60)
US 2001-291501P 20010515 (60)
DT Utility
FS APPLICATION
LN.CNT 7458
INCL INCLM: 530/350.000
NCL NCLM: 530/350.000
IC [7]
ICM: C07K001-00
ICS: C07K014-00; C07K017-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 200 OF 268 USPATFULL on STN
AN 2003:231986 USPATFULL
TI Human cDNAs and proteins and uses thereof
IN Bejanin, Stephane, Paris, FRANCE
Tanaka, Hiroaki, Antony, FRANCE
PA GENSET, S.A., Paris, FRANCE (non-U.S. corporation)
PI US 2003162186 A1 20030828
AI US 2002-154678 A1 20020522 (10)
PRAI US 2001-293574P 20010525 (60)
US 2001-298698P 20010615 (60)
US 2001-302277P 20010629 (60)
US 2001-305456P 20010713 (60)
DT Utility
FS APPLICATION
LN.CNT 25533
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 536/023.200
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 536/023.200
IC [7]
ICM: C12Q001-68
ICS: C07H021-04; C12N009-00; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 201 OF 268 USPATFULL on STN
AN 2003:225673 USPATFULL
TI Human cDNAs and proteins and uses thereof
IN Bejanin, Stephane, Paris, FRANCE
Tanaka, Hiroaki, Antony, FRANCE
PA GENSET, S.A., Paris, FRANCE (non-U.S. corporation)
PI US 2003157485 A1 20030821
AI US 2001-992095 A1 20011113 (9)
RLI Division of Ser. No. US 2001-924340, filed on 6 Aug 2001, PENDING
PRAI WO 2001-IB1715 20010806
US 2001-305456P 20010713 (60)
US 2001-302277P 20010629 (60)
US 2001-298698P 20010615 (60)
US 2001-293574P 20010525 (60)
DT Utility
FS APPLICATION
LN.CNT 25484
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/320.100; 435/325.000; 435/226.000; 800/008.000;
536/023.200; 530/388.260; 435/007.200
NCL NCLM: 435/006.000

NCLS: 435/069.100; 435/320.100; 435/325.000; 435/226.000; 800/008.000;
536/023.200; 530/388.260; 435/007.200
IC [7]
ICM: C12Q001-68
ICS: G01N033-53; G01N033-567; A01K067-00; C07H021-04; C12N009-64;
C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 202 OF 268 USPATFULL on STN
AN 2003:219273 USPATFULL
TI Compositions and methods for prevention and treatment of uncontrolled formation of intravascular fibrin clots
IN Muzykantov, Vladimir R., Warwick, PA, UNITED STATES
Higazi, Abd Al-Roof, Haverford, PA, UNITED STATES
Murciano, Juan Carlos, Sevilla, SPAIN
Cines, Douglas, Wynnewood, PA, UNITED STATES
Taylor, Ronald P., Charlottesville, VA, UNITED STATES
PI US 2003152563 A1 20030814
AI US 2002-253518 A1 20020923 (10)
RLI Division of Ser. No. US 1999-454666, filed on 3 Dec 1999, GRANTED, Pat. No. US 6488927 Continuation-in-part of Ser. No. WO 1999-US10547, filed on 12 May 1999, PENDING
PRAI US 1998-86262P 19980521 (60)
DT Utility
FS APPLICATION
LN.CNT 706
INCL INCLM: 424/093.730
NCL NCLM: 424/093.730
IC [7]
ICM: A61K045-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 203 OF 268 USPATFULL on STN
AN 2003:206862 USPATFULL
TI NUCLEIC ACID MOLECULES ENCODING A TRANSMEMBRANE SERINE PROTEASE 25, THE ENCODED POLYPEPTIDES AND METHODS BASED THEREON
IN Madison , Edwin L, 11005 Cedarcrest Way, San Diego, CA, UNITED STATES 92121
Yeh , Jiunn-Chern, 11629 Westview Parkway, San Diego, CA, UNITED STATES 92126
PI US 2003143219 A1 20030731
AI US 2002-267219 A1 20021008 (10)
PRAI US 2001-60328530 20011009
DT Utility
FS APPLICATION
LN.CNT 6385
INCL INCLM: 424/094.670
INCLS: 435/226.000; 435/006.000; 435/007.900; 435/069.100; 435/320.100; 435/325.000; 536/023.200; 530/388.260
NCL NCLM: 424/094.670
NCLS: 435/226.000; 435/006.000; 435/007.900; 435/069.100; 435/320.100; 435/325.000; 536/023.200; 530/388.260
IC [7]
ICM: C12Q001-68
ICS: G01N033-53; G01N033-542; C07H021-04; A61K038-46; C12N009-64;
C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 204 OF 268 USPATFULL on STN
AN 2003:194983 USPATFULL
TI Nucleic acid molecules encoding serine protease 17, the encoded polypeptides and methods based thereon
IN Madison, Edwin L., San Diego, CA, UNITED STATES
Ong, Edgar O., San Diego, CA, UNITED STATES
PI US 2003134794 A1 20030717
AI US 2002-302840 A1 20021120 (10)
PRAI US 2001-332015P 20011120 (60)
DT Utility
FS APPLICATION
LN.CNT 7203
INCL INCLM: 514/012.000
INCLS: 435/006.000; 435/069.100; 435/226.000; 435/320.100; 435/325.000; 530/388.260; 536/023.200; 424/146.100
NCL NCLM: 514/012.000
NCLS: 435/006.000; 435/069.100; 435/226.000; 435/320.100; 435/325.000; 530/388.260; 536/023.200; 424/146.100

IC [7]
ICM: A61K038-17
ICS: C12Q001-68; C07H021-04; C12N009-64; C12P021-02; C12N005-06; C07K016-40; A61K039-395
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 205 OF 268 USPATFULL on STN
AN 2003:194487 USPATFULL
TI Nucleic acid molecules encoding a transmembrane serine protease 20, the encoded polypeptides and methods based thereon
IN Madison, Edwin L., San Diego, CA, UNITED STATES
Ong, Edgar O., San Diego, CA, UNITED STATES
PI US 2003134298 A1 20030717
AI US 2002-190030 A1 20020703 (10)
PRAI US 2001-302939P 20010703 (60)
DT Utility
FS APPLICATION
LN.CNT 8187
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/226.000; 435/320.100; 435/325.000; 536/023.200
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/226.000; 435/320.100; 435/325.000; 536/023.200
IC [7]
ICM: C12Q001-68
ICS: C07H021-04; C12N009-64; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 206 OF 268 USPATFULL on STN
AN 2003:173324 USPATFULL
TI Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
IN Madison, Edwin L., San Diego, CA, UNITED STATES
Ong, Edgar O., San Diego, CA, UNITED STATES
Yeh, Jiunn-Chern, San Diego, CA, UNITED STATES
PA Corvas International, Inc. (U.S. corporation)
PI US 2003119168 A1 20030626
AI US 2001-776191 A1 20010202 (9)
RLI Continuation-in-part of Ser. No. US 2000-657986, filed on 8 Sep 2000, PENDING
PRAI US 2000-179982P 20000203 (60)
US 2000-183542P 20000218 (60)
US 2000-213124P 20000622 (60)
US 2000-220970P 20000726 (60)
US 2000-234840P 20000922 (60)
DT Utility
FS APPLICATION
LN.CNT 9872
INCL INCLM: 435/226.000
INCLS: 536/023.200; 435/007.230; 435/069.100; 435/320.100; 435/325.000
NCL NCLM: 435/226.000
NCLS: 536/023.200; 435/007.230; 435/069.100; 435/320.100; 435/325.000
IC [7]
ICM: G01N033-574
ICS: C07H021-04; C12N009-64; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 207 OF 268 USPATFULL on STN
AN 2003:159408 USPATFULL
TI Polynucleotide encoding a novel metalloprotease highly expressed in the testis, MMP-29
IN Wu, Shujian, Langhorne, PA, UNITED STATES
Chen, Jian, Princeton, NJ, UNITED STATES
Feder, John N., Belle Mead, NJ, UNITED STATES
Lee, Liana, North Brunswick, NJ, UNITED STATES
Krystek, Stanley R., Ringoes, NJ, UNITED STATES
PI US 2003109021 A1 20030612
AI US 2002-133797 A1 20020426 (10)
PRAI US 2001-286764P 20010426 (60)
DT Utility
FS APPLICATION
LN.CNT 19916
INCL INCLM: 435/226.000
INCLS: 435/069.100; 435/320.100; 435/325.000; 536/023.200
NCL NCLM: 435/226.000
NCLS: 435/069.100; 435/320.100; 435/325.000; 536/023.200
IC [7]

ICM: C12N009-64
ICS: C07H021-04; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 208 OF 268 USPATFULL on STN
AN 2003:140406 USPATFULL
TI Human cDNAs and proteins and uses thereof
IN Bejanin, Stephane, Paris, FRANCE
Tanaka, Hiroaki, Antony, FRANCE
PA GENSET, S.A., Paris, FRANCE, 75008 (non-U.S. corporation)
PI US 2003096247 A1 20030522
AI US 2001-986 A1 20011114 (10)
RLI Division of Ser. No. US 2001-924340, filed on 6 Aug 2001, PENDING
PRAI WO 2001-IB1715 20010806
US 2001-305456P 20010713 (60)
US 2001-302277P 20010629 (60)
US 2001-298698P 20010615 (60)
US 2001-293574P 20010525 (60)
DT Utility
FS APPLICATION
LN.CNT 25656
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000; 536/023.200; 800/008.000
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000; 536/023.200; 800/008.000
IC [7]
ICM: C12Q001-68
ICS: A01K067-00; C07H021-04; C12N009-00; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 209 OF 268 USPATFULL on STN
AN 2003:133926 USPATFULL
TI Human cDNAs and proteins and uses thereof
IN Bejanin, Stephane, Paris, FRANCE
Tanaka, Hiroaki, Antony, FRANCE
PA GENSET, S.A., Paris, FRANCE, 75008 (non-U.S. corporation)
PI US 2003092011 A1 20030515
AI US 2001-489 A1 20011114 (10)
RLI Division of Ser. No. US 2001-924340, filed on 6 Aug 2001, PENDING
PRAI WO 2001-IB1715 20010806
US 2001-305456P 20010713 (60)
US 2001-302277P 20010629 (60)
US 2001-298698P 20010615 (60)
US 2001-293574P 20010525 (60)
DT Utility
FS APPLICATION
LN.CNT 25607
INCL INCLM: 435/006.000
INCLS: 800/003.000; 435/007.900; 435/183.000; 435/069.100; 435/320.100; 435/325.000; 536/023.200
NCL NCLM: 435/006.000
NCLS: 800/003.000; 435/007.900; 435/183.000; 435/069.100; 435/320.100; 435/325.000; 536/023.200
IC [7]
ICM: C12Q001-68
ICS: G01N033-53; G01N033-542; C07H021-04; C12N009-00; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 210 OF 268 USPATFULL on STN
AN 2003:89375 USPATFULL
TI Brain-associated inhibitor of tissue-type plasminogen activator
IN Hastings, Gregg A., Thousand Oaks, CA, United States
Coleman, Timothy A., Gaithersburg, MD, United States
Lawrence, Daniel A., Derwood, MD, United States
Dillon, Patrick J., Carlsbad, CA, United States
PA Human Genome Sciences, Inc., Rockville, MD, United States (U.S. corporation)
PI US 6541452 B1 20030401
AI US 2000-722292 20001128 (9)
RLI Division of Ser. No. US 1999-348817, filed on 8 Jul 1999, now patented, Pat. No. US 6191260, issued on 20 Feb 2001 Division of Ser. No. US 1997-948997, filed on 10 Oct 1997, now patented, Pat. No. US 6008020, issued on 28 Dec 1999

PRAI US 1996-28117P 19961011 (60)
DT Utility
FS GRANTED
LN.CNT 3580
INCL INCLM: 514/012.000
INCLS: 514/002.000; 530/350.000
NCL NCLM: 514/012.000
NCLS: 514/002.000; 530/350.000
IC [7]
ICM: A61K038-57
ICS: C07K014-47
EXF 514/2; 514/12; 530/350
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 211 OF 268 USPATFULL on STN
AN 2003:78525 USPATFULL
TI Polynucleotide encoding a novel human serpin secreted from lymphoid cells, LSI-01
IN Chen, Jian, Princeton, NJ, UNITED STATES
Feder, John N., Belle Mead, NJ, UNITED STATES
Nelson, Thomas, Lawrenceville, NJ, UNITED STATES
Seiler, Steven, Pennington, NJ, UNITED STATES
Bassolino, Donna A., Hamilton, NJ, UNITED STATES
Cheney, Daniel L., Flemington, NJ, UNITED STATES
Duclos, Franck, Washington Crossing, PA, UNITED STATES
PI US 2003054445 A1 20030320
AI US 2001-993180 A1 20011114 (9)
PRAI US 2000-248434P 20001114 (60)
US 2000-257610P 20001221 (60)
US 2001-282745P 20010410 (60)
DT Utility
FS APPLICATION
LN.CNT 14427
INCL INCLM: 435/069.100
INCLS: 514/012.000; 435/320.100; 435/325.000; 530/350.000; 536/023.200
NCL NCLM: 435/069.100
NCLS: 514/012.000; 435/320.100; 435/325.000; 530/350.000; 536/023.200
IC [7]
ICM: A61K038-17
ICS: C07K014-435; C07H021-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 212 OF 268 USPATFULL on STN
AN 2003:74127 USPATFULL
TI Methods of inhibiting clot formation
IN Reed, Guy L., Winchester, MA, United States
PA President and Fellows of Harvard College, Cambridge, MA, United States (U.S. corporation)
PI US 6534035 B1 20030318
AI US 1999-321969 19990528 (9)
PRAI US 1998-87218P 19980529 (60)
DT Utility
FS GRANTED
LN.CNT 1490
INCL INCLM: 424/001.690
INCLS: 530/380.000; 530/350.000
NCL NCLM: 424/001.690
NCLS: 530/350.000; 530/380.000
IC [7]
ICM: A61K051-00
ICS: C07K014-00
EXF 530/350; 530/380; 424/1.69; 435/7.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 213 OF 268 USPATFULL on STN
AN 2003:37603 USPATFULL
TI Human cDNAs and proteins and uses thereof
IN Bejanin, Stephane, Paris, FRANCE
Tanaka, Hiroaki, Antony, FRANCE
PA GENSET, S.A., Paris, FRANCE, 75008 (non-U.S. corporation)
PI US 2003027248 A1 20030206
AI US 2001-924340 A1 20010806 (9)
PRAI US 2001-305456P 20010713 (60)
US 2001-302277P 20010629 (60)
US 2001-298698P 20010615 (60)
US 2001-293574P 20010525 (60)

DT Utility
FS APPLICATION
LN.CNT 25650
INCL INCLM: 435/069.100
INCLS: 435/183.000; 435/320.100; 435/325.000; 530/350.000; 536/023.200; 435/006.000
NCL NCLM: 435/069.100
NCLS: 435/183.000; 435/320.100; 435/325.000; 530/350.000; 536/023.200; 435/006.000
IC [7]
ICM: C12P021-02
ICS: C12Q001-68; C07H021-04; C12N009-00; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 214 OF 268 USPATFULL on STN
AN 2003:37516 USPATFULL
TI Human cDNAs and proteins and uses thereof
IN Bejanin, Stephane, Paris, FRANCE
Tanaka, Hiroaki, Antony, FRANCE
PA GENSET, S.A., Paris, FRANCE, 75008 (non-U.S. corporation)
PI US 2003027161 A1 20030206
AI US 2001-992600 A1 20011113 (9)
RLI Division of Ser. No. US 2001-924340, filed on 6 Aug 2001, PENDING
PRAI WO 2001-IB1715 20010806
US 2001-305456P 20010713 (60)
US 2001-302277P 20010629 (60)
US 2001-298698P 20010615 (60)
US 2001-293574P 20010525 (60)
DT Utility
FS APPLICATION
LN.CNT 25529
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000; 536/023.200; 800/008.000
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000; 536/023.200; 800/008.000
IC [7]
ICM: C12Q001-68
ICS: A01K067-00; C07H021-04; C12N009-00; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 215 OF 268 USPATFULL on STN
AN 2003:10677 USPATFULL
TI Nucleic acid molecules encoding a transmembrane serine protease 7, the encoded polypeptides and methods based thereon
IN Madison, Edwin L., San Diego, CA, UNITED STATES
Ong, Edgar O., San Diego, CA, UNITED STATES
PA Corvas International, Inc. (U.S. corporation)
PI US 2003008372 A1 20030109
AI US 2002-99700 A1 20020313 (10)
PRAI US 2001-275592P 20010313 (60)
DT Utility
FS APPLICATION
LN.CNT 6667
INCL INCLM: 435/226.000
INCLS: 435/069.100; 435/320.100; 435/325.000; 536/023.200
NCL NCLM: 435/226.000
NCLS: 435/069.100; 435/320.100; 435/325.000; 536/023.200
IC [7]
ICM: C12N009-64
ICS: C07H021-04; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 216 OF 268 USPATFULL on STN
AN 2002:337434 USPATFULL
TI Process for the production of a reversibly inactive acidified ***plasmin*** composition
IN Dadd, Christopher A., Cary, NC, UNITED STATES
Stenland, Christopher J., Cary, NC, UNITED STATES
Kent, Jonathan D., Holly Springs, NC, UNITED STATES
Korneyeva, Marina N., Raleigh, NC, UNITED STATES
Baumbach, George A., Knightdale, NC, UNITED STATES
Cook, Scoot A., Garner, NC, UNITED STATES
Bradley, Rita T., Cary, NC, UNITED STATES
Novokhatny, Valery, Raleigh, NC, UNITED STATES

Villines, Tanette B., Raleigh, NC, UNITED STATES
PI US 2002192794 A1 20021219
AI US 2002-143156 A1 20020510 (10)
RLI Continuation of Ser. No. WO 2000-US42143, filed on 13 Nov 2000, UNKNOWN Continuation-in-part of Ser. No. US 1999-435331, filed on 5 Nov 1999, GRANTED, Pat. No. US 6093485
DT Utility
FS APPLICATION
LN.CNT 886
INCL INCLM: 435/217.000
NCL NCLM: 435/217.000
IC [7]
ICM: C12N009-68
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 217 OF 268 USPATFULL on STN
AN 2002:322495 USPATFULL
TI Method to determine TGF-beta
IN Grainger, David J., Cambridge, UNITED KINGDOM
Kemp, Paul R., Suffolk, UNITED KINGDOM
PA NeoRx Corporation (non-U.S. corporation)
PI US 2002182659 A1 20021205
AI US 2002-106761 A1 20020326 (10)
RLI Continuation of Ser. No. US 1995-477393, filed on 7 Jun 1995, GRANTED, Pat. No. US 6395494 Continuation-in-part of Ser. No. US 1994-242161, filed on 12 May 1994, GRANTED, Pat. No. US 5847007 Continuation-in-part of Ser. No. US 1993-61714, filed on 13 May 1993, ABANDONED Continuation-in-part of Ser. No. US 1994-241844, filed on 12 May 1994, ABANDONED Continuation-in-part of Ser. No. US 1993-62451, filed on 13 May 1993, ABANDONED
DT Utility
FS APPLICATION
LN.CNT 3692
INCL INCLM: 435/007.920
NCL NCLM: 435/007.920
IC [7]
ICM: G01N033-53
ICS: G01N033-537; G01N033-543
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 218 OF 268 USPATFULL on STN
AN 2002:250787 USPATFULL
TI Antithrombotic agents
IN Blackburn, Michael Neal, Phoenixville, PA, UNITED STATES
Feuerstein, Giora Zeev, Wynnewood, PA, UNITED STATES
Patel, Arunbhai Haribhai, Phoenixville, PA, UNITED STATES
PA SmithKline Beecham Corporation (U.S. corporation)
PI US 2002136725 A1 20020926
AI US 2001-965099 A1 20010926 (9)
RLI Continuation of Ser. No. US 1999-346487, filed on 1 Jul 1999, ABANDONED Continuation-in-part of Ser. No. US 1997-783853, filed on 16 Jan 1997, GRANTED, Pat. No. US 6005091
PRAI US 1996-10108P 19960117 (60)
US 1996-29119P 19961024 (60)
DT Utility
FS APPLICATION
LN.CNT 3613
INCL INCLM: 424/146.100
INCLS: 424/094.640
NCL NCLM: 424/146.100
NCLS: 424/094.640
IC [7]
ICM: A61K039-395
ICS: A61K038-48
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 219 OF 268 USPATFULL on STN
AN 2002:209740 USPATFULL
TI Transgenic models of inflammatory disease
IN Duff, Gordon W., Sheffield, UNITED KINGDOM
Nicklin, Martin, Sheffield, UNITED KINGDOM
PA Interleukin Genetics Inc., Waltham, MA, United States (U.S. corporation)
PI US 6437216 B1 20020820
WO 9925857 19990527
AI US 2001-647826 20010312 (9)
WO 1998-US24287 19981113

20010312 PCT 371 date
PRAI GB 1997-23835 19971113
DT Utility
FS GRANTED
LN.CNT 3230
INCL INCLM: 800/021.000
INCLS: 800/018.000; 800/003.000; 435/320.100; 435/325.000; 536/023.100
NCL NCLM: 800/021.000
NCLS: 435/320.100; 435/325.000; 536/023.100; 800/003.000; 800/018.000
IC [7]
ICM: C12N015-00
EXF 800/3; 800/8; 800/21; 800/18; 435/320.1; 435/325; 536/23.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 220 OF 268 USPATFULL on STN
AN 2002:186079 USPATFULL
TI COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF UNCONTROLLED FORMATION OF INTRAVASCULAR FIBRIN CLOTS
IN MUZYKANTOV, VLADIMIR R., WARWICK, PA, UNITED STATES
HIGAZI, ABD AL-ROOF, BALA CYNWYD, PA, UNITED STATES
MURCIANO, JUAN CARLOS, PHILADELPHIA, PA, UNITED STATES
CINES, DOUGLAS, WYNNEWOOD, PA, UNITED STATES
PI US 2002099000 A1 20020725
US 6488927 B2 20021203
AI US 1999-454666 A1 19991203 (9)
RLI Continuation-in-part of Ser. No. WO 1999-US10547, filed on 12 May 1999, UNKNOWN
PRAI US 1998-86262P 19980521 (60)
DT Utility
FS APPLICATION
LN.CNT 706
INCL INCLM: 514/002.000
INCLS: 514/044.000
NCL NCLM: 424/094.300
NCLS: 435/188.000; 435/215.000; 435/216.000; 436/519.000; 514/002.000
IC [7]
ICM: A01N037-18
ICS: A01N043-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 221 OF 268 USPATFULL on STN
AN 2002:179162 USPATFULL
TI Human therapeutic uses of BPI Protein products
IN Friedmann, Nadav, Lafayette, CA, UNITED STATES
Scannon, Patrick J., San Francisco, CA, UNITED STATES
van Deventer, Sander J.H., Amsterdam, NETHERLANDS
von der Mohlen, Marijke A.M., Amsterdam, NETHERLANDS
Wedel, Nancy, Oakland, CA, UNITED STATES
PA XOMA Corporation (U.S. corporation)
PI US 2002094952 A1 20020718
US 6586400 B2 20030701
AI US 2000-733613 A1 20001208 (9)
RLI Continuation of Ser. No. US 1999-388758, filed on 2 Sep 1999, GRANTED, Pat. No. US 6191112 Continuation of Ser. No. US 1998-81166, filed on 18 May 1998, GRANTED, Pat. No. US 5952302 Continuation of Ser. No. US 1995-378228, filed on 24 Jan 1995, GRANTED, Pat. No. US 5753620 Continuation-in-part of Ser. No. US 1994-291112, filed on 16 Aug 1994, GRANTED, Pat. No. US 5643875 Continuation-in-part of Ser. No. US 1994-188221, filed on 24 Jan 1994, ABANDONED
DT Utility
FS APPLICATION
LN.CNT 1557
INCL INCLM: 514/012.000
NCL NCLM: 514/012.000
NCLS: 424/085.100; 424/085.200; 424/529.000; 424/534.000; 514/021.000; 514/921.000; 530/324.000; 530/350.000; 530/351.000; 530/830.000
IC [7]
ICM: A61K038-17
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 222 OF 268 USPATFULL on STN
AN 2002:143940 USPATFULL
TI Cancer treatment methods using antibodies to aminophospholipids
IN Thorpe, Philip E., Dallas, TX, United States
Ran, Sophia, Dallas, TX, United States
PA Board of Regents, The University of Texas System, Austin, TX, United

States (U.S. corporation)
PI US 6406693 B1 20020618
AI US 1999-351543 19990712 (9)
PRAI US 1998-110608P 19981202 (60)
US 1998-92672P 19980713 (60)
DT Utility
FS GRANTED
LN.CNT 7541
INCL INCLM: 424/130.100
INCLS: 424/132.100; 424/133.100; 424/135.100; 424/138.100; 424/141.100; 424/152.100; 424/184.100; 530/387.100; 435/006.000
NCL NCLM: 424/130.100
NCLS: 424/132.100; 424/133.100; 424/135.100; 424/138.100; 424/141.100; 424/152.100; 424/184.100; 435/006.000; 530/387.100
IC [7]
ICM: A61K039-395
ICS: C07K016-00; C07K016-28; C07K016-30; C12Q001-68
EXF 424/130.1; 424/184.1; 424/132.1; 424/133.1; 424/135.1; 424/138.1; 424/141.1; 424/152.1; 530/387.1; 435/6
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 223 OF 268 USPATFULL on STN
AN 2002:133873 USPATFULL
TI Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
IN Grainger, David J., Cambridge, UNITED KINGDOM
Metcalfe, James C., Cambridge, UNITED KINGDOM
Kunz, Lawrence L., Redmond, WA, UNITED STATES
Schroff, Robert W., Edmonds, WA, UNITED STATES
PA NeoRx Corporation (non-U.S. corporation)
PI US 2002068731 A1 20020606
AI US 2001-754775 A1 20010104 (9)
RLI Continuation of Ser. No. US 1997-973570, filed on 5 Dec 1997, GRANTED, Pat. No. US 6197789 A 371 of International Ser. No. WO 1996-US10211, filed on 7 Jun 1996, UNKNOWN Continuation-in-part of Ser. No. US 1995-478936, filed on 7 Jun 1995, ABANDONED Continuation-in-part of Ser. No. US 1995-476735, filed on 7 Jun 1995, GRANTED, Pat. No. US 5595722 Continuation-in-part of Ser. No. US 1995-477393, filed on 7 Jun 1995, PENDING Continuation-in-part of Ser. No. US 1995-486334, filed on 7 Jun 1995, GRANTED, Pat. No. US 5770609
DT Utility
FS APPLICATION
LN.CNT 4207
INCL INCLM: 514/212.010
INCLS: 514/317.000; 514/428.000; 514/648.000; 514/651.000
NCL NCLM: 514/212.010
NCLS: 514/317.000; 514/428.000; 514/648.000; 514/651.000
IC [7]
ICM: A61K031-55
ICS: A61K031-445; A61K031-40; A61K031-137
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 224 OF 268 USPATFULL on STN
AN 2002:122443 USPATFULL
TI Method to determine TGF-.beta.
IN Grainger, David J., Cambridge, UNITED KINGDOM
Kemp, Paul R., Suffolk, UNITED KINGDOM
PA NeoRx Corporation, Seattle, WA, United States (U.S. corporation)
PI US 6395494 B1 20020528
AI US 1995-477393 19950607 (8)
RLI Continuation-in-part of Ser. No. US 1994-242161, filed on 12 May 1994, now patented, Pat. No. US 5847007 Continuation-in-part of Ser. No. US 1994-241844, filed on 12 May 1994, now abandoned Continuation-in-part of Ser. No. US 1993-61714, filed on 13 May 1993, now abandoned Continuation-in-part of Ser. No. US 1993-62451, filed on 13 May 1993, now abandoned
DT Utility
FS GRANTED
LN.CNT 4476
INCL INCLM: 435/007.100
INCLS: 435/007.800; 435/007.900; 435/007.920; 435/007.940; 436/501.000; 530/387.100; 530/388.100; 530/388.220; 424/178.100
NCL NCLM: 435/007.100
NCLS: 424/178.100; 435/007.800; 435/007.900; 435/007.920; 435/007.940; 436/501.000; 530/387.100; 530/388.100; 530/388.220
IC [7]

ICM: G01N033-53
ICS: C07K016-00; A61K039-395
EXF 436/518; 436/501; 428/178.1; 435/7.92; 435/7.1; 435/7.8; 435/7.9; 435/7.94; 530/387.1; 530/388.1; 530/388.22; 530/388.23; 424/178.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 225 OF 268 USPATFULL on STN
AN 2002:50610 USPATFULL
TI Method of thrombolysis by local delivery of active ***plasmin***
IN Novokhatny, Valery V., Raleigh, NC, United States
Jesmok, Gary J., Richmond, CA, United States
Landskroner, Kyle A., Mill Valley, CA, United States
Taylor, Kathryn K., Apex, NC, United States
Zimmerman, Thomas P., Raleigh, NC, United States
PA Bayer Corporation, Pittsburgh, PA, United States (U.S. corporation)
PI US 6355243 B1 20020312
AI US 1999-438331 19991113 (9)
DT Utility
FS GRANTED
LN.CNT 820
INCL INCLM: 424/094.640
INCLS: 424/094.630; 435/212.000; 435/215.000; 435/217.000
NCL NCLM: 424/094.640
NCLS: 424/094.630; 435/212.000; 435/215.000; 435/217.000
IC [7]
ICM: A61K038-48
ICS: C12N009-48; C12N009-72; C12N009-68
EXF 435/217; 435/215; 435/212; 424/94.64; 424/94.63
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 226 OF 268 USPATFULL on STN
AN 2001:196603 USPATFULL
TI Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids
IN Thorpe, Philip E., Dallas, TX, United States
Ran, Sophia, Dallas, TX, United States
PA Board of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)
PI US 6312694 B1 20011106
AI US 1999-351457 19990712 (9)
PRAI US 1998-92589P 19980713 (60)
US 1998-110600P 19981202 (60)
DT Utility
FS GRANTED
LN.CNT 8243
INCL INCLM: 424/178.100
INCLS: 424/133.100; 424/134.100; 424/135.100; 424/136.100; 424/137.100; 424/141.100; 424/142.100; 424/143.100; 424/181.100; 424/193.100; 514/012.000; 530/387.100; 530/388.100
NCL NCLM: 424/178.100
NCLS: 424/133.100; 424/134.100; 424/135.100; 424/136.100; 424/137.100; 424/141.100; 424/142.100; 424/143.100; 424/181.100; 424/193.100; 514/012.000; 530/387.100; 530/388.100
IC [7]
ICM: A61K039-395
ICS: C12P021-08; C07K016-00
EXF 514/12; 424/133.1; 424/135.1; 424/136.1; 424/137.1; 424/141.1; 424/142.1; 424/143.1; 424/178.1; 424/181.1; 424/193.1; 530/387.1; 530/388.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 227 OF 268 USPATFULL on STN
AN 2001:112344 USPATFULL
TI Prevention and treatment of cardiovascular pathologies
IN Grainger, David J., Cambridge, United Kingdom
Metcalfe, James C., Cambridge, United Kingdom
Kunz, Lawrence L., Redmond, WA, United States
Schroff, Robert W., Edmonds, WA, United States
Weissberg, Peter L., Cambridge, United Kingdom
PA NeoRx Corporation, Seattle, WA, United States (U.S. corporation)
PI US 6262079 B1 20010717
AI US 1999-306606 19990506 (9)
RLI Continuation of Ser. No. US 1998-82643, filed on 21 May 1998 Division of Ser. No. US 1995-486334, filed on 7 Jun 1995, now patented, Pat. No. US 5770609 Continuation-in-part of Ser. No. US 1994-242161, filed on 12 May 1994, now patented, Pat. No. US 5847007 Continuation-in-part of Ser. No.

US 1993-61714, filed on 13 May 1993, now abandoned Continuation-in-part of Ser. No. US 1994-241844, filed on 12 May 1994, now abandoned Continuation-in-part of Ser. No. US 1993-62451, filed on 13 May 1993, now abandoned Continuation-in-part of Ser. No. US 1993-11669, filed on 28 Jan 1993, now abandoned Continuation-in-part of Ser. No. WO 1992-US8220, filed on 25 Sep 1992
DT Utility
FS GRANTED
LN.CNT 4234
INCL INCLM: 514/319.000
INCLS: 514/324.000; 514/422.000; 514/428.000; 514/444.000; 514/448.000; 514/451.000
NCL NCLM: 514/319.000
NCLS: 514/324.000; 514/422.000; 514/428.000; 514/444.000; 514/448.000; 514/451.000
IC [7]
ICM: A61K031-445
ICS: A61K031-40; A61K031-38; A61K031-135
EXF 514/319; 514/324; 514/422; 514/428; 514/444; 514/448; 514/651
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 228 OF 268 USPATFULL on STN
AN 2001:97942 USPATFULL
TI Prevention and treatment of cardiovascular pathologies
IN Grainger, David J., Cambridge, United Kingdom
Metcalfe, James C., Cambridge, United Kingdom
Weissberg, Peter L., Cambridge, United Kingdom
PA NeoRx Corporation, Seattle, WA, United States (U.S. corporation)
PI US 6251920 B1 20010626
AI US 1998-82643 19980521 (9)
RLI Division of Ser. No. US 1995-486334, filed on 7 Jun 1995, now patented, Pat. No. US 5770609 Continuation-in-part of Ser. No. US 1994-242161, filed on 12 May 1994, now patented, Pat. No. US 5847007 Continuation-in-part of Ser. No. US 1993-61714, filed on 13 May 1993, now abandoned Continuation-in-part of Ser. No. US 1994-241844, filed on 12 May 1994, now abandoned Continuation-in-part of Ser. No. US 1993-62451, filed on 13 May 1993, now abandoned Continuation-in-part of Ser. No. US 1993-11669, filed on 28 Jan 1993, now abandoned Continuation-in-part of Ser. No. WO 1992-US8220, filed on 25 Sep 1992, now abandoned
DT Utility
FS GRANTED
LN.CNT 4366
INCL INCLM: 514/319.000
INCLS: 514/324.000; 514/422.000; 514/428.000; 514/444.000; 514/448.000; 514/651.000
NCL NCLM: 514/319.000
NCLS: 514/324.000; 514/422.000; 514/428.000; 514/444.000; 514/448.000; 514/651.000
IC [7]
ICM: A61K031-445
ICS: A61K031-40; A61K031-38; A61K031-135
EXF 514/651; 514/319; 514/324; 514/422; 514/428; 514/444; 514/448
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 229 OF 268 USPATFULL on STN
AN 2001:33286 USPATFULL
TI Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
IN Grainger, David J., Cambridge, United Kingdom
Metcalfe, James C., Cambridge, United Kingdom
Kunz, Lawrence L., Redmond, WA, United States
Schroff, Robert W., Edmonds, WA, United States
PA NeoRx Corporation, Seattle, WA, United States (U.S. corporation)
PI US 6197789 B1 20010306
WO 9640098 19961219
AI US 1997-973570 19971205 (8)
WO 1996-US10211 19960607
19980908 PCT 371 date
19980908 PCT 102(e) date
RLI Continuation-in-part of Ser. No. US 1995-478936, filed on 7 Jun 1995, now abandoned Continuation-in-part of Ser. No. US 1995-476735, filed on 7 Jun 1995, now patented, Pat. No. US 5595722 Continuation-in-part of Ser. No. US 1995-477393, filed on 7 Jun 1995 Continuation-in-part of Ser. No. US 1995-486334, filed on 7 Jun 1995, now patented, Pat. No. US 5770609

DT Utility
FS Granted
LN.CNT 4577
INCL INCLM: 514/319.000
INCLS: 514/324.000; 514/422.000; 514/428.000; 514/444.000; 514/448.000; 514/651.000; 514/866.000
NCL NCLM: 514/319.000
NCLS: 514/324.000; 514/422.000; 514/428.000; 514/444.000; 514/448.000; 514/651.000; 514/866.000
IC [7]
ICM: A61K031-445
ICS: A61K031-40; A61K031-38; A61K031-135
EXF 514/319; 514/324; 514/422; 514/428; 514/444; 514/448; 514/651; 514/866
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 230 OF 268 USPATFULL on STN
AN 2001:25877 USPATFULL
TI Human therapeutic uses of BPI protein products
IN Friedmann, Nadav, Lafayette, CA, United States
Scannon, Patrick J., San Francisco, CA, United States
van Deventer, Sander J. H., Amsterdam, Netherlands
von der Mohlen, Marijke A. M., Amsterdam, Netherlands
Wedel, Nancy, Oakland, CA, United States
PA Xoma Corporation, Berkeley, CA, United States (U.S. corporation)
PI US 6191112 B1 20010220
AI US 1999-388758 19990902 (9)
RLI Continuation of Ser. No. US 1998-81166, filed on 18 May 1998, now patented, Pat. No. US 5952302 Continuation of Ser. No. US 1995-378228, filed on 24 Jan 1995, now patented, Pat. No. US 5753620 Continuation-in-part of Ser. No. US 1994-291112, filed on 16 Aug 1994, now patented, Pat. No. US 5643875 Continuation-in-part of Ser. No. US 1994-188221, filed on 24 Jan 1994, now abandoned
DT Utility
FS Granted
LN.CNT 1608
INCL INCLM: 514/012.000
INCLS: 514/021.000; 514/921.000; 530/324.000; 530/350.000; 530/351.000; 530/830.000; 424/085.100; 424/085.200; 424/529.000; 424/534.000
NCL NCLM: 514/012.000
NCLS: 424/085.100; 424/085.200; 424/529.000; 424/534.000; 514/021.000; 514/921.000; 530/324.000; 530/350.000; 530/351.000; 530/830.000
IC [7]
ICM: A61K038-00
ICS: A61K045-05
EXF 514/12; 514/21; 514/921; 530/324; 530/350; 530/351; 530/830; 424/85.1; 424/85.2; 424/529; 424/534
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 231 OF 268 USPATFULL on STN
AN 2000:174716 USPATFULL
TI Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
IN Grainger, David J., Cambridge, United Kingdom
Metcalfe, James C., Cambridge, United Kingdom
Weissberg, Peter L., Cambridge, United Kingdom
PA NeoRx Corporation, Seattle, WA, United States (U.S. corporation)
PI US 6166090 20001226
AI US 1997-965589 19971106 (8)
RLI Continuation of Ser. No. US 1994-242161, filed on 12 May 1994, now patented, Pat. No. US 5847007 which is a continuation-in-part of Ser. No. US 1993-61714, filed on 13 May 1993, now abandoned
DT Utility
FS Granted
LN.CNT 2490
INCL INCLM: 514/651.000
INCLS: 514/824.000
NCL NCLM: 514/651.000
NCLS: 514/824.000
IC [7]
ICM: A61K031-135
EXF 514/651; 514/824
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 232 OF 268 USPATFULL on STN
AN 2000:117277 USPATFULL
TI Pharmaceutical compositions containing ecotin and homologs thereof

IN Lazarus, Robert A., Millbrae, CA, United States
Dennis, Mark S., San Carlos, CA, United States
Ulmer, Jana Seymour, San Rafael, CA, United States
PA Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)
PI US 6113896 20000905
AI US 1994-319501 19941004 (8)
RLI Continuation of Ser. No. US 1993-121004, filed on 14 Sep 1993, now abandoned
DT Utility
FS Granted
LN.CNT 2208
INCL INCLM: 424/094.640
INCLS: 435/212.000; 514/012.000; 530/350.000
NCL NCLM: 424/094.640
NCLS: 435/212.000; 514/012.000; 530/350.000
IC [7]
ICM: A61K038-55
ICS: C12N009-48; C07K014-81
EXF 435/212-218; 514/12; 424/94.64; 530/350
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 233 OF 268 USPATFULL on STN
AN 1999:110292 USPATFULL
TI Human therapeutic uses of BPI protein products
IN Friedmann, Nadav, Lafayette, CA, United States
Scannon, Patrick J., San Francisco, CA, United States
van Deventer, Sander J.H., Amsterdam, Netherlands
von der Mohlen, Marijke A.M., Amsterdam, Netherlands
Wedel, Nancy, Oakland, CA, United States
PA Xoma Corporation, Berkeley, CA, United States (U.S. corporation)
PI US 5952302 19990914
AI US 1998-81166 19980518 (9)
RLI Continuation of Ser. No. US 1995-378228, filed on 24 Jan 1995, now patented, Pat. No. US 5753620 which is a continuation-in-part of Ser. No. US 1994-291112, filed on 16 Aug 1994, now patented, Pat. No. US 5643875 which is a continuation-in-part of Ser. No. US 1994-188221, filed on 24 Jan 1994, now abandoned
DT Utility
FS Granted
LN.CNT 1788
INCL INCLM: 514/012.000
INCLS: 514/021.000; 514/921.000; 530/324.000; 530/350.000; 530/351.000; 530/830.000; 424/085.100; 424/085.200; 424/529.000; 424/534.000
NCL NCLM: 514/012.000
NCLS: 424/085.100; 424/085.200; 424/529.000; 424/534.000; 514/021.000; 514/921.000; 530/324.000; 530/350.000; 530/351.000; 530/830.000
IC [6]
ICM: A61K038-00
ICS: A61K045-05
EXF 514/12; 514/21; 514/921; 530/350; 530/351; 530/324; 530/830; 424/85.1; 424/85.2; 424/529; 424/534
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 234 OF 268 USPATFULL on STN
AN 1999:102686 USPATFULL
TI Process for screening candidate agents that modulate the hemostatic system
IN Gadbut, Albert P., San Mateo, CA, United States
PA MetaXen LLC, Hayward, CA, United States (U.S. corporation)
PI US 5945297 19990831
AI US 1998-69888 19980429 (9)
DT Utility
FS Granted
LN.CNT 740
INCL INCLM: 435/013.000
INCLS: 436/069.000; 436/172.000; 424/529.000; 424/531.000; 424/532.000; 530/381.000; 530/382.000
NCL NCLM: 435/013.000
NCLS: 424/529.000; 424/531.000; 424/532.000; 436/069.000; 436/172.000; 530/381.000; 530/382.000
IC [6]
ICM: C12Q001-56
ICS: G01N033-86; G01N033-48; G01N021-76
EXF 435/13; 436/69; 436/172; 424/529; 424/531; 424/532; 530/381; 530/382
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 235 OF 268 USPATFULL on STN
AN 1999:88792 USPATFULL
TI Modified ***plasmin*** precursors with resistance to inhibitors of ***plasmin***
IN Dawson, Keith Martyn, Cowley, United Kingdom
 Gilbert, Richard James, Cowley, United Kingdom
PA British Biotech Pharmaceuticals, Ltd., Oxford, United Kingdom (non-U.S. corporation)
PI US 5932213 19990803
AI US 1997-889078 19970707 (8)
RLI Continuation of Ser. No. US 1995-379621, filed on 3 Feb 1995
PRAI GB 1992-16558 19920804
DT Utility
FS Granted
LN.CNT 1059
INCL INCLM: 424/094.640
 INCLS: 435/217.000; 536/023.200
NCL NCLM: 424/094.640
 NCLS: 435/217.000; 536/023.200
IC [6]
 ICM: C12N009-68
 ICS: C12N015-55; A61K038-48
EXF 424/94.64; 435/217; 435/320.1; 536/23.2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 236 OF 268 USPATFULL on STN
AN 1999:30937 USPATFULL
TI Factor VIIa inhibitors from Kunitz domain proteins
IN Dennis, Mark S., San Carlos, CA, United States
 Lazarus, Robert A., Milbrae, CA, United States
PA Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)
PI US 5880256 19990309
AI US 1995-399115 19950303 (8)
RLI Continuation-in-part of Ser. No. US 1994-206310, filed on 4 Mar 1994, now abandoned
DT Utility
FS Granted
LN.CNT 2832
INCL INCLM: 530/324.000
 INCLS: 435/069.200; 514/012.000; 514/822.000; 530/300.000; 930/250.000
NCL NCLM: 530/324.000
 NCLS: 435/069.200; 530/300.000; 930/250.000
IC [6]
 ICM: C07K014-81
 ICS: C12N015-15; A61K038-55
EXF 435/69.2; 514/2; 514/12; 514/822; 530/300; 530/324; 530/350; 930/250
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 237 OF 268 USPATFULL on STN
AN 1999:13025 USPATFULL
TI Methods of forming a pre-clotted clot supporter, methods of storing a pre-clotted clot supporter and clots adhered to fluid permeable membranes
IN Brubaker, Daniel B., Clovis, CA, United States
PA Espress Tech, Inc., Clovis, CA, United States (U.S. corporation)
PI US 5864017 19990126
AI US 1997-775365 19970103 (8)
RLI Division of Ser. No. US 1995-431276, filed on 28 Apr 1995, now patented, Pat. No. US 5612187 which is a continuation-in-part of Ser. No. US 1994-216189, filed on 22 Mar 1994, now patented, Pat. No. US 5432084
DT Utility
FS Granted
LN.CNT 626
INCL INCLM: 530/380.000
 INCLS: 530/381.000; 530/382.000; 435/002.000; 435/013.000; 435/069.600; 435/287.900; 422/068.100; 422/073.000
NCL NCLM: 530/380.000
 NCLS: 422/068.100; 422/073.000; 435/002.000; 435/013.000; 435/069.600; 435/287.900; 530/381.000; 530/382.000
IC [6]
 ICM: A61K035-14
 ICS: C12Q001-56
EXF 530/380; 530/381; 530/382; 435/2; 435/13; 435/69; 435/61; 435/287.9; 422/68.1; 422/73

L4 ANSWER 238 OF 268 USPATFULL on STN
AN 1999:12902 USPATFULL
TI Factor VIIa inhibitors from kunitz domain proteins
IN Dennis, Mark S., San Carlos, CA, United States
 Lazarus, Robert A., Millbrae, CA, United States
PA Genentech, Inc., San Francisco, CA, United States (U.S. corporation)
PI US 5863893 19990126
AI US 1995-398628 19950303 (8)
RLI Continuation-in-part of Ser. No. US 1994-206310, filed on 4 Mar 1994
DT Utility
FS Granted
LN.CNT 2603
INCL INCLM: 514/012.000
 INCLS: 435/226.000; 514/822.000; 930/250.000
NCL NCLM: 514/012.000
 NCLS: 435/226.000; 514/822.000; 930/250.000
IC [6]
 ICM: A61K038-55
 ICS: A61K038-57; C07K014-81; C12N009-64
EXF 514/2; 514/12; 530/300; 530/324; 530/350; 435/69.2; 435/226; 930/250
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 239 OF 268 USPATFULL on STN
AN 1998:154312 USPATFULL
TI Prevention and treatment of pathologies associated with abnormally
 proliferative smooth muscle cells
IN Grainger, David J., Cambridge, England
 Metcalfe, James C., Cambridge, England
 Weissberg, Peter L., Cambridge, England
PA NeoRx Corporation, Seattle, WA, United States (U.S. corporation)
PI US 5847007 19981208
AI US 1994-242161 19940512 (8)
RLI Continuation-in-part of Ser. No. US 1993-61714, filed on 13 May 1993,
 now abandoned
DT Utility
FS Granted
LN.CNT 2429
INCL INCLM: 514/651.000
 INCLS: 514/824.000
NCL NCLM: 514/651.000
 NCLS: 514/824.000
IC [6]
 ICM: A61K031-135
EXF 514/56; 514/651; 514/824
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 240 OF 268 USPATFULL on STN
AN 1998:150899 USPATFULL
TI Pharmaceutical administration of ecotin homologs
IN Lazarus, Robert A., Millbrae, CA, United States
 Dennis, Mark S., San Carlos, CA, United States
 Ulmer, Jana Seymour, San Rafael, CA, United States
PA Genentech, Inc., South San Francisco, CA, United States (U.S.
 corporation)
PI US 5843895 19981201
AI US 1995-439005 19950511 (8)
RLI Division of Ser. No. US 1994-319501, filed on 4 Oct 1994 which is a
 continuation of Ser. No. US 1993-121004, filed on 14 Sep 1993, now
 abandoned
DT Utility
FS Granted
LN.CNT 2162
INCL INCLM: 514/012.000
 INCLS: 530/350.000
NCL NCLM: 514/012.000
 NCLS: 530/350.000
IC [6]
 ICM: C07K014-81
 ICS: A61K038-55
EXF 514/12; 424/94.64; 530/350
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 241 OF 268 USPATFULL on STN
AN 1998:138687 USPATFULL
TI Factor VIIa inhibitors from Kunitz domain proteins

IN Dennis, Mark S., San Carlos, CA, United States
Lazarus, Robert A., Millbrae, CA, United States
PA Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)
PI US 5834244 19981110
AI US 1995-398010 19950303 (8)
RLI Continuation-in-part of Ser. No. US 1994-206310, filed on 4 Mar 1994
DT Utility
FS Granted
LN.CNT 2676
INCL INCLM: 435/069.200
INCLS: 435/172.300; 435/252.300; 435/320.100; 435/325.000; 536/023.500; 930/250.000
NCL NCLM: 435/069.200
NCLS: 435/252.300; 435/320.100; 435/325.000; 536/023.500; 930/250.000
IC [6]
ICM: C07K014-81
ICS: C12N015-15; C12N015-63; C12N001-21
EXF 435/69.2; 435/172.3; 435/320.1; 435/240.2; 435/252.3; 435/325; 536/23.1; 536/23.5; 930/250
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 242 OF 268 USPATFULL on STN
AN 1998:115581 USPATFULL
TI Hybrid immunoglobulin-thrombolytic enzyme molecules which specifically bind a thrombus, and methods of their production and use
IN Quertermous, Thomas, Nashville, TN, United States
Runge, Marschall Stevens, Atlanta, GA, United States
Haber, Edgar, Salisbury, NH, United States
PA The General Hospital Corporation, Boston, MA, United States (U.S. corporation)
PI US 5811265 19980922
AI US 0961736 19930726 (8)
RLI Continuation-in-part of Ser. No. 2861, filed on 15 Jan 1993, now abandoned And a continuation-in-part of Ser. No. 589435, filed on 27 Sep 1990, now abandoned which is a continuation-in-part of Ser. No. 435485, filed on 7 Jul 1989, now abandoned , said Ser. No. 2861 which is a continuation of Ser. No. 234051, filed on 19 Aug 1988, now abandoned
DT Utility
FS Granted
LN.CNT 4098
INCL INCLM: 435/069.300
INCLS: 435/172.200; 435/172.300; 435/252.300; 536/023.400; 536/023.530
NCL NCLM: 435/069.300
NCLS: 435/252.300; 536/023.400; 536/023.530
IC [6]
ICM: A61K039-395
EXF 435/69.3; 435/252.3; 435/172.2; 435/172.3; 536/23.4; 536/23.53
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 243 OF 268 USPATFULL on STN
AN 1998:98974 USPATFULL
TI Factor VIIa inhibitors from Kunitz domain proteins
IN Lazarus, Robert A., Milbrae, CA, United States
Dennis, Mark S., San Carlos, CA, United States
PA Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)
PI US 5795954 19980818
AI US 1994-206310 19940304 (8)
DT Utility
FS Granted
LN.CNT 2051
INCL INCLM: 530/324.000
INCLS: 530/300.000; 514/012.000
NCL NCLM: 530/324.000
NCLS: 530/300.000
IC [6]
ICM: C07K014-81
ICS: A61K038-16; A61K038-57
EXF 435/69.2; 530/300; 530/324; 530/350; 514/2; 514/12
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 244 OF 268 USPATFULL on STN
AN 1998:72634 USPATFULL
TI Prevention and treatment of cardiovascular pathologies

IN Grainger, David J., Cambridge, England
Metcalfe, James C., Cambridge, England
Kunz, Lawrence L., Redmond, WA, United States
Schroff, Robert W., Edmonds, WA, United States
Weissberg, Peter L., Cambridge, England
PA NeoRx Corporation, Seattle, WA, United States (U.S. corporation)
PI US 5770609 19980623
AI US 1995-486334 19950607 (8)
RLI Continuation-in-part of Ser. No. US 1994-242161, filed on 12 May 1994 which is a continuation-in-part of Ser. No. US 1993-61714, filed on 13 May 1993, now abandoned And a continuation-in-part of Ser. No. US 1994-241844, filed on 12 May 1994 which is a continuation-in-part of Ser. No. US 1993-62451, filed on 13 May 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-11669, filed on 28 Jan 1993, now abandoned
DT Utility
FS Granted
LN.CNT 4318
INCL INCLM: 514/319.000
INCLS: 514/324.000; 514/422.000; 514/428.000; 514/444.000; 514/448.000; 514/651.000
NCL NCLM: 514/319.000
NCLS: 514/324.000; 514/422.000; 514/428.000; 514/444.000; 514/448.000; 514/651.000
IC [6]
ICM: A61K031-445
ICS: A61K031-40; A61K031-38; A61K031-135
EXF 514/651; 514/324; 514/212; 514/422; 514/428; 514/444; 514/448; 514/319
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 245 OF 268 USPATFULL on STN
AN 1998:68822 USPATFULL
TI Cysteine-pegylated proteins
IN Braxton, Scott M., San Mateo, CA, United States
PA Incyte Pharmaceuticals, Inc., Palo Alto, CA, United States (U.S. corporation)
PI US 5766897 19980616
AI US 1995-427100 19950421 (8)
RLI Continuation-in-part of Ser. No. US 1993-144758, filed on 29 Oct 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-924294, filed on 3 Aug 1992, now patented, Pat. No. US 5457090 which is a continuation of Ser. No. US 1990-542484, filed on 21 Jun 1990, now patented, Pat. No. US 5187089, issued on 16 Feb 1993
DT Utility
FS Granted
LN.CNT 2765
INCL INCLM: 435/172.100
INCLS: 435/188.000; 435/212.000; 435/219.000
NCL NCLM: 435/463.000
NCLS: 435/188.000; 435/212.000; 435/219.000
IC [6]
ICM: C12N015-00
ICS: C12N009-96; C12N009-48; C12N009-50
EXF 514/12; 530/350; 435/69.2; 435/188; 435/172.1; 435/212; 435/219
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 246 OF 268 USPATFULL on STN
AN 1998:54865 USPATFULL
TI Human therapeutic uses of BPI protein products
IN Friedmann, Nadav, Lafayette, CA, United States
Scannon, Patrick J., San Francisco, CA, United States
van Deventer, Sander J. H., Amsterdam, Netherlands
von der Mohlen, Marijke A. M., Amsterdam, Netherlands
Wedel, Nancy, Oakland, CA, United States
PA XOMA Corporation, Berkeley, CA, United States (U.S. corporation)
PI US 5753620 19980519
AI US 1995-378228 19950124 (8)
RLI Continuation-in-part of Ser. No. US 1994-291112, filed on 16 Aug 1994, now patented, Pat. No. US 5643875 which is a continuation-in-part of Ser. No. US 1994-188221, filed on 24 Jan 1994, now abandoned
DT Utility
FS Granted
LN.CNT 1742
INCL INCLM: 514/012.000
INCLS: 514/021.000; 514/921.000; 530/324.000; 530/350.000; 530/351.000; 530/830.000; 424/085.100; 424/085.200; 424/529.000; 424/534.000

NCL NCLM: 514/012.000
NCLS: 424/085.100; 424/085.200; 424/529.000; 424/534.000; 514/021.000; 514/921.000; 530/324.000; 530/350.000; 530/351.000; 530/830.000
IC [6]
ICM: A61K038-00
ICS: A61K045-05
EXF 514/12; 514/21; 514/921; 530/350; 530/351; 530/324; 530/830; 424/85.1; 424/85.2; 424/529; 424/534
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 247 OF 268 USPATFULL on STN
AN 1998:42340 USPATFULL
TI Thrombolytic composition
IN Dawson, Keith Martyn, Oxford, United Kingdom
Wood, Lars Michael, Oxford, United Kingdom
Comer, Michael Berisford, Oxford, United Kingdom
PA British Biotech Pharmaceuticals Ltd., England (non-U.S. corporation)
PI US 5741771 19980421
WO 9535117 19951228
AI US 1997-750711 19970318 (8)
WO 1995-GB1388 19950614
19970318 PCT 371 date
19970318 PCT 102(e) date
PRAI GB 1994-12131 19940617
DT Utility
FS Granted
LN.CNT 499
INCL INCLM: 514/002.000
INCLS: 514/017.000; 435/217.000; 435/212.000; 435/214.000; 530/324.000; 530/329.000
NCL NCLM: 514/002.000
NCLS: 435/212.000; 435/214.000; 435/217.000; 514/017.000; 530/324.000; 530/329.000
IC [6]
ICM: A61K038-49
ICS: A61K038-48
EXF 514/2; 514/17; 530/324; 530/329
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 248 OF 268 USPATFULL on STN
AN 1998:17207 USPATFULL
TI DNA encoding ecotin homologs
IN Lazarus, Robert A., Millbrae, CA, United States
Dennis, Mark S., San Carlos, CA, United States
Ulmer, Jana Seymour, San Rafael, CA, United States
PA Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)
PI US 5719041 19980217
AI US 1995-439534 19950511 (8)
RLI Division of Ser. No. US 1994-319501, filed on 4 Oct 1994 which is a continuation of Ser. No. US 1993-121004, filed on 14 Sep 1993, now abandoned
DT Utility
FS Granted
LN.CNT 2188
INCL INCLM: 435/069.200
INCLS: 435/320.100; 435/252.300; 536/023.700
NCL NCLM: 435/069.200
NCLS: 435/252.300; 435/320.100; 536/023.700
IC [6]
ICM: C12P021-02
ICS: C12N015-63; C12N001-21; C07H021-04
EXF 435/69.1; 435/320.1; 435/252.3; 435/252.33; 435/69.2; 536/23.7; 536/23.2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 249 OF 268 USPATFULL on STN
AN 97:106953 USPATFULL
TI Thrombin activatable plasminogen analogues
IN Dawson, Keith Martyn, Oxford, England
Gilbert, Richard James, Oxford, England
Hunter, Michael George, Oxford, England
PA British Bio-Technology Ltd., England (non-U.S. corporation)
PI US 5688664 19971118
AI US 1993-147000 19931029 (8)
RLI Continuation-in-part of Ser. No. US 1992-854603, filed on 4 Jun 1992
PRAI WO 1990-GB1912 19901207

GB 1992-22758 19921029
DT Utility
FS Granted
LN.CNT 971
INCL INCLM: 435/069.200
INCLS: 435/217.000; 424/094.640
NCL NCLM: 435/069.200
NCLS: 424/094.640; 435/217.000
IC [6]
ICM: A61K038-48
ICS: C12N009-68; C12P021-00
EXF 435/217; 435/69.2; 424/94.64
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 250 OF 268 USPATFULL on STN
AN 97:106796 USPATFULL
TI Modification of plasminogen activators
IN Blasi, Francesco, Teglgardsvej 19A, DK-2920 Charlottenlund, Denmark
Stoppelli, Maria Patrizia, IIa Trav. L. Bianchi, 389, I-80131 Napoli, Italy
Mastronicola, Maria Rosaria, Via Nicolardi, 109, I-80131 Napoli, Italy
Welinder, Karen Gjersing, Amosebakken 14, DK-2830 Virum, Denmark
Correas, Isabel, C. Doctor Esquerdo 140-1, 7c, E-28007 Madrid, Spain
PI US 5688503 19971118
AI US 1995-441358 19950515 (8)
RLI Division of Ser. No. US 1991-603675, filed on 18 Dec 1991, now patented, Pat. No. US 5416006
PRAI DK 1989-1822 19890414
DT Utility
FS Granted
LN.CNT 1328
INCL INCLM: 424/094.640
INCLS: 424/094.630; 435/212.000; 435/215.000
NCL NCLM: 424/094.640
NCLS: 424/094.630; 435/212.000; 435/215.000
IC [6]
ICM: A61K038-49
ICS: A61K038-48; C12N009-48; C12N009-72
EXF 424/94.63; 424/94.64; 435/212; 435/215; 435/226
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 251 OF 268 USPATFULL on STN
AN 97:58898 USPATFULL
TI Inhibitor resistant serine proteases
IN Dawson, Keith Martyn, Cowley, United Kingdom
Gilbert, Richard James, Cowley, United Kingdom
PA British Biotech Pharmaceuticals Limited, Oxford, United Kingdom (non-U.S. corporation)
PI US 5645833 19970708
WO 9403614 19940217
AI US 1995-379621 19950203 (8)
WO 1993-GB1632 19930803
19950203 PCT 371 date
19950203 PCT 102(e) date
PRAI GB 1992-16558 19920804
DT Utility
FS Granted
LN.CNT 1070
INCL INCLM: 424/094.640
INCLS: 435/217.000; 435/252.300; 435/320.100; 435/325.000; 435/358.000; 435/365.000; 435/367.000; 435/369.000; 435/357.000; 435/352.000; 435/356.000; 536/023.200
NCL NCLM: 424/094.640
NCLS: 435/217.000; 435/252.300; 435/320.100; 435/325.000; 435/352.000; 435/356.000; 435/357.000; 435/358.000; 435/365.000; 435/367.000; 435/369.000; 536/023.200
IC [6]
ICM: A61K038-48
ICS: C12N009-68; C12N015-55; C12N015-63
EXF 424/94.64; 435/217; 435/172.3; 435/240.2; 435/252.3; 435/320.1; 536/23.2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 252 OF 268 USPATFULL on STN
AN 97:56641 USPATFULL
TI Human therapeutic uses of bactericidal/permeability increasing (BPI) protein products

IN Friedmann, Nadav, 91 Bacon Ct., Lafayette, CA, United States 94549
Scannon, Patrick J., 176 Edgewood Ave., San Francisco, CA, United States 94117
van Deventer, Sander J. H., Meibergdreff 9, 1105 AZ, Amsterdam, Netherlands
von der Mohlen, Marijke A. M., Meibergdreff 9, 1105 AZ, Amsterdam, Netherlands
Wedel, Nancy, 5800 Ayala Ave., Oakland, CA, United States 94609
PI US 5643875 19970701
AI US 1994-291112 19940816 (8)
RLI Continuation-in-part of Ser. No. US 1994-188221, filed on 24 Jan 1994, now abandoned
DT Utility
FS Granted
LN.CNT 1524
INCL INCLM: 514/012.000
INCLS: 514/021.000; 514/921.000; 530/324.000; 530/325.000; 530/351.000; 530/820.000; 424/085.100; 424/085.200; 424/529.000; 424/534.000
NCL NCLM: 514/012.000
NCLS: 424/085.100; 424/085.200; 424/529.000; 424/534.000; 514/021.000; 514/921.000; 530/324.000; 530/325.000; 530/351.000; 530/820.000
IC [6]
ICM: A61K038-00
ICS: A61K045-05
EXF 514/12; 514/21; 514/921; 530/324; 530/325; 530/820; 530/351; 424/85.1; 424/85.2; 424/529; 424/534
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 253 OF 268 USPATFULL on STN
AN 97:51973 USPATFULL
TI Peptide mediated enhancement of thrombolysis methods and compositions
IN Lawrence, Daniel A., Ann Arbor, MI, United States
Ginsburg, David, Ann Arbor, MI, United States
Shore, Joseph D., Grosse Point Farms, MI, United States
Fay, William P., Ann Arbor, MI, United States
Olson, Steven T., Chicago, IL, United States
Francis-Chmura, Ann Marie, Warren, MI, United States
Eitzman, Daniel T., Ypsilanti, MI, United States
Paielli, Dell, Wyandotte, MI, United States
PA The Regents of the University of Michigan, Ann Arbor, MI, United States (U.S. corporation)
Henry Ford Health System, Detroit, MI, United States (U.S. corporation)
PI US 5639726 19970617
AI US 1994-315461 19940930 (8)
DT Utility
FS Granted
LN.CNT 4817
INCL INCLM: 514/012.000
INCLS: 514/013.000; 514/014.000; 514/015.000; 514/016.000; 530/324.000; 530/325.000; 530/326.000; 530/327.000; 530/328.000
NCL NCLM: 514/012.000
NCLS: 514/013.000; 514/014.000; 514/015.000; 514/016.000; 530/324.000; 530/325.000; 530/326.000; 530/327.000; 530/328.000
IC [6]
ICM: A61K038-00
ICS: A61K038-02; C07K005-00; C07K007-00
EXF 530/324; 530/325; 530/326; 530/327; 530/328; 514/12; 514/13; 514/14; 514/15; 514/16
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 254 OF 268 USPATFULL on STN
AN 97:49542 USPATFULL
TI Activatable fibrinolytic and anti-thrombotic proteins
IN Dawson, Keith, Marlow, United Kingdom
Edwards, Richard M., Thame, United Kingdom
Forman, Joan M., Oxford, United Kingdom
PA British Biotech Pharmaceuticals, England (non-U.S. corporation)
PI US 5637492 19970610
WO 9109118 19910627
AI US 1992-854603 19920604 (7)
WO 1990-GB1912 19901207
19920604 PCT 371 date
19920604 PCT 102(e) date
PRAI GB 1989-27722 19891207
DT Utility
FS Granted

LN.CNT 1908
INCL INCLM: 435/217.000
INCLS: 435/212.000; 435/172.300; 424/094.640
NCL NCLM: 435/217.000
NCLS: 424/094.640; 435/212.000
IC [6]
ICM: A61K037-48
ICS: C12N009-68; C12N015-59
EXF 435/69.1; 435/172.3; 435/214; 435/217; 435/212; 435/226; 435/193; 530/384; 530/381; 424/94.63; 424/94.64
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 255 OF 268 USPATFULL on STN
AN 97:38188 USPATFULL
TI Use of intra-platelet urokinase-type plasminogen activators for long-term inhibition of thrombosis
IN Gurewich, Victor, 11 Reservoir St., Cambridge, MA, United States 02138
PI US 5626841 19970506
AI US 1994-254922 19940607 (8)
RLI Continuation-in-part of Ser. No. US 1993-14207, filed on 5 Feb 1993, now abandoned
DT Utility
FS Granted
LN.CNT 876
INCL INCLM: 424/094.630
INCLS: 424/094.640; 435/215.000; 435/226.000
NCL NCLM: 424/094.630
NCLS: 424/094.640; 435/215.000; 435/226.000
IC [6]
ICM: A61K038-49
ICS: C12N009-64; C12N009-72
EXF 424/94.63; 424/94.64; 435/212; 435/215; 435/216; 514/12
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 256 OF 268 USPATFULL on STN
AN 97:22632 USPATFULL
TI Clot lysis time determining device and method for determining the time necessary for fluid to lyse a clot, and clot supporter
IN Brubaker, Daniel B., Clovis, CA, United States
PA Espress Tech, Inc., Clovis, CA, United States (U.S. corporation)
PI US 5612187 19970318
AI US 1995-431276 19950428 (8)
RLI Continuation-in-part of Ser. No. US 1994-216189, filed on 22 Mar 1994, now patented, Pat. No. US 5432084
DT Utility
FS Granted
LN.CNT 838
INCL INCLM: 435/013.000
INCLS: 435/002.000; 435/287.900; 422/068.100; 436/069.000
NCL NCLM: 435/013.000
NCLS: 422/068.100; 435/002.000; 435/287.900; 436/069.000
IC [6]
ICM: C12Q001-56
ICS: C12M001-40
EXF 435/13; 435/40.5; 435/283.1; 435/287.1; 435/287.9; 435/297.2; 435/2; 436/69; 436/165; 436/809; 422/58; 422/61; 422/69; 422/73; 422/101; 422/99; 422/68.1; 422/104; 073/64.41; 073/64.43

L4 ANSWER 257 OF 268 USPATFULL on STN
AN 97:20243 USPATFULL
TI Hybrid immunoglobulin-thrombolytic enzyme molecules which specifically bind a thrombus, and methods of their production and use
IN Quertermous, Thomas, Nashville, TN, United States
Runge, Marschall S., Atlanta, GA, United States
Haber, Edgar, Salisbury, NH, United States
PA The General Hospital Corporation, Boston, MA, United States (U.S. corporation)
PI US 5609869 19970311
AI US 1995-453779 19950530 (8)
RLI Division of Ser. No. US 1993-96173, filed on 26 Jul 1993 which is a continuation-in-part of Ser. No. US 1993-2861, filed on 15 Jan 1993 And Ser. No. US 1990-589435, filed on 27 Sep 1990 which is a continuation-in-part of Ser. No. US 1989-435485, filed on 7 Jul 1989, now abandoned , said Ser. No. US -2861 which is a continuation of Ser. No. US 1988-234051, filed on 19 Aug 1988, now abandoned
DT Utility

FS Granted
LN.CNT 3876
INCL INCLM: 424/133.100
INCLS: 424/134.100; 424/136.100; 424/139.100; 424/178.100; 424/192.100; 435/069.300; 435/252.300; 435/172.200; 435/172.300; 530/387.300; 530/388.250; 530/389.300; 536/023.400; 536/023.530
NCL NCLM: 424/133.100
NCLS: 424/134.100; 424/136.100; 424/139.100; 424/178.100; 424/192.100; 435/069.300; 435/252.300; 530/387.300; 530/388.250; 530/389.300; 536/023.400; 536/023.530
IC [6]
ICM: A61K039-395
EXF 435/69.3; 435/252.3; 435/172.2; 435/172.3; 435/7.1; 435/7.9; 435/7.6; 435/69.7; 536/23.4; 536/23.53; 530/350; 530/387.1; 530/387.3; 530/388.25; 530/389.3; 424/133.1; 424/134.1; 424/136.1; 424/178.1; 424/192.1; 424/139.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 258 OF 268 USPATFULL on STN
AN 97:5708 USPATFULL
TI Method for identifying an agent which increases TGF-beta levels
IN Grainger, David J., Cambridge, England
Metcalfe, James C., Cambridge, England
PA NeoRx Corporation, Seattle, WA, United States (U.S. corporation)
PI US 5595722 19970121
AI US 1995-476735 19950607 (8)
RLI Continuation-in-part of Ser. No. US 1994-242161, filed on 12 May 1994 which is a continuation-in-part of Ser. No. US 1993-61714, filed on 13 May 1993, now abandoned And Ser. No. US 1994-241844, filed on 12 May 1994 which is a continuation-in-part of Ser. No. US 1993-62451, filed on 13 May 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-11669, filed on 28 Jan 1993, now abandoned
DT Utility
FS Granted
LN.CNT 4090
INCL INCLM: 424/009.200
NCL NCLM: 424/009.200
IC [6]
ICM: A61K049-00
EXF 424/9.2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 259 OF 268 USPATFULL on STN
AN 96:72817 USPATFULL
TI Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
IN Grainger, David J., Cambridge, United Kingdom
Metcalfe, James C., Cambridge, United Kingdom
Weissberg, Peter L., Cambridge, United Kingdom
PA NeoRx Corporation, Seattle, WA, United States (U.S. corporation)
PI US 5545569 19960813
AI US 1995-450520 19950525 (8)
RLI Division of Ser. No. US 1994-242161, filed on 12 May 1994 which is a continuation-in-part of Ser. No. US 1993-61714, filed on 13 May 1993, now abandoned
DT Utility
FS Granted
LN.CNT 2263
INCL INCLM: 436/518.000
NCL NCLM: 436/518.000
IC [6]
ICM: G01N033-543
EXF 436/518; 424/178.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 260 OF 268 USPATFULL on STN
AN 95:105947 USPATFULL
TI Immunoinhibitors of factor XIII
IN Reed, Guy, Winchester, MA, United States
PA President and Fellows of Harvard College, Cambridge, MA, United States (U.S. corporation)
The General Hospital Corporation, Boston, MA, United States (U.S. corporation)
PI US 5470957 19951128
AI US 1993-131199 19931001 (8)
DT Utility

FS Granted
LN.CNT 849
INCL INCLM: 530/388.250
INCLS: 530/388.100; 424/145.100; 424/158.100; 435/172.200; 435/240.270
NCL NCLM: 530/388.250
NCLS: 424/145.100; 424/158.100; 530/388.100
IC [6]
ICM: A61K039-395
ICS: C07K016-36; C07K016-18
EXF 435/70.21; 435/172.2; 435/240.27; 530/387.1; 530/388.1; 530/388.25; 424/141.1; 424/145.1; 424/158.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 261 OF 268 USPATFULL on STN
AN 95:90514 USPATFULL
TI Protease nexin-I variants
IN Scott, Randy W., Sunnyvale, CA, United States
Golini, Fred, San Mateo, CA, United States
McGrogan, Michael, San Carlos, CA, United States
PA Incyte Pharamaceuticals, Inc., Palo Alto, CA, United States (U.S. corporation)
PI US 5457090 19951010
AI US 1992-924294 19920803 (7)
RLI Continuation of Ser. No. US 1990-542484, filed on 21 Jun 1990, now patented, Pat. No. US 5187089
DT Utility
FS Granted
LN.CNT 1221
INCL INCLM: 514/012.000
INCLS: 424/094.640
NCL NCLM: 514/012.000
NCLS: 424/094.640
IC [6]
ICM: A61K038-55
ICS: A61K038-57
EXF 530/388.26; 435/214; 435/218; 424/94.64; 514/12
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 262 OF 268 USPATFULL on STN
AN 95:43167 USPATFULL
TI Modification of plasminogen activators
IN Blasi, Francesco, T1glg.ang.rdsvej 19A,, DK-2920 Charlottenlund, Denmark
Stoppelli, Maria P., IIa Trav. L. Bianchi, 389,, I-80131 Napoli, Italy
Mastronicola, Maria R., Via Nicolardi, 109,, I-80131 Napoli, Italy
Welinder, Karen G., .ANG.mosebakken 14,, DK-2830 Virum, Denmark
Correas, Isabel, C. Doctor Esquerdo 140-1, 7c, E-28007 Madrid, Spain
PI US 5416006 19950516
WO 9012872 19901101
AI US 1991-603675 19911218 (7)
WO 1990-DK96 19900411
19911218 PCT 371 date
19911218 PCT 102(e) date
PRAI DK 1989-1822 19890414
DT Utility
FS Granted
LN.CNT 1409
INCL INCLM: 435/068.100
INCLS: 435/069.100; 435/070.300; 435/131.000; 435/215.000; 530/412.000
NCL NCLM: 435/068.100
NCLS: 435/069.100; 435/070.300; 435/131.000; 435/215.000; 530/412.000
IC [6]
ICM: C07K003-12
ICS: C12N005-06; C12N009-72; C12P009-00
EXF 435/70.1; 435/70.3; 435/215; 435/803; 435/226; 435/69.1; 435/212; 435/172.3; 435/194; 435/68.1; 424/94.63; 530/417
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 263 OF 268 USPATFULL on STN
AN 93:12449 USPATFULL
TI Protease nexin-I variants which inhibit elastase
IN Scott, Randy W., Sunnyvale, CA, United States
Golini, Fred, San Mateo, CA, United States
McGrogan, Michael, San Carlos, CA, United States
PA Incyte Pharmaceuticals, Inc., Palo Alto, CA, United States (U.S. corporation)
PI US 5187089 19930216

AI US 1990-542484 19900621 (7)
DT Utility
FS Granted
LN.CNT 1089
INCL INCLM: 435/212.000
INCLS: 435/218.000
NCL NCLM: 435/212.000
NCLS: 435/218.000
IC [5]
ICM: C12N009-48
ICS: C12N009-66
EXF 435/218; 435/212; 435/184; 435/69.2; 530/350
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 264 OF 268 USPATFULL on STN
AN 91:20509 USPATFULL
TI Two-chain urokinase plasminogen activators for treatment of thrombotic disease
IN Broeze, Robert J., Framingham, MA, United States
Vovis, Gerald F., Marlborough, MA, United States
PA Collaborative Research, Inc., Bedford, MA, United States (U.S. corporation)
PI US 4999194 19910312
AI US 1988-143975 19880114 (7)
DT Utility
FS Granted
LN.CNT 440
INCL INCLM: 424/094.630
INCLS: 435/215.000; 435/226.000; 435/212.000
NCL NCLM: 424/094.630
NCLS: 435/212.000; 435/215.000; 435/226.000
IC [5]
ICM: C12N009-72
ICS: A61K037-547
EXF 435/212; 435/215; 435/226; 435/214; 435/172.3; 424/94.63; 935/10; 935/14
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 265 OF 268 WPIDS COPYRIGHT 2004 THOMSON DERWENT on STN
AN 2002-500632 [53] WPIDS
DNC C2002-141848
TI Novel expression vector for expressing mammalian plasminogen derivatives in yeast, has nucleotide sequence coding for catalytic domain of plasminogen and/or coding for kringle domains of plasminogen linked to promoter.
DC B04 D16
IN COLLEN, D J; LAROCHE, Y; NAGAI, N
PA (THRO-N) THROMB-X NV
CYC 98
PI WO 2002050290 A1 20020627 (200253)* EN 56p C12N015-81
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TR TZ UG ZM ZW
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
AU 2002018890 A 20020701 (200264) C12N015-81
EP 1343903 A1 20030917 (200362) EN C12N015-81
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI TR
ADT WO 2002050290 A1 WO 2001-BE217 20011220; AU 2002018890 A AU 2002-18890 20011220; EP 1343903 A1 EP 2001-271444 20011220, WO 2001-BE217 20011220
FDT AU 2002018890 A Based on WO 2002050290; EP 1343903 A1 Based on WO 2002050290
PRAI GB 2001-16702 20010709; GB 2000-31196 20001221; GB 2001-16690 20010709
IC ICM C12N015-81
ICS C12N005-10; C12N009-68

L4 ANSWER 266 OF 268 WPIDS COPYRIGHT 2004 THOMSON DERWENT on STN
AN 1999-602901 [52] WPIDS
DNN N1999-444618 DNC C1999-175560
TI New protease for activating blood clotting factor VII, useful for treating hemorrhage prophylaxis or hemostasis.
DC B04 D16 P34 S03
IN FEUSSNER, A; ROMISCH, J; STOHR, H; ROEMISCH, J; STOEHR, H
PA (AVET) AVENTIS BEHRING GMBH; (CENT-N) CENTEON PHARMA GMBH

CYC 30
PI EP 952215 A2 19991027 (199952)* EN 24p C12N009-64
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI
DE 19903693 A1 19991028 (199952) C12N009-48
AU 9923935 A 19991104 (200003) A61K038-48
CA 2269109 A1 19991024 (200014) EN C12N009-96
JP 2000023696 A 20000125 (200016) 18p C12Q001-56
KR 99083444 A 19991125 (200055) C12N009-50
AU 748221 B 20020530 (200247) A61K038-48
US 6528299 B1 20030304 (200320) C12N009-50
US 2003152567 A1 20030814 (200355) C12Q001-37
ADT EP 952215 A2 EP 1999-106913 19990408; DE 19903693 A1 DE 1999-19903693 19990201; AU 9923935 A AU 1999-23935 19990423; CA 2269109 A1 CA 1999-2269109 19990423; JP 2000023696 A JP 1999-116411 19990423; KR 99083444 A KR 1999-14636 19990423; AU 748221 B AU 1999-23935 19990423; US 6528299 B1 US 1999-295316 19990421; US 2003152567 A1 Div ex US 1999-295316 19990421, US 2002-319592 20021216
FDT AU 748221 B Previous Publ. AU 9923935; US 2003152567 A1 Div ex US 6528299
PRAI DE 1999-19903693 19990201; DE 1998-19818495 19980424; DE 1998-19827734 19980622; DE 1998-19851332 19981106; DE 1998-19851335 19981106; DE 1998-19851336 19981106
IC ICM A61K038-48; C12N009-48; C12N009-50; C12N009-64; C12N009-96; C12Q001-37; C12Q001-56
ICS A61K031-00; A61K038-00; A61K038-43; A61K038-46; A61K038-49; A61K038-55; A61K038-57; A61L015-38; C07H021-04; C07K014-745; C07K016-40; C12N005-06; C12P021-02; G01N033-566; G01N033-573; G01N033-577; G01N033-86

L4 ANSWER 267 OF 268 WPIDS COPYRIGHT 2004 THOMSON DERWENT on STN
AN 1998-297926 [26] WPIDS
DNC C1998-092971
TI Single-chain variants of tissue plasminogen activator - with basic residue replaced in serine protease region useful for treating or diagnosing thrombotic disorders.
DC B04 D16
IN MADISON, E L
PA (SCRI) SCRIPPS RES INST
CYC 80
PI WO 9821320 A2 19980522 (199826)* EN 45p C12N009-72
RW: AT BE CH DE DK EA ES FI FR GB GH GR IE IT KE LS LU MC MW NL OA PT SD SE SZ UG ZW
W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW
AU 9855850 A 19980603 (199842) C12N009-72
EP 950095 A2 19991020 (199948) EN C12N009-72
R: AL AT BE CH DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI
CN 1244894 A 20000216 (200027) C12N009-72
JP 2001505765 W 20010508 (200131) 61p C12N015-09
AU 735519 B 20010712 (200147) C12N009-72
US 6706504 B1 20040316 (200420) C12N009-00
ADT WO 9821320 A2 WO 1997-US20226 19971112; AU 9855850 A AU 1998-55850 19971112; EP 950095 A2 EP 1997-952176 19971112, WO 1997-US20226 19971112; CN 1244894 A CN 1997-181346 19971112; JP 2001505765 W WO 1997-US20226 19971112, JP 1998-522661 19971112; AU 735519 B AU 1998-55850 19971112; US 6706504 B1 Provisional US 1996-30655P 19961112, WO 1997-US20226 19971112, US 2000-600985 20001113
FDT AU 9855850 A Based on WO 9821320; EP 950095 A2 Based on WO 9821320; JP 2001505765 W Based on WO 9821320; AU 735519 B Previous Publ. AU 9855850, Based on WO 9821320; US 6706504 B1 Based on WO 9821320
PRAI US 1996-30655P 19961112; US 2000-600985 20001113
IC ICM C12N009-00; C12N009-72; C12N015-09
ICS C12N005-10; C12N009-64; C12Q001-68; G01N033-53
ICI C12N009-64; C12R001:91

L4 ANSWER 268 OF 268 WPIDS COPYRIGHT 2004 THOMSON DERWENT on STN
AN 1998-217271 [19] WPIDS
CR 1998-217268 [19]; 2003-438927 [41]; 2003-466215 [44]
DNN N1998-171727 DNC C1998-068961
TI Chimeric and humanised antibodies which bind to and inhibit circulating alpha-2-anti- ***plasmin*** - useful for, e.g. enhancing fibrinolysis for treatment of pulmonary embolism(s) and heart attack(s).
DC B04 D16 S03

IN BAJORATH, J; HARRIS, L; HSU, M; MATSUEDA, G; NOVOTNY, J; REED, G L; MATSUEDA, G R

PA (BRIM) BRISTOL-MYERS SQUIBB CO; (GEHO) GEN HOSPITAL CORP; (HARD) HARVARD COLLEGE; (BAJO-I) BAJORATH J; (HARR-I) HARRIS L; (HSUM-I) HSU M; (MATS-I) MATSUEDA G; (NOVO-I) NOVOTNY J; (REED-I) REED G L

CYC 21

PI WO 9812334 A2 19980326 (199819)* EN 103p C12N015-62
RW: AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE
W: AU CA JP
AU 9744135 A 19980414 (199839) C12N015-62
EP 941345 A2 19990915 (199942) EN C12N015-62
R: AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
JP 2001502895 W 20010306 (200116) 156p C12N015-09
AU 741338 B 20011129 (200206) C12N015-62

ADT WO 9812334 A2 WO 1997-US16123 19970919; AU 9744135 A AU 1997-44135 19970919; EP 941345 A2 EP 1997-942436 19970919, WO 1997-US16123 19970919; JP 2001502895 W WO 1997-US16123 19970919, JP 1998-514756 19970919; AU 741338 B AU 1997-44135 19970919

FDT AU 9744135 A Based on WO 9812334; EP 941345 A2 Based on WO 9812334; JP 2001502895 W Based on WO 9812334; AU 741338 B Previous Publ. AU 9744135, Based on WO 9812334

PRAI US 1996-26356P 19960920

IC ICM C12N015-09; C12N015-62
ICS A61P007-02; C07K016-18; C07K016-38; C07K016-46; C12N005-10; C12N015-13

ICA A61K039-395; A61K045-00; G01N033-53; G01N033-86

STN INTERNATIONAL LOGOFF AT 12:11:28 ON 12 APR 2004

US 0916664910P1



Creation date: 04-13-2004
Indexing Officer: HABDULEKADER - HUDA ABDULEKADER
Team: OIPEScanning
Dossier: 09166649

Legal Date: 02-11-2004

No.	Doccode	Number of pages
1	XRUSH	1

Total number of pages: 1

Remarks:

Order of re-scan issued on